Menstrual cycles, vasomotor symptoms, hormone therapy and risk of cardiovascular disease by Gast, Gerrie-Cor
Menstrual cycles, vasomotor symptoms, hormone 
therapy and risk of cardiovascular disease
Gerrie-Cor Gast
Menstrual cycles, vasomotor symptoms, hormone therapy and risk of 
cardiovascular disease
Thesis, Utrecht University, with a summary in Dutch
ISBN   978-90-5335-255-7
Author   Gerrie-Cor Gast
Lay-out   Simone Vinke
Cover design   Susanne Karlsson
Printed by   Ridderprint, Ridderkerk, The Netherlands
Menstrual cycles, vasomotor symptoms, hormone 
therapy and risk of cardiovascular disease
Menstruele cycli, vasomotore symptomen, hormoontherapie 
en risico op hart- en vaatziekten
(met een samenvatting in het Nederlands)
Proefschrift
ter verkrijging van de graad van doctor aan de Universiteit Utrecht 
op gezag van de rector magnificus, prof. dr. J.C. Stoof,  
ingevolge het besluit van het college voor 
promoties in het openbaar te verdedigen 
op donderdag 25 maart 2010 des middags te 12.45 uur
door
Gerrie-Cor Margarethe Gast
geboren op 22 april 1982 te Woerden
Promotoren:  Prof.dr. Y.T. van der Schouw
   Prof.dr. D.E. Grobbee
   Prof.dr. G.N. Samsioe
Financial support by the Julius Center for Health Sciences and Primary 
Care and The Netherlands Heart Foundation for the publication of this 
thesis is gratefully acknowledged.
Additional financial support was provided by Jurriaanse Stichting, Bayer 
and Solvay Pharmaceuticals.
This project was funded through an Incentive Grant from the Board of 
the UMC Utrecht, The Netherlands, and through Region Skåne and the 
medical faculty of Lund University, Sweden.
Manuscript based on the studies described in this thesis
Chapter 2
Tan YY, Gast GCM, van der Schouw YT. Gender differences in risk factors of 
coronary heart disease. Maturitas 2010;65:149-160.
Chapter 3.1
Gast GCM, van der Schouw YT. Clinical features of polycystic ovary syndrome 
and risk of coronary heart disease in postmenopausal women. Submitted.
Chapter 3.2
Gast GCM, Grobbee DE, Smit HA, Bueno-de-Mesquita HB, Samsioe GN, van der 
Schouw YT. Menstrual cycle characteristics and risk of coronary heart disease 
and type 2 diabetes. In revision Fertility and Sterility.
Chapter 4
Gast GCM, Grobbee DE, Pop VJM, Keyzer JJ, Wijnands-van Gent CJM, Samsioe 
GN, Nilsson PM, van der Schouw YT. Vasomotor symptoms are associated with 
a lower bone mineral density. Menopause 2009;16:231-238.
Chapter 5.1
Gast GCM, Grobbee DE, Pop VJM, Keyzer JJ, Wijnands-van Gent CJM, Samsioe 
GN, Nilsson PM, van der Schouw YT. Menopausal complaints are associated 
with cardiovascular risk factors. Hypertension 2008;51:1492-1498.
Chapter 5.2
Gast GCM, Samsioe GN, Grobbee DE, Nilsson PM, van der Schouw YT. Vasomotor 
symptoms, estradiol levels, and cardiovascular risk profile. Submitted.
Chapter 5.3
Gast GCM, Pop VJM, Samsioe GN, Grobbee DE, Nilsson PM, Keyzer JJ, Wijnands-
van Gent CJM, van der Schouw YT. Menopausal vasomotor symptoms are 
associated with increased risk of coronary heart disease. Submitted.
Chapter 6
Gast GCM, Pop VJM, Samsioe GN, Grobbee DE, Nilsson PM, Keyzer JJ, Wijnands-
van Gent CJM, van der Schouw YT. Hormone therapy, vasomotor symptoms and 
risk of coronary heart disease. Submitted.
Contents
Chapter 1 General introduction  9
Chapter 2 Gender differences in risk factors for coronary 
  heart disease  19
Chapter 3 Menstrual cycles, polycystic ovary syndrome and   
  vascular risk  47
    3.1 Clinical features of polycystic ovary syndrome   
  and risk for coronary heart disease in 
  postmenopausal women  49
    3.2 Menstrual cycle characteristics and risk of coronary 
  heart disease and type 2 diabetes  61
Chapter 4  Vasomotor symptoms are associated with a lower 
  bone mineral density  83
Chapter 5 Menopausal vasomotor symptoms and vascular risk    105
   5.1 Menopausal complaints are associated with 
  cardiovascular risk factors   107
   5.2 Vasomotor symptoms, estradiol levels and 
  cardiovascular risk profile   125 
   5.3 Vasomotor symptoms are associated with increased
  risk of coronary heart disease   143
Chapter 6 Hormone therapy and risk of coronary heart disease 
  by vasomotor menopausal symptoms  159
Chapter 7 General discussion    175
Chapter 8 Summary   189
  Samenvatting     195
  Dankwoord    203
  Curriculum Vitae   209
  List of other publications   213

 Chapter 1
 
General introduction
10
Chapter 1
In western countries, cardiovascular disease (CVD) is the leading 
cause of death in women. In Europe, 54% of deaths in women are due to 
CVD as compared to 43% in men (Figure 1) (1). Despite these convincing 
numbers, many women still perceive CVD as a disease that mainly affects 
middle-aged men, and also physicians underestimate the cardiovascular 
risk in women (2;3). Interestingly, CVD presents about 10 years later in 
women than in men (4;5). Several risk factors predispose women to CVD; 
some are shared with men, and some are exclusive to women.
Figure 1. Deaths of cardiovascular disease for men and women, latest available year, Europe
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Polycystic ovary syndrome and irregular menstrual cycles 
Polycystic ovary syndrome (PCOS) is a common endocrine/
metabolic disorder of women of reproductive age. Its principal 
manifestations include ovulatory dysfunction (resulting in irregular 
menstrual cycles), androgen excess, polycystic ovaries, and obesity. 
Women with PCOS also have increased long term risk of higher blood 
pressure, hyperlipidemia, type 2 diabetes (6;7), and coronary calcification 
(8) compared with normally cycling women. In spite of the presence 
of these CVD risk factors in women with PCOS, definitive evidence 
for an increased incidence in CVD is lacking (9). While some studies 
found no increased CVD risk among women with PCOS (10;11), others 
found the CVD risk to be increased (12;13). However, it is unclear 
whether an augmented CVD risk is due primarily to a PCOS related 
hyperandrogenism and/or to the associated overweight, and eventually 
CVD risk factor clustering. Furthermore, there is a considerable group of 
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women not fulfilling diagnostic criteria for PCOS, but still having long 
or irregular menstrual cycles. Those women have been suggested to also 
have an increased risk of type 2 diabetes (14) and CVD factors (15), but 
whether this is independent of associated altered sex hormone levels 
and/or CVD risk factors is currently not known either. 
Menopause
The incidence of CVD is low in premenopausal women but 
increases with age, especially after menopause (4;5). A low lifetime 
endogenous estrogen exposure is suggested to promote CVD and 
related death after menopause. As a logical consequence, the view that 
the CVD risk might be reversed by replacing the endogenous estrogens 
by exogenous estrogens in the form of hormone therapy (HT) became 
popular. Indeed, a large number of observational studies unanimously 
showed a protective effect of postmenopausal HT on the risk of CVD (16-
20). The Nurses’ Health Study, the largest and most important prospective 
observational study, which included over 70,000 women aged 30-55 
years, showed that postmenopausal women who used HT had a 40% risk 
reduction in major coronary events after 20 years of follow-up (18). Large 
randomized controlled trials, however, unexpectedly showed that HT 
does not improve and might even increase CVD risk in postmenopausal 
women (Figure 2) (21;22). The Women’s Health Initiative (WHI) study, 
for instance, was designed to assess the impact of HT in apparently 
healthy postmenopausal women on primary CVD prevention. Combined 
estrogen-progestin HT was associated with an increased risk of coronary 
heart disease (CHD) (hazard ratio (HR)=1.24, [95% confidence interval 
(CI) 1.00-1.54]) after 5.2 years of follow-up, with the elevated risk being 
most apparent in the first year (HR=1.81, [95% CI 1.09-3.01]), despite the 
favourable effects of HT on most metabolic factors (decrease in total and 
low density lipoprotein (LDL) cholesterol, glucose and insulin, increase in 
high density lipoprotein (HDL) cholesterol, although also in triglycerides) 
(23). 
12
Chapter 1
Figure 2. Comparison of results from the observational NHS study of postmenopausal 
HT and the WHI Trial. 
Vasomotor menopausal symptoms an explanation for discrepancy? 
These conflicting findings created great confusion about the 
effects of HT on risk of CVD (24). Several hypotheses to explain these 
discrepancies have been proposed. The number of years since menopause 
differs substantially between women in the observational studies and in 
the trials, with younger women dominating in the observational studies. 
Conceivably, the older women in the trials, on average, had more extensive 
subclinical atherosclerosis than did their younger counterparts, and it was 
suggested that a healthy endothelium is necessary for beneficial effects of 
estrogens (25). Another important difference between women using HT 
in trials and in real life is that outside trials women tend to receive HT by 
indication, which commonly is the presence and severity of vasomotor 
menopausal symptoms (VMS), such as hot flushes and night sweats. A 
hot flush is a sensation of heat and flushing that occurs suddenly. Night 
sweats are hot flushes occurring during night. These VMS are the hallmark 
of the menopausal transition in midlife women (26) and are likely to be 
caused by a combination of low and fluctuating estrogen levels during 
menopause (27-29). While these VMS were predominant among the 
populations examined in the observational studies, women with severe 
VMS were either excluded (30) or comprised only a minority of the total 
population studied in the trials (31), as these symptoms could reduce 
adherence to placebo treatment. 
0 0,5 1 1,5 2
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Vasomotor menopausal symptoms, estrogenic effects, bone mineral 
density and CVD risk 
We hypothesized that the presence of VMS could be a marker of 
susceptibility to beneficial effects of estrogens in postmenopausal women 
on several end organs (32). To study this hypothesis, it is of importance to 
first clarify the role of VMS in relation to estrogenic effects on end organs. 
Bone mineral density is an appropriate proxy measure to study estrogenic 
effects, because it is well known that estrogens have strong effects on the 
bone (33-36). There are limited data published showing that women with 
VMS had a lower forearm bone mineral density than women without 
VMS. Furthermore, these women gained more in bone mineral density 
when they started HT than did the women who started HT, but did not 
have VMS (37). These findings indicate that women suffering from VMS 
might benefit most from HT. Still, this study was very small and did not 
permit definitive conclusions. 
If VMS indeed appear to be an indicator for estrogenic effects 
or estrogen sensitivity, it is also of interest to study possible underlying 
differences in CVD risk between women with and without VMS. The 
most common indication for which HT is prescribed is VMS. However, 
following the results of the clinical trials (21;22), conflicting guidelines 
have been circulated. Also for women with VMS, physicians and 
women themselves are in doubt whether HT is safe. It is therefore of 
utmost importance to gain a better understanding of which subgroups 
of postmenopausal women may experience the greatest benefit or harm 
from exogenous HT. These studies could provide an explanation for the 
large discrepancy between the findings of observational and experimental 
studies on the effects of HT on CVD risk. 
objeCtives
The main aim of this thesis was to study female specific risk 
factors for CHD. In particular, we aimed at investigating a perceived 
association between menstrual cycle characteristics, androgens, PCOS 
and incidence of CHD. Furthermore, we studied the role of the presence 
of VMS on estrogenic effects, CVD risk factors and clinical endpoints of 
CHD. Finally, we evaluated whether HT use is safe with regard to CHD 
risk in women with VMS.
14
Chapter 1
outline oF this thesis
In chapter 2, a review summarizes the literature on gender 
differences of risk factors for CHD. In chapter 3.1, the association between 
clinical features of PCOS, androgens and risk of CHD is examined. In 
chapter 3.2, the relationship between menstrual cycle characteristics and 
the risk of CHD and type 2 diabetes are investigated. In chapter 4 we 
studied whether VMS are related to estrogenic effects on bone mineral 
density. In chapter 5 we studied whether the presence, frequency and 
intensity of VMS are associated with the CVD risk profile and CHD risk. 
In chapter 6 we evaluated whether HT is safe with regard to CHD risk in 
women with VMS. In chapter 7, the findings of this thesis are discussed, 
and in chapter 8, the findings of the different studies presented in this 
thesis are summarized.
15
General introduction
reFerenCes
1. Allender S, Scarborough P, Peto V, Rayner M. European cardiovascular disease 
statistics 2008.2008.
2. Mosca L, Mochari H, Christian A, Berra K, Taubert K, Mills T, Burdick KA, Simpson 
SL. National study of women’s awareness, preventive action, and barriers to 
cardiovascular health. Circulation 2006; 113:525-534.
3. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, Fabunmi RP, 
Kwan J, Mills T, Simpson SL. National study of physician awareness and adherence 
to cardiovascular disease prevention guidelines. Circulation 2005; 111:499-510.
4. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. 
Menopause and the risk of coronary heart disease in women. N. Engl. J. Med. 1987; 
316:1105-1110.
5. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N. 
Engl. J. Med. 1993; 329:247-256.
6. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of 
risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary 
syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. 
Metab 1999; 84:165-169.
7. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. Coronary heart 
disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. 
Vasc. Biol. 1995; 15:821-826.
8. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick 
DS. Evidence for an association between metabolic cardiovascular syndrome and 
coronary and aortic calcification among women with polycystic ovary syndrome. J. 
Clin. Endocrinol. Metab 2004; 89:5454-5461.
9. Guzick DS. Do cardiovascular risk factors in polycystic ovarian syndrome result in 
more cardiovascular events? J. Clin. Endocrinol. Metab 2008; 93:1170-1171.
10. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with 
polycystic ovary syndrome at long-term follow-up. Journal of Clinical Epidemiology 
1998; 51:581-586.
11. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with 
polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. 
Clinical Endocrinology 2000; 52:595-600.
12. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome 
and risk for myocardial infarction. Evaluated from a risk factor model based on a 
prospective population study of women. Acta Obstet. Gynecol. Scand. 1992; 71:599-
604.
13. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, 
Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson 
TK, Rogers W, Pepine CJ. Postmenopausal women with a history of irregular menses 
and elevated androgen measurements at high risk for worsening cardiovascular 
event-free survival: results from the National Institutes of Health--National Heart, 
Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J. 
Clin. Endocrinol. Metab 2008; 93:1276-1284.
16
Chapter 1
14. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, Colditz GA, 
Speizer FE, Manson JE. Long or highly irregular menstrual cycles as a marker for risk 
of type 2 diabetes mellitus. JAMA 2001; 286:2421-2426.
15. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer 
FE, Manson JE. Menstrual cycle irregularity and risk for future cardiovascular disease. 
Journal of Clinical Endocrinology & Metabolism 2002; 87:2013-2017.
16. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 
1991; 265:1861-1867.
17. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer 
FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of 
cardiovascular disease. N. Engl. J. Med. 1996; 335:453-461.
18. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A 
prospective, observational study of postmenopausal hormone therapy and primary 
prevention of cardiovascular disease. Ann. Intern. Med. 2000; 133:933-941.
19. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen 
replacement therapy. Arch. Intern. Med. 1991; 151:75-78.
20. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of 
cardiovascular disease-related mortality among postmenopausal women who use 
hormones: evidence from a national cohort. Am. J. Obstet. Gynecol. 1991; 164:489-494.
21. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. 
Randomized trial of estrogen plus progestin for secondary prevention of coronary 
heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement 
Study (HERS) Research Group. JAMA 1998; 280:605-613.
22. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, 
Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks 
and benefits of estrogen plus progestin in healthy postmenopausal women: principal 
results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 
288:321-333.
23. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black 
HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman 
M. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 
2003; 349:523-534.
24. Mendelsohn ME, Karas RH. HRT and the young at heart. N. Engl. J. Med. 2007; 
356:2639-2641.
25. Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R, Merriam GR, 
Miller VM, Naftolin F, Santoro N. Postmenopausal hormone therapy: new questions 
and the case for new clinical trials. Menopause. 2006; 13:139-147.
26. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002; 
360:1851-1861.
27. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000; 36:155-164.
28. Deecher DC. Physiology of thermoregulatory dysfunction and current approaches 
to the treatment of vasomotor symptoms. Expert. Opin. Investig. Drugs 2005; 14:435-
448.
29. Freedman RR. Physiology of hot flashes. Am. J. Hum. Biol. 2001; 13:453-464.
30. Design of the Women’s Health Initiative clinical trial and observational study. The 
Women’s Health Initiative Study Group. Control Clin. Trials 1998; 19:61-109.
17
General introduction
31. Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart and Estrogen/
progestin Replacement Study (HERS): design, methods, and baseline characteristics. 
Control Clin. Trials 1998; 19:314-335.
32. van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart 
disease risk: an explanation for discrepant findings on the benefits of post-menopausal 
hormone therapy. Eur. Heart J. 2005; 26:1358-1361.
33. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, 
Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, 
Watts NB. Effects of estrogen plus progestin on risk of fracture and bone mineral 
density: the Women’s Health Initiative randomized trial. JAMA 2003; 290:1729-1738.
34. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, Ettinger B. 
Endogenous hormones and the risk of hip and vertebral fractures among older 
women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 1998; 
339:733-738.
35. Hagemans ML, van der Schouw YT, de Kleijn MJ, van Staveren WA, Pop VJ, Leusink 
GL, Grobbee DE. Indicators for the total duration of premenopausal endogenous 
estrogen exposure in relation to BMD. Hum. Reprod. 2004; 19:2163-2169.
36. Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR. Hormonal 
predictors of bone loss in elderly women: a prospective study. The Study of 
Osteoporotic Fractures Research Group. J. Bone Miner. Res. 1998; 13:1167-1174.
37. Naessen T, Persson I, Ljunghall S, Bergstrom R. Women with climacteric symptoms: 
a target group for prevention of rapid bone loss and osteoporosis. Osteoporos. Int. 
1992; 2:225-231.

 Chapter 2
Gender differences in risk factors of coronary 
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Chapter 2
abstraCt
Coronary heart disease (CHD), traditionally considered a male 
disease, is also a major threat to women. This review article addresses 
independent risk factors for CHD that are specific for women as well as 
non-gender specific risk factors and how their effects differ between men 
and women. Although polycystic ovary syndrome (PCOS) in women 
is associated with an adverse metabolic risk profile, current evidence 
regarding future risk of CHD is conflicting. Preeclampsia is consistently 
associated with higher risk of CHD later in life. Menopause is associated 
with an increased risk of CHD, and the earlier the onset of menopause, the 
larger the risk. Existing data on postmenopausal hormone therapy (HT) 
was inconclusive with regard to possible protection when HT is initiated 
close to menopause in young peri- or postmenopausal women. Evidence 
on use of low-dose oral contraceptives strongly suggests no increased 
risk of CHD. Although levels of physical inactivity are similar for both 
men and women, the higher prevalences of hypertension, diabetes, and 
obesity in older women portends a greater risk in women than in men. 
Additionally, risk factors like smoking, hypertriglyceridemia and low 
high-density lipoprotein cholesterol levels have greater impact in women 
than in men. This review indicates that acknowledgement of non-gender 
specific risk factors in addition to those that are unique to women would 
help optimize diagnosis, treatment and earlier prevention of CHD in 
women. Further research is needed to ascertain if incorporating these 
gender specific risks into a clinically used risk stratification model would 
change outcome in women. 
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introduCtion
Coronary heart disease (CHD) is the leading cause of death in the 
world, accounting for 12 percent of deaths (1). In Europe, it is responsible 
for 22 percent of all deaths in women and 21 percent in men each year (2). 
However, due to the misconception that CHD is a disease of middle-aged 
men, most women lack the awareness and perceive that they are more at 
risk for breast cancer than for CHD (3). 
Since women are more likely to develop CHD a decade later than 
men, they usually have more adverse outcomes than men do. Women are 
twice as likely to die of a first myocardial infarction (MI) (3), and have a 
less favorable long-term survival as compared with men. As women have 
smaller coronary vessels than men, they are twice as likely to die as a 
result from coronary artery bypass surgery, and are more likely to undergo 
repeat revascularization (3;4). Contrary to men, women with CHD often 
present with atypical symptoms such as nausea, fatigue, dyspnea, jaw 
pain, numbness of the arms and milder chest pain (3;4), yet physicians 
often fail to recognize these symptoms in women (5). 
Women have many risk factors that predispose them to CHD; 
most of which are age related and some of which are exclusive to women. 
While many traditional risk factors are the same for both sexes, there 
is a growing body of evidence to support pronounced gender specific 
differences (6). This article reviews the gender specific risk factors such 
as polycystic ovary syndrome (PCOS), preeclampsia and menopause, 
including oral contraceptives (OCs) and hormone therapy (HT), along 
with traditional risk factors for both men and women. Our review aims to 
increase awareness and improve diagnosis, treatment and prevention for 
CHD in women. 
methods
Boolean searches of MEDLINE/Pub Med® were performed by 
combining the MeSH terms cardiovascular disease with sex OR gender 
OR women OR female and each of the following: polycystic ovary 
syndrome, preeclampsia, menopause, oral contraceptives, hormone 
therapy, smoking, hypertension, diabetes mellitus, dyslipidemia, obesity 
and physical activity. Searches were restricted to English language 
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publications, but no other restrictions applied. The reference lists and 
related articles from relevant articles were also searched to identify 
additional studies. Websites of World Health Organization (WHO), 
American Heart Association (AHA) and Mayo Clinic were reviewed for 
further information and current recommendations. 
risk FaCtors unique to women
Polycystic Ovary Syndrome (PCOS) 
PCOS is a common reproductive endocrine disorder characterized 
by at least two of the following: oligo- or anovulation, hyperandrogenism 
or polycystic ovaries as defined by ultrasonography (7). Women with 
PCOS are generally more obese (8), and have an increased prevalence of the 
metabolic syndrome, a clustering of CHD risk factors such as hypertension, 
hyperglycemia, and dyslipidemia (9). Although these risk factors are 
known to increase CHD risk, convincing evidence thus far indicating an 
increased CHD risk in women with PCOS is lacking (Table 1). 
The Nurses’ Health Study (NHS) studied women with a history 
of irregular or very irregular menses as a proxy for PCOS and found an 
increased relative risk (RR) of CHD of 1.3 [95% confidence interval (CI) 1.1-
1.5] and 1.7 [95% CI 1.4-2.1], respectively, when compared with normally 
cycling women. The results remained significant even after adjusting for 
body mass index (BMI) and other CHD risk factors (10). The Women’s 
Ischemia Syndrome Evaluation (WISE) Study found greater angiographic 
CHD (odds ratio (OR) 1.9 [95% CI 1.1-3.4]) and more CHD events (OR 
1.6 [95% CI 1.2-2.1]) among women with PCOS (n=104) than among 
women without PCOS (n=286) (11). However, PCOS was defined using 
postmenopausal androgen levels only. In another study, women with 
PCOS were also found to have higher risk for coronary artery calcification 
than control women (OR 2.0 [95% CI 0.7-5.8]) (12). These studies suggest 
that women with PCOS are at increased risk for atherosclerosis, a pre-stage 
of clinical CHD. In a small cohort study, five cardiovascular events were 
identified among women with PCOS (n=127), whereas no events were 
observed among the age-matched controls (n=142) (13). On the contrary, 
the results from two cohort studies in England suggests that women with 
PCOS do not have a higher than average morbidity and mortality of CHD 
as compared to their controls despite an increased prevalence of CHD risk 
23
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factors (14;15). 
The results from available studies are inconsistent. Most studies 
looked at surrogate endpoints, and are hampered by methodological 
constraints such as small sample sizes, short periods of follow-up and 
poor definition of PCOS. A prospective study of a large cohort of women 
with well-defined PCOS criteria followed over time for the incidence of 
CHD is sorely needed to better address the perplexing relation between 
PCOS and CHD. 
Preeclampsia
Preeclampsia is a syndrome unique to human pregnancy. It 
is characterized by the onset of hypertension and proteinuria after the 
twentieth week of gestation, and is responsible for 12% of maternal 
mortality and preterm delivery (16). During pregnancy, the mother’s 
body makes metabolic and vascular changes to facilitate the growth of 
the conceptus. However, the changes may persist in some women post-
pregnancy even though the changes are expected to normalize after 
delivery (17). 
 A systematic review and meta-analysis on epidemiological studies 
of 198,252 women affected with preeclampsia concluded that women with 
a history of preeclampsia have approximately double the risk of future 
CHD compared to women with uncomplicated pregnancies (16) (Table 
2). A dose-response, with higher risk of CHD, was further observed in 
women with a history of moderate (RR 3.0 [95% CI 2.5-3.6]) and severe 
preeclampsia (RR 5.4 [95% CI 4.0-7.3]) compared with normotensive 
women (18). This suggests that preeclampsia is an independent risk factor 
of CHD in women. Additionally, a history of preeclampsia has also been 
shown to increase the risk of future hypertension by four-fold [95% CI 
2.7-5.1] (16). 
Although the mechanism underlying the association between 
preeclampsia and CHD is not well understood, studies have shown 
that women with a history of preeclampsia exhibit impaired endothelial 
function and vasodilatation remote from pregnancy that might induce 
a cascade of events that progresses to atherosclerosis (17;19). Further 
research is needed to understand the pathogenesis of preeclampsia 
and CHD, but whatever its nature a history of preeclampsia should be 
considered in the evaluation of women’s risk of CHD. 
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Gender differences in coronary heart disease
Menopause
Premenopausal women appear to be relatively safe from CHD 
compared with men of the same age. However, women’s risk of CHD 
increases after menopause. Loss of ovarian function and subsequent 
deficiency in endogenous estrogens lead to the observation that 
postmenopausal women are at higher risk of CHD in comparison to 
premenopausal women (RR 1.4 [95% CI 1.2-1.6]) (20) (Table 3). The CHD 
risk in women who experienced early menopause (prior to 50 years of 
age) is also higher than those with a late menopausal age (RR 1.3 [95% CI 
1.2-1.4]) (20).
Epidemiological studies have reported women have undergone 
bilateral oophorectomy have a two-fold [95%CI 1.5-2.7] increased risk of 
CHD as compared to those who experienced a natural menopause (20). 
Additionally, women who underwent the procedure early in life were 
found to have higher risk of CHD (RR 4.6 [95% CI 2.6-8.0]) when compared 
with older women who had the same procedure (RR 2.6 [95% CI 2.1-
3.4]) (20). This might be explained by the abrupt decline of endogenous 
estrogen levels in women with surgical menopause as oppose to the 
gradual decline in hormone levels in naturally menopausal women (20).
Hormone therapy
For many years, HT has been used in hopes of lowering CHD risk in 
women. Numerous observational studies have concluded the use of HT to 
be protective, especially in postmenopausal women (21;22). However, the 
cardioprotective effect of HT has been challenged by placebo-controlled 
randomized trials that found null (23) to even harmful effects (24) of HT 
on the risk of cardiovascular events. (Table 4)
Since atherosclerosis accelerates after estrogen deficiency, it would 
be logical to think that timing of HT initiation is important for potentially 
protective effects. In a secondary analysis of the Women’s Health Initiative 
(WHI) data, women who initiated HT within 10 years from the onset of 
menopause were found to be protected from CHD compared with women 
initiating HT more distant from menopause (25). Although this study did 
not show a statistically significant trend, it suggests that the risk of CHD 
may be modified by the time of HT initiation. Additionally, the findings 
from a meta-analysis of 39,049 participants showed that HT reduced total 
mortality among younger women (mean age<60 years) (OR 0.7 [95% CI 
28
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Chapter 2
0.5-0.96]) but not in older women (OR 1.03 [95% CI 0.9-1.2]) (26). In fact, 
a delayed protective effect of HT against CHD was observed in the older 
women (26). The results from the observational NHS showing higher 
protection against CHD among women who began HT near menopause 
(RR 0.7 [95% CI 0.5-0.8] for estrogen alone; RR 0.7 [95%CI 0.6-0.9] for 
estrogen and progestin) compared with women who began HT 10 or 
more years after menopause (RR 0.9 [95% CI 0.7-1.1] for estrogen alone; 
RR 0.9 [95% CI 0.6-1.3] for estrogen and progestin) further supports that 
HT initiation in relation to menopause onset and age may influence CHD 
risk (27). 
Despite millions of dollars spend on studies to research the 
effect of HT and its association to CHD, the results remain inconclusive. 
Evidence seems to suggest that HT may be beneficial in the young peri- 
or postmenopausal women, but this suggestion remains to be confirmed 
in prospective trials. The use of HT as a prevention agent is still not 
recommended, especially when there are other agents (eg. anticoagulants, 
anti-hypertensive drugs, and lipid-lowering agents) that are proven to be 
more beneficial in managing CHD risk factors.
Oral contraceptives
Ever since the Pill became available in the 1960s, its effect on CHD 
has been widely studied. The use of older high-dose OCs has consistently 
shown an increased CHD risk among current users as compared to never 
users (28) (Table 5). The World Health Organization (WHO) Study found 
an overall five-fold increased risk among current OC-using women in 
Europe [95% CI 2.54-9.9], and also a five-fold increased risk among current 
OC-using women in non-European developing countries as compared 
with never and past users combined [95% CI 2.5-9.1] (29). Similarly, 
the NHS found a 2.5-fold [95% CI 1.3-4.9] elevated risk in current users 
compared to never users (30). 
In contemporary low-dose OCs, epidemiological studies seem 
to suggest lower risk of CHD for current users compared to never users 
(31) (Table 5). The prospective Women’s Lifestyle and Health (WHL) 
Study found that current use of low-dose estrogen and second- or third-
generation progestins was associated with a lower risk of CHD (RR 0.7 
[95% CI 0.4-1.4]), even after adjusting for age and other cardiac risk factors 
(32). Additionally, the study found no increased CHD risk in women 
35
Gender differences in coronary heart disease
who have used OCs for more than 15 years (RR 0.7 [95% CI 0.4-1.2]) (32). 
Although some studies still find that a low dose is associated with an 
almost doubling of risk of CHD, this finding was far from statistically 
significant (33). Moreover, since MI is a rare event in young women, a 
doubling in risk does have a low attributable risk. 
Concern has been expressed that the use of OCs in the past may 
lead to an increased risk of CHD (30). However, a meta-analysis of 13 
studies of 119,061 women concluded that no increased risk of CHD was 
observed among women who have used OCs in the past (34). The WHL 
study further reported former use of OCs was not associated with an 
increased risk of CHD (RR 1.0 [95% CI 0.7-1.4]) (32). Current evidence 
suggests that modern OCs convey neither harm nor benefit towards CHD. 
risk FaCtors For men and women
Smoking
Smoking is the leading preventable cause of CHD in both men 
and women (6). Although the prevalence of men smoking is higher than 
women, recent studies found that women are less likely to quit smoking 
than men (6). Smoking has a greater harmful effect in women than in 
men; women who smoke have about 60 percent increased risk for CHD as 
compared to men who smoke (RR 2.2 [95% CI 1.9-2.7] and 1.6 [95% CI 1.3-
2.0] respectively) and that risk increases proportionally with the amount 
of tobacco consumed per day (35). Other studies have also consistently 
shown that the coexistence of smoking in OC-using women is associated 
with a striking ten-fold increased risk of CHD (29;36). 
Hypertension
As in men, hypertension is also an important risk factor of CHD in 
women (3). In the Framingham study subjects aged 65 to 74 years, women 
who have hypertension have a four-fold increased CHD risk compared 
with normotensive women, where as hypertension in men is associated 
with a three-fold increased CHD risk compared to normotensive men 
(37). Hypertension control rates, although improving, tend to be lower in 
older women when compared with men (38). 
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Diabetes mellitus
Diabetes is also a stronger CHD risk factor for women than for 
men (39). A recent meta-analysis of 37 studies consisting of almost 450,000 
patients of type 2 diabetes found that women have a three-fold increased 
risk of fatal CHD, whereas men have a two-fold increased risk (pooled 
ratio of the RRs for fatal CHD (women: men) is 1.5 [95% CI 1.1-1.9]) (40). 
It shows that diabetic women are at increased risk for CHD as compared 
to diabetic men. This might be due to the more adverse cardiovascular 
profiles among diabetic women (40). 
Dyslipidemia
Premenopausal women tend to have more favorable lipid 
profiles than men. However, after age 50, women tend to have increased 
triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) levels, 
and decreased levels of high-density lipoprotein cholesterol (HDL-C) (6). 
Hypertriglyceridemia and low HDL-C are more important risk factors 
of CHD for women than for men (6). A meta-analysis of 17 prospective 
studies (n=46,413 men and 10,864 women) show that elevated TG levels, 
adjusted for HDL-C, were associated with 37 percent increase in risk of 
CHD in women (RR 1.37 [95% CI 1.1-1.7]) as compared with a 14 percent 
increase in men (RR 1.14 [95% CI 1.1-1.3]) (6;41). 
Obesity 
Obesity, especially when distributed centrally, has been shown to 
be associated with increased risk of CHD. In a recent European Prospective 
Study Into Cancer and Nutrition (EPIC)-Norfolk Study, the hazard ratio 
for the highest versus lowest waist-hip ratio in women was 1.9 [95% CI 
1.4-2.5] while for men was 1.6 [95% CI 1.3-1.7], after adjusting for BMI and 
other CHD risk factors (42). This suggests that women with high central 
obesity are about 20 percent more likely to develop CHD as compared to 
their male counterparts. Hypertension, dyslipidemia and hyperglycemia 
(the metabolic syndrome) are also more prevalent in obese people, and 
often lead to increased type 2 diabetes and CHD (3). Obese people are also 
less likely to be physically active (43).
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Physical inactivity
Lower fitness levels are associated with increased CHD risk in 
both men (RR 3.4 [95% CI 2.1-5.8) and women (RR 4.7 [95% CI 2.2-9.8), 
and the prevalence of lower fitness levels and CHD risk is greatest among 
ethnic minorities in the Western society (44). The WHI Study found that 
women who spent more than 12 hours sitting have an increased risk of 
CHD (RR 1.4 [95% CI 1.01-1.9]) as compared with those who spent sitting 
less than 4 hours per day (45). Vigorous exercise and other low intensity 
activities, such as walking, have been shown to favorably alter the 
metabolic syndrome and promote weight loss, which could substantially 
reduce CHD risk in men and especially women (45;46).  
ConClusion
CHD, traditionally considered a male disease, is also a major threat 
to women. It is clear that although women share the same risk factors as 
men, there are risk factors that pertain only to women which may have 
increased their predisposition to developing CHD. 
Our review shows that a history of preeclampsia, menopausal 
status and age at menopause and potentially PCOS increase the risk of 
CHD, although the exact role of PCOS as an independent risk factor of 
CHD has yet to be established. More long-term well designed studies are 
needed to address the hypothesis regarding elevated CHD risk in women 
with PCOS, and the effectiveness of earlier preventive interventions, 
which in hope would reduce morbidity and mortality among women.
Existing data concerning the use of HT and CHD are mixed with 
regard to possible protection when HT is initiated close to menopause, 
particularly in young peri- or postmenopausal women. Evidence on use 
of low-dose OCs suggests no increased risk of CHD. Therefore, more 
studies will be needed to assess the use of exogenous hormones and its 
association with CHD.
Cigarette smoking, hypertriglyceridemia and low HDL-C levels 
are found to have greater impact in women than in men; the higher 
prevalence of diabetes, hypertension and obesity in postmenopausal 
women also predispose them to a greater risk of CHD as compared with 
men. The importance of exercise and weight control could further reduce 
complications that are caused by obesity. Acknowledgement of these 
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risk factors in addition to those that are unique to women would help 
optimize diagnosis, treatment and earlier prevention of CHD in women.
Although gender differences in CHD risk is currently receiving 
increasing attention in the medical profession, the fact that clinicians 
are more likely to fail to recognize the atypical symptoms in women 
presenting with coronary disease should be addressed. Furthermore, 
current risk stratification models in treating CHD, such as the SCORE 
and Framingham Score score, do not involve any gender specific risks. 
Further research should be done to ascertain if incorporating such risks 
such as PCOS, previous preeclampsia and years from menopause into a 
clinically used risk stratification model would change outcome in female 
patients.
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Chapter 3.1
abstraCt
Recently, the WISE study showed that high androgens levels 
or clinical features of the polycystic ovary syndrome (PCOS), defined 
as postmenopausal biochemical evidence of hyperandrogenemia and 
a history of irregular menses are related to increased cardiovascular 
disease (CVD) risk in a high CVD risk population. We examined whether 
androgens or clinical features of PCOS, using a similar definition, are 
related to risk of coronary heart disease (CHD) in a low risk population. 
In 879 postmenopausal women, data on irregular cycles, blood pressure, 
serum glucose, lipid, and plasma levels of C-reactive protein (CRP), and 
sex hormones were measured. After a mean ± SD follow-up of 10.0 ± 2.0 
years, 57 women were diagnosed with CHD. There was no association 
between all androgen levels measured and CHD risk (multivariate hazard 
ratio’s (HRs) [95% confidence interval (CI)] for androstenedione: 1.37 
[0.66, 2.85], testosterone: 1.01 [0.996, 1.03] and free testosterone: 1.04 [0.99, 
1.09]). Clinical features of PCOS were not associated with risk for CHD 
(multivariate HR 1.00 [95% CI 0.42-2.37]. In conclusion, in a population-
based sample we could not corroborate previous findings in a high risk 
population that androgens and clinical features or PCOS are associated 
with an increased CVD risk.
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introduCtion
The key features of polycystic ovary syndrome (PCOS) are 
oligo-or anovulation and hyperandrogenism. Most women with PCOS 
are obese, hyperinsulinemic (1) and insulin resistant (2). Women with 
PCOS also have increased longer term risks of higher blood pressure, 
hyperlipidemia, type 2 diabetes (T2D) (1;3), and increased risk of coronary 
calcification (4) compared with normally cycling women. However, there 
are no convincing data showing that elevated risk translates into increased 
events (5). 
In existing studies information on PCOS is often lacking. Recently, 
investigators from the WISE study used biochemical evidence of 
hyperandrogenemia and a history of irregular menstrual cycles among 
postmenopausal women to define clinical features of PCOS. This study 
among women at high cardiovascular disease (CVD) risk reported that 
women with clinical features of PCOS had an elevated risk of angiographic 
coronary artery disease and also of cardiovascular death or non-fatal 
myocardial infarction (6). They also showed that CVD event rates were 
significantly higher in the women having increased androgen levels only. 
The aim of the present study is to examine whether androgen 
levels or clinical features of PCOS, using a similar definition, are also 
related to an increased risk of CHD in a low CVD risk population. 
methods
Population
From the Prospect - European Prospective Study Into Cancer and 
Nutrition (EPIC) cohort, comprising 17,357 women aged 49-70 years (7), 
a random sample of 1,736 (10%) women was taken at baseline for non-
fasting laboratory measurements. Serum samples were missing for 36 
women. Sex hormones were measured in postmenopausal women only 
(n=1,248). We selected the subpopulation of 879 women who were free of 
CHD, not using hormone therapy (HT) or oral contraceptives (OCs) at the 
time of the blood donation, providing data on their usual menstrual cycle 
characteristics, and consented to medical registry linkage.
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Data collection
At baseline, a general questionnaire containing questions on 
demographic characteristics, presence of chronic diseases and related 
potential risk factors was administered. Furthermore, systolic and 
diastolic blood pressures were measured twice at the left arm with an 
automated and calibrated oscillomat (Bosch & Son, Jungingen, Germany) 
with the subject in supine position, and the mean was calculated. Body 
weight was measured in light indoor clothing without shoes to the 
nearest 0.5 kg with a floor scale (Seca, Atlanta, GA, USA). Body mass 
index (BMI) was calculated as weight divided by height squared (kg/m2). 
Waist and hip circumference were measured as well and waist hip ratio 
(WHR) was obtained by dividing waist circumference in centimetres by 
hip circumference in centimetres.
Laboratory analysis
Serum total cholesterol and glucose were determined using an 
automated enzymatic procedure on a Vitros 250 (Johnson & Johnson, 
Rochester, New York, USA). Serum low-density lipoprotein (LDL) - 
and high-density lipoprotein (HDL)-cholesterol were measured using a 
colorimetric assay on a Hitachi 904 (Johnson & Johnson, Rochester, New 
York, USA). C-reactive protein (CRP) was measured in citrated plasma 
using the Behring BNII nephelometric method (Dade Behring, Deerfield, 
II, USA). 
Levels of sex hormone binding globulin (SHBG), androstenedione 
and testosterone were measured in plasma using commercially available 
double-antibody RIA kits (Diagnostic System Laboratories Inc.) (8). The 
kits that we used for measurement of androstenedione, and testosterone 
levels were validated earlier (9), and showed a high relative validity in 
terms of ranking postmenopausal women by relative hormone levels. Free 
testosterone were calculated using the measured values for testosterone, 
SHBG, and an assumed constant for albumin (10;11).
PCOS determination
Women were classified as ‘postmenopausal’ if they reported 
not having had any menses over the last year, or if they had a bilateral 
ovariectomy at baseline. The usual menstrual cycle characteristics of the 
women were assessed by the question: How was your usual menstrual 
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cycle length/pattern between the age of 30 and 40 years irrespective of 
periods of OCs use, pregnancies and breastfeeding? Response choices were 
irregular, regular cycle ≤26 days, regular cycle of 27–29 days, or regular 
cycle ≥30 days. Irregular cycles were considered to be a combination of 
long (≥30 days) and short (≤26 days) menstrual periods.
Clinical features of PCOS included biochemical evidence of 
hyperandrogenemia [top quartile of androstenedione (≥701 pg/ml), 
testosterone (≥30.9 ng/dl), or free testosterone (≥4.5 pg/ml)] and a history 
of irregular menses (6). 
Morbidity and mortality follow-up
Data on morbidity, vital status, and causes of death were 
determined as previously described (12). For our analyses, incident 
CHD (ICD-9; 410-414, 427.5 or ICD-10 I20, I23-I25) was the endpoint of 
interest. For all women who had a CHD event, follow up ended at the 
date of diagnosis or, when hospital admission had not occurred, at the 
date of death. Mortality from noncardiovascular causes, loss to follow-up 
and withdrawn alive were considered censoring events. All others were 
censored on January 1st 2006. 
Data analysis
Means and standard deviations, medians and interquartile 
ranges (IQR) (for non-normally distributed variables) or frequencies 
(for categorical variables) were presented. Hazard ratio’s (HRs) and 95% 
confidence intervals (CIs) for risk on CHD were estimated using Cox 
regression analysis. Androstenedione, testosterone and free testosterone 
levels were evaluated as continuous variables. For the PCOS analysis, 
women without clinical features of PCOS were considered as the reference 
category. We first fitted a crude model (model 1). Subsequently, we fitted 
models adjusted for age at enrollment, BMI (model 2), smoking, physical 
activity level, and T2D (model 3). Additionally, like in the WISE study, we 
also evaluated effect modification of PCOS status by hsCRP categories of 
below 1, 1 to less than 3, and 3 or greater mg/dl by performing stratified 
analyses. 
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results
The study had a mean follow-up of 9.96 ± 2.0 y and comprised 
8,755 person-years. The mean age of the study group was 59.7 ± 5.6 y. In 
total, 11% were classified as having features of PCOS. These women had a 
higher BMI, blood pressure, glucose and CRP level, but WHR, lipid levels 
and prevalence of T2D were similar among women with and without 
features of PCOS. However, the prevalence of smoking, physical inactivity, 
and ever usage of OCs and HT was greater among women with features 
of PCOS compared with women without features of PCOS. Furthermore, 
while median SHBG levels were lower in women with clinical features 
of PCOS, androstenedione, total testosterone, and free testosterone levels 
were higher in women with PCOS as compared to women without clinical 
features of PCOS. In total, 57 women experienced an incident CHD event 
during follow-up, of which seven were fatal. (Table 1)
Table 1 Baseline characteristics of the study population of 879 women
All women
N=879
Features of PCOS
n=99
No features of PCOS 
n=780
Follow-up time, months 119.5 ± 24.4 116.8 ± 27.3 119.8 ± 24.0
Cardiovascular disease risk factors
   Age, years 59.7 ± 5.6 58.8 ± 5.2 59.9 ± 5.6
   Body mass index, kg/m2 26.0 ± 3.9 27.1 ± 4.2 25.8 ± 3.9
   Waist/hip ratio 0.80 ± 0.06 0.80 ± 0.06 0.79 ± 0.06
   Voorrips physical activity score 6.9 ± 5.0 6.0 ± 5.2 7.0 ± 5.0
   Systolic blood pressure, mm/Hg 135.1 ± 21.0 138.9 ± 22.3 134.7 ± 20.8
   Diastolic blood pressure, mm/Hg 79.7 ± 10.5 82.2 ± 10.3 79.4 ± 10.5
   Glucose, mmol/L 4.7 ± 1.7 5.2 ± 3.0 4.6 ± 1.5
   Cholesterol, mmol/L 6.0 ± 1.0 6.1 ± 1.0 6.0 ± 1.0
   HDL-cholesterol, mmol/L 1.6 ± 0.4 1.5 ± 0.4 1.6 ± 0.4
   LDL-cholesterol, mmol/L 4.1 ± 1.0 4.1 ± 0.9 4.0 ± 1.0
   hsCRP 1.2 (0.6-2.4)* 1.6 (0.7-3.1)* 1.1 (0.6-2.3)*
Hormone levels
   SHBG, nmol/L 21.0 (13.0-30.0)* 16.0 (6.4-23.0)* 22.0 (13.0-31.0)*
   Androstenedione, pg/mL 530 (340-790)* 620 (390-940)* 520 (330-775)*
   Testosterone total, ng/dL 27.0 (19.0-37.0)* 33.0 (25.0-42.0)* 26.0 (18.0-36.0)*
   Free testosterone, pg/mL 5.7 (3.7-8.7)* 7.5 (5.8-10.6)* 5.4 (3.5-8.4)*
   Irregular menstrual cycles 133 (15.1) 99 (100) 34 (4.4)
N (%) N (%) N (%)
Type 2 diabetes cases 37 (4.3) 4 (4.2) 33 (4.3)
Coronary heart disease cases 57 (6.5) 7 (7.1) 50 (6.4)
High educational level 123 (14.0) 13 (13.1) 110 (14.1)
Current smokers 182 (21.1) 27 (28.1) 155 (20.2)
Ever used oral contraceptives 459 (52.2) 54 (54.6) 405 (51.9)
Ever used hormone therapy 119 (13.5) 16 (16.2) 103 (13.2)
Abbreviations: PCOS, polycystic ovary syndrome, HDL, high density lipoprotein, LDL, low density 
lipoprotein; hsCRP, high sensitive C-reactive protein; SHBG, sex hormone binding globulin.
Data presented as the mean ± standard deviation, unless stated otherwise: * Median (interquartile range).
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In the crude and fully adjusted analyses, there was no association 
between all androgen levels measured and CHD risk (HRs [95% CIs] for 
androstenedione: 1.37 [0.66, 2.85], testosterone: 1.01 [0.996, 1.03] and free 
testosterone: 1.04 [0.99, 1.09], Table 2, models 4).
In the crude analysis, clinical features of PCOS were not associated 
with risk of CHD (HR 1.15 [95% CI 0.52-2.53], Table 2, model 1), a pattern 
that did not change after multivariate adjustment (HR 1.00 [95% CI 0.42-
2.37] Table 2, model 4). 
Hs-CRP was not an effect modifier (P-value for effect modification 
was 0.47) (data not shown).
Table 2. Hazard ratio’s for androgens, clinical features of PCOS and risk of CHD
HR (95% CI)
Androstenedione, ng/mL
Model 1 1.12 (0.56, 2.24)
Model 2 1.18 (0.58, 2.40)
Model 3 1.37 (0.66, 2.84)
Model 4 1.37 (0.66, 2.85)
Testosterone, ng/dL
Model 1 1.01 (0.99, 1.03)
Model 2 1.01 (0.99, 1.03)
Model 3 1.01 (0.996, 1.03)
Model 4 1.01 (0.996, 1.03)
Free testosterone, pg/mL
Model 1 1.04 (0.99, 1.08)
Model 2 1.04 (0.99, 1.09)
Model 3 1.04 (0.99, 1.09)
Model 4 1.04 (0.99, 1.09)
Clinical features of PCOS
Model 1 1.15 (0.52, 2.53)
Model 2 1.19 (0.53, 2.64)
Model 3 1.00 (0.42, 2.37)
Model 4 1.00 (0.42, 2.37)
 
Abbreviations: HR, hazard ratio; CI, confidence interval; PCOS, polycystic ovary syndrome.
Model 1 = univariate (crude) model; model 2 = adjusted for age (continuous) and body mass 
index (continuous); model 3 = model 2 with smoking (never, past, current), physical activity level 
(continuous); model 4 = model 3 with type 2 diabetes.
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disCussion
In this prospective study of almost 900 postmenopausal women, 
androgen levels and clinical features of PCOS were not associated with 
risk of CHD. 
The results of the present study are in contrast with recent findings 
from the WISE study showing that CVD event rates were significantly 
higher in the women with increased androgen levels. They also found 
that women with clinical features of PCOS have more angiographic 
coronary artery disease and lower 5-yr cardiovascular event-free survival 
than women without clinical features of PCOS (6). We used a similar 
definition to identify women with PCOS and had a sample size twice as 
large, and a longer follow-up than the WISE study. An explanation for 
the different findings may be related to the different study populations; 
whereas the WISE study investigated a high CVD risk population, we 
performed our study in a population-based sample. However, since our 
findings remained similar when we performed an additional analysis in 
the group of women in which prevalent CHD cases were not excluded, it 
is not likely that a low CVD risk study population could fully explain our 
findings.  
Another explanation for these inconsistencies possibly relates to 
the differences in hormone levels in women between the WISE study 
and ours. In the WISE study the prevalences of hyperglycemia, T2D, and 
obesity, were 44%, 27% and 36%, respectively, which is more than double 
the prevalences in our study of 8%, 4% and 17%, respectively. Central 
obesity and hyperinsulinemia are known to increase androgen production 
and circulating concentrations of free, biologically available testosterone 
by decreasing hepatic production of SHBG (13). Thus, women with PCOS 
tend to have low serum SHBG but high free testosterone concentrations. 
Instead, in the WISE study, the women with PCOS had higher SHBG 
levels, but lower free testosterone levels as compared to the  women with 
PCOS in the present study (low SHBG: 82% vs 92% respectively; high free 
testosterone: 64% vs 97% respectively). Furthermore, other studies that 
also raised the possibility of a neutral or beneficial effect of androgens on 
the heart (14-18), all had comparable androgen levels to ours. It is probable 
that the androgen levels in the latter studies were of an optimal range for 
cardiovascular health, but not for those women who participated in the 
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WISE study. This merits some further investigation. 
Furthermore, it is not clear yet whether the definition used to define 
women with PCOS is appropriate, since postmenopausal hormone levels 
are not a reliable reflection of hormone levels in their premenopausal 
years. There is an urgent need for more rigorous prospective cohort 
studies of CVD outcomes in women with PCOS, with better definition of 
PCOS and a long follow-up. 
In conclusion, we could not confirm the previously reported 
associations that androgens and clinical features of PCOS are associated 
with an increased CVD risk in a population-based sample. 
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abstraCt
We prospectively examined whether long, or irregular menstrual 
cycles are related to future risk of coronary heart disease (CHD) and type 
2 diabetes (T2D). In addition, we investigated the associations between 
cycle characteristics and metabolic factors and sex hormone levels. Data 
were used from the Dutch EPIC cohort consisting of 23,571 women, 
enrolled between 1993-1997, aged 20-70 years, and free of CHD and T2D at 
baseline. Data on usual menstrual cycle characteristics were collected by 
questionnaires. Among a subpopulation of 843 postmenopausal women 
blood pressure, serum glucose, lipid, and plasma levels of C-reactive 
protein (CRP), fibrinogen, and hormones were measured. After a mean ± 
SD follow-up of 10.1 ± 1.9 years, 755 women were diagnosed with CHD, 
and 533 with T2D. A regular menstrual cycle length of ≥30 days was not 
associated with risk of CHD compared to shorter regular cycles. Women 
with irregular menstrual cycles, compared to women with a regular 
cycle length of 27-29 days had an increased risk for CHD (hazard ratio 
(HR) 1.31 [95% confidence interval (CI) 1.07-1.59]), and a non-significant 
increased risk for T2D (HR 1.20 [95% CI 0.94-1.53]). Irregular cycles were 
associated with a 0.34 mmol/L [95% CI 0.07-0.62] higher glucose level, but 
were not related to blood pressure, lipid-, CRP-, and hormone levels after 
multivariate adjustment. Women with a history of irregular menstrual 
cycles have a significantly moderately increased risk of CHD, and tend to 
have an increased risk of T2D, which can not be explained by metabolic 
risk factors nor altered hormone levels. 
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introduCtion
Highly irregular menstrual cycles have been associated with 
hyperinsulinemia (1), and increased risk of type 2 diabetes (T2D) (2;3) 
and coronary heart disease (CHD) (4). It has been hypothesized that 
oligomennorrhea is frequently caused by polycystic ovary syndrome 
(PCOS) (5). PCOS is characterized by a long history of chronic anovulation, 
insulin resistance and androgen excess (6). Women with PCOS also have 
increased longer term risks of a higher blood pressure, hyperlipidemia, 
T2D (7;8), and coronary calcification (9) compared with normally cycling 
women. These risk factors may predispose women with PCOS to CHD 
(10). Also very long cycles of ≥ 40 days are associated with increased risk 
of T2D (2;3). Although it is obvious that PCOS is related to the extreme 
menstrual cycle abnormalities mentioned above, many women may 
experience less extreme long (≥ 30 days) or irregular (combination of 
short and long) menstrual cycles. However, knowledge on whether this 
less extreme long cycle length or irregularity in the female population 
translates into increased CHD events and/or T2D, and whether these 
associations are mediated by metabolic disturbances or sex hormone 
imbalances, is not fully clear.
In the present study we examined whether long, or irregular 
menstrual cycles are related to future risk of CHD or T2D in a cohort 
of 23,571 women who were followed for 10.1 years. In addition, we 
aimed at examining whether the association between menstrual cycle 
characteristics and CHD or T2D is mediated by metabolic factors or sex 
hormone levels. For the latter purpose, we investigated the associations 
between menstrual cycles and metabolic factors and sex hormone levels 
in a sub-population of 843 women.
materials and methods
Population
The EPIC-NL study consists of the Prospect- and MORGEN-cohorts 
that cover the Dutch contribution to the European Prospective Study 
Into Cancer and Nutrition (EPIC) cohort (11). Prospect is a prospective 
cohort study among 17,357 women aged 49–70 who participated in the 
breast cancer screening between 1993 and 1997 (12). The MORGEN 
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cohort consists of men and women aged 20-59 years recruited from 3 
Dutch towns (Amsterdam, Doetinchem and Maastricht) (13). From 1993 
to 1997 each year a new random sample of ~5000 subjects was examined. 
These rounds of enrolment add up to 23,100 subjects, of which 12,434 
are women. For the present study, 29,791 women were eligible. Prospect 
participants were excluded if they did not have periods or reported oral 
contraceptives (OCs) use (n=1,671) between the age of 30-40 years, which 
was the period they had to define their menstrual cycle characteristics. 
Women were also excluded if they did not respond or did not know the 
answer to the question regarding their menstrual cycle pattern (n=3,210), 
did not give written informed consent to perform linkages with medical 
registries (n=561) or did not consent to linkage with vital status registries 
(n=63), or reported a history of CHD (ICD-9; 410-414, 427.5) (n= 355) or 
T2D (ICD-9; 250) (n=360) before the baseline measurements. The final 
study population consisted of 23,571 women. 
Among all Prospect-EPIC participants, a random sample of 1,736 
women was taken for non-fasting laboratory measurements. Serum 
samples were missing for 36 women, leaving 1,700 women. Sex hormones 
were measured in postmenopausal women only (n=1,248). For the present 
study, we selected the subpopulation of 843 women who provided data 
on their usual menstrual cycle characteristics, but did not report hormone 
therapy (HT) or OCs use at the time of the blood donation, and were free 
of CHD and T2D at baseline.
General questionnaire
At baseline, a general questionnaire containing questions on 
demographic characteristics, presence of chronic diseases and related 
potential risk factors was administered. Comparable information on 
lifestyle and disease history was collected in the Prospect and MORGEN 
cohorts, although each project had additional questions on different topics. 
Smoking behaviour was categorized as no, former or current smokers. Based 
on the validated Cambridge Physical Activity Index (CPAI), participants 
were divided in four physical activity categories: inactive (sedentary job 
and no recreational activity), moderately inactive (sedentary job with < 
0.5 hour recreational activity per day or standing job with no recreational 
activity), moderately active (sedentary job with 0.5-1 hour recreational 
activity per day or standing job with 0.5 hour recreational activity per 
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day or physical job with no recreational activity) and active (sedentary 
job with < 1 hour recreational activity per day or standing job with < 
0.5 hour recreational activity per day or physical job with at least some 
recreational activity or heavy manual job) (14). The highest attained level 
of education of the participants was classified into three categories: low 
(primary education up to completing intermediate vocational education), 
middle (up to higher secondary education) and high (those with higher 
vocational education and university). Women who were currently using 
HT or OCs at baseline or who had previously used HT or OCs prior to 
study entry were classified as ‘ever-users’ of HT or OCs, respectively. 
Women who, at study entry, had never used and were not currently using 
HT or OCs were classified as ‘never-users’ of HT or OCs, respectively. 
Menopausal status at enrolment was defined as described in figure 1. In 
short, women were ‘premenopausal’ if they reported having had regular 
menses over the past 12 months; ‘postmenopausal’ if they reported not 
having had any menses over the past 12 months, or if they had a bilateral 
ovariectomy; and ‘perimenopausal/unknown’ if they reported to have 
had 1-9 cycles over the past 12 months or if they indicated having had 
menses over the past 12 months but were no longer menstruating at the 
time of recruitment. Women with incomplete questionnaire data, or who 
reported current use of OCs or HT, were classified as premenopausal if 
they were less than 46 years of age, perimenopausal/unknown if they 
were between 46 and 55 years of age, and postmenopausal if they were 
older than 55 years.
Physical examination
In both cohorts, a physical examination was performed at baseline. 
In Prospect, systolic and diastolic blood pressures were measured twice at 
the left arm with an automated and calibrated oscillomat (Bosch & Son, 
Jungingen, Germany) with the subject in supine position, and the mean 
was calculated. In MORGEN, blood pressure was measured twice at the 
left arm, using a Random Zero Sphygmomano-meter, while the subject 
was in sitting position, and the mean was calculated. For both cohorts, 
body weight was measured in light indoor clothing without shoes to the 
nearest 0.5 kg with a floor scale (Seca, Atlanta, GA, USA). Body mass 
index (BMI) was calculated as weight divided by height squared (kg/m2). 
Waist and hip circumference were measured as well and waist hip ratio 
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(WHR) was obtained by dividing waist circumference in centimetres by 
hip circumference in centimetres.
Menstrual cycle characteristics
The usual menstrual cycle characteristics of the women 
participating in the Prospect study were assessed by the question: How 
was your usual menstrual cycle length/pattern between the age of 30 and 
40 years irrespective of periods of OCs use, pregnancies and breastfeeding? 
In MORGEN, the usual menstrual cycle characteristics were assessed by 
the question: What is your usual menstrual cycle length/pattern? For 
both studies, response choices were irregular, regular cycle ≤26 days, 
regular cycle of 27–29 days, or regular cycle ≥30 days, which were also 
the categories used for the present analysis. A regular menstrual cycle 
means that menstrual cycles occurred at regular intervals, with intervals 
being ≤26 days, 27-29 days or ≥30 days respectively. Irregular cycles were 
considered to be combination of long (≥30 days) and short (≤26 days) 
menstrual periods. 
Laboratory analysis
Serum total cholesterol and glucose were determined using an 
automated enzymatic procedure on a Vitros 250 (Johnson & Johnson, 
Rochester, New York, USA). Serum low-density lipoprotein (LDL) - 
and high-density lipoprotein (HDL)-cholesterol were measured using a 
colorimetric assay on a Hitachi 904 (Johnson & Johnson, Rochester, New 
York, USA). C-reactive protein (CRP) was measured in citrated plasma 
using the Behring BNII nephelometric method (Dade Behring, Deerfield, II, 
USA). Total fibrinogen concentrations were determined in citrated plasma 
according to Clauss using the Sta-R automatic coagulation analyzer with 
STA Fibrinogen reagent (Diagnostica Stago, Taverny, France).
Levels of estrone, estradiol, dehydroepiandrosterone (DHEAS), 
sex hormone binding globulin (SHBG), androstenedione and testosterone 
were measured in plasma using commercially available double-antibody 
RIA kits (Diagnostic System Laboratories Inc.) (15). The kits that we used 
for measurement of estrone, estradiol, androstenedione, and testosterone 
levels were validated earlier (16), and showed a high relative validity in 
terms of ranking postmenopausal women by relative hormone levels. 
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Free estradiol and free testosterone were calculated using the measured 
values for estradiol or testosterone, SHBG, and an assumed constant for 
albumin (17;18).
Morbidity and mortality follow-up
Occurrence of T2D during follow-up was obtained by self-report 
in two follow-up questionnaires, sent to the participants within regular 
intervals of three to five years. The questionnaires were similar for both 
Prospect and MORGEN participants. Participants were asked whether 
T2D was diagnosed and if so in what year. Moreover, in Prospect, a urinary 
glucose strip test was sent out with the first follow-up questionnaire and 
participants were asked to report whether the strip had turned purple 
after waiting 10 seconds, indicating glucosuria. Data on morbidity 
regarding T2D and CHD were also obtained from the Dutch Centre for 
Health Care Information, which holds a standardized computerized 
register of hospital discharge diagnoses. Admission files have been filed 
continuously from all general and university hospitals in the Netherlands 
since 1990. Whenever a patient is discharged from a hospital, data on sex, 
date of birth, dates of admission and discharge, 1 mandatory principal 
diagnosis, and up to 9 optional additional diagnoses are recorded. All 
diagnoses are coded according to the ICD-9. The database was linked to the 
cohort on the basis of birth date, sex, postal code, and general practitioner 
with a validated probabilistic method (19). Potential cases of incident 
T2D notified by any of these methods were verified against information 
from the participants’ general practitioner or pharmacist through mailed 
questionnaires. T2D was defined present when the general practitioner or 
pharmacist confirmed the diagnosis. For those who could not be verified, 
T2D was defined present when two or more of the above described 
notification methods reported a positive response. Information on vital 
status was obtained through linkage with the municipal administration 
registries. Causes of death were obtained from the Dutch Central Bureau 
of Statistics, coded according to the ICD-10. For our analyses, CHD events 
(ICD-9; 410-414, 427.5 or ICD-10 I20, I23-I25) were the endpoints of interest. 
Whenever multiple events of CHD occurred, the first diagnosis was taken 
as endpoint. For all women who had been diagnosed as T2D or had a 
CHD event, follow up ended at the date of diagnosis or, when hospital 
admission had not occurred, at the date of death. Mortality because of 
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noncardiovascular causes, loss to follow-up because of moves outside the 
Netherlands and withdrawn alive were considered censoring events. All 
others were censored on January 1st 2006.
Data analysis
Means and standard deviations (for normally distributed 
variables), medians and interquartile ranges (IQR) (for not-normally 
distributed variables) or numbers and frequencies (for categorical 
variables) were presented. Because laboratory measurements were only 
performed in postmenopausal women, we presented their age-adjusted 
means and medians. The person-time for each woman was calculated 
from the month of return of the baseline questionnaire to the month of 
diagnosis of the endpoint (CHD or T2D), the month of death from other 
causes, or the end of follow-up (January 1, 2006). Hazard ratio’s (HRs) and 
95% confidence intervals (CIs) for risk on CHD or T2D were estimated 
using Cox regression analysis. We considered women reporting a regular 
menstrual cycle with an interval of 27-29 days as the reference group. We 
first fitted a crude model. Subsequently, we fitted models adjusted for age 
at enrollment, BMI, WHR, physical activity, smoking, educational level, 
ever use of OCs or HT, and menopausal status (model 2). To explore the 
possibility that the usage of exogenous hormones might modify the risk 
for CHD, we conducted a subgroup analysis for never users of OCs or HT. 
To elucidate whether the observed associations between menstrual 
cycle characteristics and CHD might be explained by intermediates, we 
used linear regression analyses to assess the association of menstrual 
cycle characteristics with blood pressure, serum lipid-, fibrinogen-, CRP- 
and glucose levels and plasma hormone levels, correcting for the same 
confounders described above. The linear regression coefficients (β) are 
presented with 95% CIs. As log-transformation of the skewed variables 
revealed similar results, we present the non-transformed values for ease 
of interpretation.
Results were considered statistically significant at 2-sided P ≤ 
0.05. All statistical analyses were performed using the Statistical Analysis 
System, version 9.1 (SAS Institute, Inc.).
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results
Baseline characteristics of the 23,571 women from the individual 
Prospect and MORGEN cohorts and the studies combined are shown 
in Table 1. The study had a mean follow-up of 10.1 ± 1.9 years, which 
was similar for CHD and T2D, and comprised 239,885 person-years. The 
mean age at baseline was 50 years (range: 20-70), and was higher in the 
Prospect than in the MORGEN cohort. Consequently, adjusting for age 
explained the higher BMI, prevalence of HT use, age at menopause, and 
percentage of postmenopausal women in the Prospect cohort, and the 
lower prevalence of ever OCs use in Prospect than the MORGEN cohort. 
Percentages of low educated women, current smokers, less active women 
and women with short or irregular cycles were higher in the MORGEN 
cohort than the Prospect cohort. In total, 10% reported a cycle length of 
≥30 days, while 17% reported to have an irregular cycle. 
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Table 1 Baseline characteristics of the total study population (N=23,571)
Characteristics Prospect MORGEN All women
Mean ± SD Mean ± SD Mean ± SD
N 13,435 10,496 23,571
CHD follow-up time, months 119.7 ± 22.5 123.5 ± 23.0 121.5 ± 22.7
T2D follow-up time, months 120.0 ± 22.0 123.8 ± 22.6 121.7 ± 22.4
Age, years 57.6 ± 6.0 41.7 ± 11.1 50.6 ± 11.7
Age diagnosed with CHD 65.7 ± 6.7 56.7 ± 8.3 63.1 ± 8.2
Age diagnosed with T2D 64.2 ± 6.8 57.7 ± 7.4 62.5 ± 7.5
BMI, kg/m2 25.9 ± 4.0 25.0 ± 4.2 25.5 ± 4.1
Waist/hip ratio 0.79 ± 0.06 0.79 ± 0.07 0.79 ± 0.06
Age at menopause 48.5 ± 5.0 47.9 ± 5.7 48.4 ± 5.1
Gravidity* 2.8 ± 1.8 2.4 ± 1.3 2.6 ± 1.6
Parity† 2.2 ± 1.2 2.0 ± 0.9 2.2 ± 1.1
N (%) N (%) N (%)
CHD 533 (4.1) 217 (2.1) 750 (3.2)
T2D 395 (3.0) 138 (1.3) 533 (2.3)
Educational level‡
  Low 5,868 (44.7) 3,502 (33.7) 9,370 (39.9)
  Middle 5,019 (38.2) 4,588 (44.2) 9,607 (40.9)
  High 2,239 (17.1) 2,289 (22.1) 4,528 (19.3)
Smoking
  No 5,727 (43.6) 3,921 (37.7) 9,648 (41.0)
  Former 4,490 (34.2) 2,840 (27.3) 7,330 (31.1)
  Current 2,923 (22.3) 3,653 (35.1) 6,576 (27.9)
Physical activity CPAI§
   Inactive 885 (6.7) 742 (9.5) 1,627 (7.8)
   Moderately inactive 3,395 (25.8) 2,471 (31.7) 5,866 (28.0)
   Moderately active 3,449 (26.3) 2,328 (29.9) 5,777 (27.6)
   Active 5,412 (41.2) 2,259 (29.0) 7,671 (36.6)
Menstrual cycle
    ≤26 days 3,522 (26.8) 3,637 (34.9) 7,159 (30.4)
    27-29 days 6,389 (48.6) 3,709 (35.6) 10,098 (42.8)
    ≥30 days 1,420 (10.8) 996 (9.6) 2,416 (10.3)
   Irregular cycles 1,810 (13.8) 2,088 (20.0) 3,898 (16.5)
Ever used OCs 8,137 (62.0) 8,846 (84.9) 16,983 (72.1)
Ever used HT 3,383 (25.8) 942 (9.4) 4,325 (18.7)
Menopausal status
   Premenopausal 1,192 (9.1) 7,070 (67.8) 8,262 (35.1)
   Postmenopausal 9,442 (71.9) 1,901 (18.2) 11,343 (48.1)
   Perimenopausal /unknown 2,507 (19.1) 1,459 (14.0) 3,966 (16.8)
Surgical menopause 608 (4.6) 133 (1.3) 741 (3.1)
Abbreviations: SD, standard deviation; N, number; CHD, coronary heart disease; T2D, type 2 
diabetes; BMI, body mass index; OCs, oral contraceptives; HT, hormone therapy; CPAI, cambridge 
physical activity index. 
* Gravidity is the sum of the number of the full term pregnancies, miscarriages and abortions. † Parity 
is the number of live- and stillborn children. 
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Table 2 shows the means (with standard deviations) or medians (with 
IQR) of the metabolic factors and hormone levels of the subpopulation of 
843 women.
Table 2 Age adjusted postmenopausal cardiovascular risk factors and hormone levels of 
the subpopulation of 843 women.
Mean ± SD
Postmenopausal cardiovascular risk factors
   Systolic blood pressure, mm/Hg 134.8 ± 20.0
   Diastolic blood pressure, mm/Hg 79.8 ± 10.6
   Glucose, mmol/L 4.53 ± 1.38
   Cholesterol, mmol/L 6.02 ± 1.01
   HDL-cholesterol, mmol/L 1.55 ± 0.39
   LDL-cholesterol, mmol/L 4.06 ± 0.94
   Fibrinogen, g/L 2.64 (2.23, 3.05)a
   CRP 1.15 (0.64, 2.25)a
Postmenopausal hormone levels
   Estrone, pg/mL 16.25 (10.94-22.94)a
   Estradiol, pg/mL 8.54 (6.19-11.65)a
   Free estradiol, pg/mL 0.25 (0.18-0.36)a
   DHEAS, ng/mL 496.8 (312.6-730.9)a
   SHBG, nmol/L 20.98 (12.95-30.07)a
   Androstenedione, ng/mL 0.52 (0.34-0.78)a
   Testosterone total, ng/mL 0.27 (0.19-0.36)a
   Free testosterone, pg/mL 5.70 (3.68-8.74)a
Abbreviations: CRP, C-reactive protein; DHEAS, dehydroepiandrosterone; SHBG, sex hormone 
binding globulin. Data presented as the mean ± standard deviation, unless stated otherwise: a Median 
(interquartile range).
In total, 750 women experienced an incident CHD event during 
follow-up, of which 45 were fatal. Cycle length was not associated with 
risk of CHD, HRs for regular menstrual cycle length of ≤26 days or ≥30 
days vs. 27-29 days were 0.90 [95% CI 0.75-1.07] and 0.91 [95% CI 0.70-1.18] 
respectively, a pattern that did not change after multivariate adjustment 
(Table 3). 
Compared to women with a regular cycle length of 27-29 days, 
women with irregular menstrual cycles had a borderline significant 
increased risk for CHD (Table 3, model 1), with an HR of 1.21 [95% CI 
0.99-1.46]. However, adding potential confounders (Table 3, model 2) to 
the model strengthened the association, and the HR became 1.31 [95% CI 
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1.07-1.59]. When restricting the analysis to women not using exogenous 
hormones, results were essentially similar in this group, and the formal 
test for interaction term was not statistically significant (P-value 0.32) 
(data not shown). 
In total, 533 cases were verified as incident cases of T2D. Women 
with irregular menstrual cycles had a non-significant increased risk for 
T2D (Table 3, model 2), with an HR of 1.20 [95% CI 0.94-1.53]. 
Table 3 Hazard ratio’s for menstrual cycle pattern and CHD and T2D risks among the 
total study population.
CHD cases 207 323 70 150
Model 1 0.90 (0.75, 1.07) Ref. 0.91 (0.70, 1.18) 1.21 (0.99, 1.46)
Model 2 1.01 (0.84, 1.21) Ref. 0.95 (0.73, 1.24) 1.31 (1.07, 1.59)
T2D cases 157 227 52 97
Model 1 0.97 (0.79, 1.19) Ref. 0.96 (0.71, 1.30) 1.11 (0.88, 1.41)
Model 2 1.14 (0.93, 1.40) Ref. 1.01 (0.75, 1.37) 1.20 (0.94, 1.53)
Abbreviations: HR, hazard ratio; CI, confidence interval; CHD, coronary heart disease; T2D, type 2 
diabetes. 
Model 1 = univariate (crude) model, model 2 = adjusted for age (continuous), body mass index 
(continuous), waist hip ratio (continuous), education level (low, middle, high), smoking (no, former, 
current), physical activity level (moderately inactive, moderately active, active), ever use of oral 
contraceptives (yes, no), ever use of hormone therapy (yes, no), menopausal status (premenopausal, 
postmenopausal, perimenopausal or unknown).
In the subpopulation of 843 women for whom laboratory 
measurements were done, irregular cycles were statistically significantly 
associated with higher glucose levels (0.34 mmol/L [95% CI 0.07-0.62]), 
but showed no relationship with blood pressure, lipid-, fibrinogen, and 
CRP levels after multivariate adjustment. No relationship was found 
between irregular cycles and all hormone levels measured (Table 4).
≤26 days 27-29 days ≥30 days Irregular
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
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Table 4 Adjusted* estimates for the relationship between menstrual cycle characteristics 
and cardiovascular risk factors and postmenopausal hormone levels among 843 women
Menstrual cycle characteristics
≤26 days 
n=233
β (95% CI)
27-29 days 
n=393
≥30 days 
n=93
β (95% CI)
Irregular 
n=124
β (95% CI)
CVD risk factors
SBP, mm Hg 2.01 (-1.17, 5.19) Ref. -0.79 (-5.26, 3.69) 2.89 (-1.11, 6.89)
DBP, mm Hg 0.33 (-1.35, 2.01) Ref. -0.16 (-2.51, 2.19) 1.24 (-0.89, 3.36)
Glucose, mmol/L 0.09 (-0.13, 0.31) Ref. 0.19 (-0.11, 0.50) 0.34 (0.07, 0.62)
Total cholesterol, mmol/L 0.09 (-0.08, 0.25) Ref. -0.08 (-0.31, 0.15) 0.04 (-0.17, 0.25)
HDL, mmol/L 0.02 (-0.04, 0.08) Ref. 0.01 (-0.07, 0.09) -0.04 (-0.11, 0.04)
LDL, mmol/L 0.01 (-0.14, 0.17) Ref. -0.06 (-0.27, 0.16) 0.01 (-0.18, 0.20)
Fibrinogen, g/L 0.02 (-0.09, 0.14) Ref. -0.04 (-0.20, 0.12) -0.02 (-0.16, 0.12)
CRP -0.60 (-1.23, 0.03) Ref. -0.65 (-1.53, 0.22) -0.04 (-0.83, 0.75)
Hormone levels
Estrone, pg/mL -1.60 (-5.89, 2.69) Ref. -0.28 (-6.30, 5.74) -0.60 (-5.97, 4.78)
Estradiol, pg/mL -1.30 (-3.96, 1.37) Ref. 0.14 (-3.58, 3.87) 0.27 (-3.07, 3.61)
Free estradiol, pg/mL -0.04 (-0.12, 0.04) Ref. -0.0003 (-0.11, 0.11) 0.01 (-0.09, 0.11)
DHEAS, ng/mL -14.5 (-72.7, 43.7) Ref. -6.07 (-87.3, 75.2) -47.9 (-120.8, 25.1)
SHBG, nmol/L 1.94 (-0.16, 4.04) Ref. -0.36 (-3.29, 2.56) -1.31 (-3.94, 1.31)
Androstenedione,ng/mL -0.03 (-0.09, 0.03) Ref. -0.00002 (-0.08, 0.08) -0.03 (-0.10, 0.05)
Testosterone total, ng/mL -0.01 (-0.04, 0.01) Ref. -0.01 (-0.05, 0.02) -0.01 (-0.04, 0.02)
Free testosterone, pg/mL -0.59 (-1.32, 0.14) Ref. -0.43 (-1.45, 0.59) 0.11 (-0.80, 1.03)
Abbreviations: CVD, cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; CI, confidence interval; HDL, high density lipoprotein; LDL, low density lipoprotein; CRP, 
C-reactive protein; DHEAS, dehydroepiandrosterone; SHBG, sex hormone binding globulin.
*All results are adjusted for age (continuous), body mass index (continuous), waist hip ratio 
(continuous), education level (low, middle, high), smoking (no, former, current), physical activity 
level (moderately inactive, moderately active, active), ever use of oral contraceptives (yes, no), ever 
use of hormone therapy (yes, no).
disCussion
Our data show that women with a history of irregular cycles have 
a 31% increased risk for CHD compared to women with a regular cycle 
length of 27-29 days, and a non-significant 20% increased risk of T2D. This 
association could not be explained by metabolic risk factors nor altered 
hormone levels. However, a menstrual cycle length of ≥30 days was not 
associated with risk of CHD or T2D. 
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The main advantages of this study are its prospective nature and 
the large sample size, and the availability of measured risk factors and 
sex hormone levels in a subpopulation of the cohort. Furthermore, after 
adjustment for age, baseline characteristics were similar for both cohorts. 
Therefore, it is not likely that any systematic differences in underlying 
methodology in both cohorts were present. The higher prevalence of 
short and irregular menstrual cycles in MORGEN is probably because 
most of these women were still menstruating at the time of enrolment, 
which makes it easier to recall information on their menstrual cycle 
characteristics. Women in the Prospect study, however, had to recall 
their menstrual cycle characteristics between the age of 30 and 40 years. 
Therefore, the prevalence of short and irregular cycles in Prospect may 
be underestimated. However, as adjusting for or stratifying by cohort 
yielded similar results, we believe it was justified to combine both cohorts 
to address our research questions. A limitation is that we had to rely on 
self-reported data on menstrual cycle characteristics, which are at risk for 
recall errors (20). However, it is unlikely that recall errors are related to 
CHD or T2D, if any misclassification occurred, it would have been non-
differential. 
The population attributable risk (PAR) of irregular cycles was 
21%, which is lower than the PAR of smoking (30%) and of a BMI>25 
(58%), but still suggests that irregular cycles have a moderate impact on 
the incidence of CHD in the entire population.
Since metabolic disturbances were a postulated mechanism 
through which irregular cycles might be linked to CHD, we studied 
whether irregular cycles were related to full blown disease by studying 
T2D (in the full cohort), and to postmenopausal metabolic risk factors (in 
a subpopulation of our cohort). As metabolic factors reflect effects that 
have operated over longer periods of times, it is not as much of a problem 
that we used postmenopausal levels for the latter analysis. 
Irregular cycles were only statistically significantly associated with 
higher glucose levels, which may result in impaired glucose tolerance, T2D 
and eventually CHD. Two studies indeed showed that highly irregular 
menstrual cycles were associated with an increased risk of T2D (2;3). In 
our population, the incidence of T2D was not increased significantly, and 
blood pressure, lipid- fibrinogen-, and CRP levels were not altered among 
irregular cycling women. Therefore, we do not believe that metabolic 
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factors are the only link between irregular cycles and CHD. This is in 
agreement with earlier studies, in which increased risk of coronary artery 
calcification (21) and CHD (4) among irregular cycling women were 
robust to adjustment for CVD risk factors also. These findings suggest 
that lifestyle interventions would probably not reduce the CHD risk in 
irregular cycling women to a large extent. 
Because PCOS is characterized by signs of hyperandrogenism, 
we also investigated whether irregular cycles were related to hormone 
concentrations in a subpopulation of our cohort. Irregular cycles were not 
related to any of the postmenopausal hormones measured. It would have 
been interesting to use premenopausal levels for this analysis, because 
this would have allowed us to identify women with PCOS. However, 
since a recent study showed it is also possible to identify PCOS women 
by using postmenopausal biochemical evidence of hyperandrogenemia 
and a history of irregular menstrual cycles (22), we considered it useful to 
study postmenopausal sex hormone levels as well. The latter study found 
that women with clinical features of PCOS had an elevated risk of CVD 
events. In an attempt to replicate these findings, we have used a similar 
definition to define clinical features of PCOS, but we did not find any 
association with CHD (results not shown). Altogether, the relationship 
between irregular cycles and CHD does not seem to be a reflection of long 
term effects on hormones. Until now, the role of endogenous hormone 
levels as a risk factor for CVD in postmenopausal women has not been 
well studied, and results are inconclusive. Whereas one study showed 
that levels of testosterone and estradiol did not predict cardiovascular 
mortality (23), another study found that estradiol and testosterone levels 
were nonsignificantly lower among postmenopausal diabetic women 
who died of CHD than diabetic women who remained free of CHD (24). 
Furthermore, among HT nonusers, lower SHBG and higher FAI levels 
were noted among postmenopausal women who developed CVD events 
than controls (25). 
Possible other mechanisms underlying our findings are 
speculative. Women with irregular cycles have either more anovular 
cycles or fewer ovulations in total, which leads to a less consistent 
pattern of progesterone secretion. Progesterone is related to premenstrual 
syndrome (PMS) (26;27), and PMS women are at greater risk for major 
depression (28). Since depression has been found to be related with CVD 
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(29), this may be a pathway through which irregular cycles are related 
to CHD. Furthermore, progesterone is related with increased levels of 
plasminogen activator inhibitor (PAI-1), D-dimer, but not with fibrinogen 
levels (30). High levels of plasma PAI-1 activity (31) and D-dimer (32) 
are associated with an increased risk for myocardial infarction and CHD 
respectively. Moreover, as progesterone stimulates vessel maturation 
in the mouse endometrium (33), a decreased influence of progesterone 
inhibits endometrial angiogenesis and reduced angiogenesis is known to 
be involved in the pathophysiology of many CVD (34). Finally, women 
with a less consistent pattern of progesterone secretion have lower 
bone mass (35). Since aortic calcification is likely to be more common 
among women with osteoporotic vertebral fractures (36), this may be an 
explanation for our findings too. 
In our study it is unknown what the exact cause of the irregular 
cycles was. Irregular cycles may be a marker for PCOS (37). We do not 
have information on diagnostic criteria of PCOS (hyperandrogenism, 
oligomenorrhea or amenorrhea, and polycystic ovaries on ultrasound) 
(38). However, the prevalence of irregular cycles in our study was 17%, 
which is more than double the prevalence of PCOS, which is thought to 
be 6.5-8% of women overall (39). Furthermore, PCOS is associated with 
sub- or infertility (40). In our population, however, parity and gravidity 
among irregular menstruating women were similar as in women with a 
regular cycle. Therefore, it is unlikely that PCOS could fully explain the 
occurrence of irregular cycles in our study.
Another common cause of irregular cycles is the hypothalamic 
anovulatory syndrome, which is often related to low body weight, 
undernutrition, excessive exercise and psychological stress (5). However, 
given the fact that only few women reported a very low calorie intake or 
an extreme physical activity level in our population, this syndrome is not 
likely to explain the occurrence of oligomennorrhea either.
Variations in the timing of menstrual bleeding may also occur as 
a result of the transitioning into menopause. However, as adjustment for 
menopausal status and a subgroup analysis in premenopausal women 
only yielded similar results, it is unlikely that the irregular cycles were 
a result of the menopause. Therefore, it is not likely that the irregular 
cycles in our study were caused by an underlying physical ailment, 
but rather by a normal variation in the duration of the menstrual cycle. 
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 Until now, the menstrual cycle length has only been investigated 
in relation to lipid levels (41) and T2D (2;3), but not in relation to CHD. 
Women with long cycles of ≥30 days had increased triglycerides levels, but 
no altered levels of total-, LDL-, and HDL cholesterol (41). Furthermore, 
very long cycles of ≥ 40 days or ≥ 3 months have been related to an 
increased risk of T2D. Although these very long cycles might be a marker 
for irregular cycles, our lack of association between longer menstrual 
cycles and T2D and CHD risks may be due to the fact that we used a less 
extreme definition of oligomenorrhea. Our finding that irregular cycles 
are associated with a moderately increased vascular risk is consistent 
with previous publications addressing this topic (4;21;42;43).
In conclusion, women with a history of irregular menstrual cycles 
have a significantly moderately increased risk of CHD, and tend to have 
an increased risk of T2D, which can not be explained by metabolic risk 
factors nor altered hormone levels. These findings suggest that lifestyle 
interventions would probably not reduce the CHD risk in irregular 
cycling women to a large extent.
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Chapter 4
Vasomotor symptoms are associated with a 
lower bone mineral density
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abstraCt 
The severity of vasomotor menopausal symptoms (VMS) has 
been hypothesized to be linked to a lower bone mineral density (BMD). 
We examined whether women with VMS are different from women 
without symptoms with regard to BMD. We used data from a population-
based sample of 5,600 women, aged 46 to 57 years and free from 
bone diseases, who participated in the first cross-sectional part of the 
Eindhoven Perimenopausal Osteoporosis Study between 1994 and 1995. 
Questionnaires at baseline were used to collect data on VMS and potential 
confounders. At baseline, BMD of the lumbar spine was measured using 
DXA. Linear regression analysis was used to analyse the data. Flushing 
was reported by 39% and night sweats by 38% of all women. The average 
BMD was 1.01 ± 0.14 g/cm2 and decreased with increasing frequency of 
flushing (P for trend <0.0001) and night sweats (P for trend 0.03). After 
multivariate adjustments for age, body mass index, menopausal status, 
smoking, education, exercise and hormone use, women with the highest 
frequency of symptoms had a 0.022 g/cm2 [95% CI -0.03, -0.01] lower BMD 
compared to asymptomatic women. Women who reported to have the 
highest frequency of night sweats had a 0.011 g/cm2 [95% CI -0.02, -0.001] 
lower BMD compared to women with no symptoms of night sweats. Our 
findings show that VMS are associated with a reduced bone density. It 
could be hypothesized that women with VMS might be more susceptible 
to the beneficial effects of estrogens, possibly by neutralizing the effect of 
estrogen fluctuations. Further research is needed to extend these findings 
to other estrogen sensitive end-organs. 
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introduCtion
We previously proposed that the presence of VMS may be an 
indicator of estrogen sensitivity of several end-organs, such as the 
bone, the vasculature, and the breast (1). This hypothesis was raised 
in an attempt to explain the large discrepancy between the findings of 
observational and experimental studies on the effects of hormone therapy 
(HT) and coronary heart disease (CHD) risk. Numerous observational 
studies demonstrated favourable effects of HT on cardiovascular disease, 
with risk reductions amounting to 50% (2-4). These findings, however, 
could not be corroborated by two large randomized clinical trials that 
showed null to even harmful effects of HT on the risk of cardiovascular 
events (5;6).
An important difference between observational studies and the 
clinical trials is that women in the observational studies tend to receive 
HT because of an indication, notably the presence and severity of VMS. In 
contrast, presence of VMS commonly was an exclusion criterion for trials 
because it was considered unethical to withhold treatment. Therefore, 
almost none of the trials have included women on the basis of the presence 
of this indication, whereas women enrolled in the observational studies 
will usually have started HT because they experienced VMS. This could 
indicate that women suffering from VMS differ from those without with 
respect to responses to HT or susceptibility to estrogens. 
Circumstantial evidence for this hypothesis shows that women 
with VMS have a lower level of plasma antioxidant activity, and an 
increased cardiovascular reactivity to stressful situations (7). With respect 
to the bone, it appears that women with frequent symptoms of sweating 
had a higher rate of bone loss of the forearm than women who had 
minor symptoms, and they also showed a greater gain in bone density 
after HT (8). The decline in circulating estrogen levels is considered to 
be a key factor in the occurrence of bone loss during menopause (9;10). 
Furthermore, the number of reproductive years, as an approximation of 
the duration of exposure to endogenous estrogens, is clearly related to 
bone mineral density (BMD) (11). 
The aim of the present study was to clarify whether women with 
VMS are different from women without symptoms with regard to BMD. 
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patients and methods
Population
The Eindhoven Perimenopausal Osteoporosis Study (EPOS) is a 
large population-based screening program with measurements of BMD 
in perimenopausal women. Between September 1994 and September 
1995, all women born between 1938 and 1948, living in the city of 
Eindhoven, The Netherlands, were invited to participate in this study. All 
participants gave written informed consent and the study was approved 
by two medical ethics committees. Details of the study population have 
been described before (12). For the present analysis, we used data of 6,700 
women, aged 46-57 years, who participated in the first cross-sectional 
part of the study. For this analysis, we excluded 1,052 women who did 
not provide information on VMS. Additionally, 3 women were excluded 
because BMD could not be measured. Finally, we excluded 45 women 
who reported to have a bone disease, leaving 5,600 women for the present 
analysis. 
Bone mineral density
BMD was measured at the lumbar spine (L1–4) by dual energy 
X-ray absorptiometry (DXA; S.A. Hologic Europe, Brussels, Belgium). 
For quality control, two calibrations were performed daily using a spine 
phantom. Vertebrae that could not be evaluated (due to calcification, 
operations, etc) were not included in the calculation of BMD (12).
Menopausal symptoms
To assess the frequency of flushing, three questions were asked, 
one on the number of days a participant experienced hot flushes in the 
previous week; one on the average frequency of hot flushes at one day; 
and one on the highest number of hot flushes at one day. Two questions 
were asked to assess the frequency of night sweats, one on the number 
of nights a participant wakes up in the previous week because of night 
sweating; and one on the frequency of waking up per night because of 
night sweating. From these questions, four categories of night sweats 
frequency were constructed: absent, low (having night sweats for 1 night 
per week and being awake once at night), moderate (having night sweats 
for more nights per week, but being awake once a night), and high (having 
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night sweats for more nights per week and also being awake more than 
once a night). In addition, four categories of flushing were constructed: 
absent, low (having flushes for less than or equal to 5 days per week, with 
an average of less or equal to 4 a day, with the highest amount of flushes 
at one day being less or equal to 6), moderate (having flushes for 2 till 7 
days per week, with an average of 6 or less a day, and the highest amount 
of flushes per day being less or equal to 12), and high (having flushes for 
more than 5 days a week, with an average of 3-7 a day, with the highest 
amount of flushes at one day being 4-30). In the Appendix a scheme is 
given with further details on how these categories for night sweats and 
flushing were constructed. 
Covariates
A general questionnaire containing questions on education, 
occupation, total duration of oral contraceptives (OCs) use and HT, 
menopausal status, type of menopause, drinking of alcohol, smoking 
habits and current physical exercise was administered. Height and weight 
were measured at enrolment and body mass index (BMI) was calculated as 
weight in kilograms divided by height in meters squared. The participants 
were asked about their formal education and whether education has been 
completed. From this information, the highest attained level of education 
was defined and classified into 4 categories: primary education, lower/
intermediate general and lower vocational education, higher general 
and intermediate vocational education, higher vocational education 
and university. OCs use was categorized as never (“no”), current/recent 
(“yes”, “yes, but shorter than 3 months ago”, or “yes, but 3 months till 
3 years ago”) or past (“yes, but more than 3 years ago”) use. Similarly, 
HT use was categorized as never (“no”), current/recent (“yes”, “yes, but 
shorter than 3 months ago”, or “yes, but 3 months till 3 years ago”) or past 
(“yes, but more than 3 years ago”) use. Menopausal status was classified as 
premenopausal if women had experienced at least one menstrual period 
in the last three months with no change in regularity of their menstrual 
bleeding. Women were classified as early perimenopausal if they had 
experienced at least one menstrual period in the last 3 months with 
some change in the regularity of their menstrual bleeding. Women were 
classified as late perimenopausal if they had experienced no menstrual 
bleeding in the last 3 months but some menstrual bleeding during the last 
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11 months. Early postmenopausal status was defined as amenorrhoea for 
at least 1 year but less than 3 years. Finally, late postmenopausal status 
was defined as amenorrhoea for more than 3 years (13). Menopausal 
status only applies to women not using hormones (HT+OAC) and not 
having used hormones for more than 3 years. Type of menopause was 
categorized as natural or surgical. Smoking behaviour was classified as 
never, past or current smoking and sport activities were classified as yes/
no. 
Data analysis
Distributions of personal characteristics, VMS, and BMD were 
expressed according to the distributions of flushing using mean ± SD 
for continuous normally distributed variables and as frequencies and 
percentages for categorical variables. 
Linear regression analyses were performed to evaluate the 
association between hot flushes, night sweats on the one hand and BMD 
on the other. Results are presented as the linear regression coefficient 
(β) with corresponding 95% confidence interval (95% CI). Univariate 
analyses (model 1) were performed to identify the crude relation between 
VMS and BMD, using the group of women with no symptoms as the 
reference category. Additionally, two multivariate models were fitted: 
model 2, including age and BMI, and model 3, incorporating model 2 
and menopausal status, smoking, use of OCs, use of HT, education and 
playing sports. Potential confounding variables were considered on the 
basis of the literature and analyses of their relation to both independent 
and dependent variables. We did not perform a stepwise guided analysis, 
because our goal was not to predict BMD as good as possible and to find 
the independent predictors, but rather to describe the association between 
VMS and BMD as valid (unconfounded) as possible.
HT is a successful therapy to reduce VMS, and it is probable 
that women with the worst symptoms would be given HT. Therefore, a 
possible modifying effect of sex hormone use on the relationship between 
menopausal symptoms and BMD was studied by restricting our analyses 
to the subgroup of women not using OCs or HT and by formally testing the 
interaction terms for VMS and OC or HT use respectively. Furthermore, 
as evidence showed that surgically induced women have a more rapidly 
decrease in BMD (14), and generally also experience more symptoms (15) 
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compared to women with a natural menopause, type of menopause may 
also modify our results. For this reason we repeated the analysis in the 
subgroup of women with a natural menopause and formally tested the 
interaction term for type of menopause and VMS with BMD.
Also, interaction terms were used to examine whether menopausal 
status was an effect modifier, as for instance early perimenopausal 
women have much less bone loss (13) and fewer symptoms than late 
perimenopausal women (16). 
Results were considered statistically significant at 2-sided P ≤ 0.05. 
Analyses were conducted using the Statistical Analysis System, version 
9.1 (SAS Institute, Inc.).
results
Symptoms of flushing were reported by 39% and night sweats by 
38% of all women. The mean age of the study group was 50.3 ± 2.4 y 
(range 46 to 57 y) and increased with increasing frequency of symptoms 
of flushing and night sweats. Mean BMI was 25.5, which is in line 
with comparable Dutch populations (17), but lower compared to US 
populations (18). The mean BMD was 1.01 ± 0.14 g/cm2.  Women who 
reported a high frequency of flushing were also more likely to have a high 
frequency of night sweats, to be a current smoker, and current/recent HT 
user and to have a higher BMI. However, these women were less likely to 
exercise. (Table 1) 
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Table 1 Characteristics of 5,600 Dutch women according to frequency of flushing
Frequency of flushing*
All women 
N=5,600
Absent  
n=3,390
Low 
n=957
Moderate 
n=520
High 
n=733
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age, years 50.3 ± 2.4 49.9 ± 2.3 50.6 ± 2.4 51.0 ± 2.5 51.0 ± 2.4
BMI, kg/m2 25.5 ± 4.4 25.3 ± 4.4 25.9 ± 4.7 26.3 ± 4.6 25.8 ± 4.2
Spine BMD, g/cm2 1.01 ± 0.14 1.02 ± 0.15 1.00 ± 0.14 0.99 ± 0.13 0.98 ± 0.14
N (%)† N (%) N (%) N (%) N (%)
Night sweating*
   Absent 3,461 (61.8) 2,785 (82.2) 416 (43.5) 119 (22.9) 141 (19.2)
   Low 406 (7.3) 204 (6.0) 143 (14.9) 41 (7.9) 18 (2.5)
   Moderate 644 (11.5) 213 (6.3) 192 (20.1) 130 (25.0) 109 (14.9)
   Severe 1,089 (19.5) 188 (5.6) 206 (21.5) 230 (44.2) 465 (63.4)
Gravidity 
   0 - 2 3,608 (64.5) 2,189 (64.9) 599 (63.1) 316 (61.6) 475 (65.3)
   > 2 1,988 (35.5) 1,184 (35.1) 350 (36.9) 197 (38.4) 253 (34.8)
Parity
   0 - 2 4,406 (78.7) 2,680 (79.1) 754 (78.9) 406 (78.2) 566 (77.3)
   > 2 1,190 (21.3) 709 (20.9) 202 (21.1) 113 (21.8) 166 (22.7)
Sports activities
   No 3,151 (57.3) 1,875 (56.0) 516 (55.0) 313 (61.7) 447 (63.2)
   Yes 2,347 (42.7) 1,471 (44.0) 422 (45.0) 194 (38.3) 260 (36.8)
Smoking status
   Never 1,826 (33.7) 1,167 (35.2) 298 (32.6) 167 (33.3) 194 (27.8)
   Past 1,745 (32.2) 1,089 (32.9) 294 (32.1) 154 (30.7) 208 (29.8)
   Current 1,856 (34.2) 1,056 (31.9) 323 (35.3) 181 (36.1) 296 (42.4)
HT use
   Never 4285 (77.3) 2725 (81.0) 727 (77.0) 374 (73.1) 459 (63.2)
   Past 181 (3.3) 77 (2.3) 44 (4.7) 20 (3.9) 40 (5.5)
   Current/recent 1080 (19.5) 562 (16.7) 173 (18.3) 118 (23.1) 227 (31.3)
OC use
   Never 1,040 (18.6) 570 (16.8) 169 (17.7) 128 (24.8) 173 (23.6)
   Past 3,797 (67.9) 2,290 (67.6) 669 (70.1) 339 (65.7) 499 (68.1)
   Current/recent 754 (13.5) 528 (15.6) 116 (12.2) 49 (9.5) 61 (8.3)
Education completed
   Primary 758 (13.9) 386 (11.6) 142 (15.5) 88 (17.4) 142 (20.0)
Lower/intermediate 
general, lower vocational
3,288 (60.3) 1.973 (59.3) 560 (61.0) 318 (62.9) 437 (61.6)
Higher general, 
intermediate vocational
726 (13.3) 475 (14.3) 122 (13.3) 49 (9.7) 80 (11.3)
Higher vocational, 
university
687 (12.6) 492 (14.8) 94 (10.2) 51 (10.1) 50 (7.1)
Abbreviations: SD, standard deviation; BMI, body mass index; BMD, bone mineral density; N, 
number; HT, hormone therapy use; OC, oral contraceptives use.
* Please see Appendix for how categories of flushing and night sweats were constructed. 
† Percentages include column percentages.
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Also, women in the late perimenopausal and early postmenopausal 
categories are more likely to have a high frequency of symptoms (Table 2). 
Furthermore, women who reported a high frequency of flushing or night 
sweats were more likely to have a surgical induced menopause compared 
to women with fewer symptoms (Table 3). 
Table 2 Frequency of vasomotor menopausal symptoms according to menopausal status*
Premenopausal 
n=634
Early peri-
menopausal 
n=1,099
Late peri-
menopausal 
n=385
Early post-
Menopausal 
n=538
Late post-
menopausal 
n=1,111
Flushing† N (%)‡ N (%) N (%) N (%) N (%)
Absent 583 (92.0) 774 (70.4) 157 (40.5) 203 (34.9) 609 (54.8)
Low 39 (6.2) 182 (16.6) 78 (20.3) 145 (24.9) 229 (20.6)
Moderate 7 (1.1) 71 (6.5) 61 (15.8) 103 (17.7) 113 (10.2)
High 5 (0.8) 72 (6.6) 89 (23.1) 131 (22.5) 160 (14.4)
Night sweats†
Absent 529 (83.4) 749 (68.2) 198 (51.4) 306 (52.6) 662 (59.6)
Low 40 (6.3) 86 (7.8) 36 (9.4) 45 (7.7) 75 (6.8)
Moderate 40 (6.3) 118 (10.7) 44 (11.4) 86 (14.8) 130 (11.7)
High 25 (3.9) 146 (13.3) 107 (27.8) 145 (24.9) 244 (22.0)
 
Abbreviations:N, number. * Menopausal status only applies to women not using hormones and not 
having used hormones for more than 3 years.† Please see Appendix for how categories of flushing and 
night sweats were constructed. ‡ Percentages include column percentages.
Table 3 Frequency of vasomotor menopausal symptoms according to type of menopause
Natural menopause 
n=5,113
Surgical menopause 
n=427
Flushing* N (%)† N (%)
Absent 3130 (61.2) 228 (53.4)
Low 863 (16.9) 86 (20.1)
Moderate 470 (9.2) 41 (9.6)
High 650 (12.7) 72 (16.9)
Night sweats*
Absent 3187 (62.3) 242 (56.7)
Low 379 (7.4) 23 (5.4)
Moderate 585 (11.4) 50 (11.7)
High 962 (18.8) 112 (26.2) 
Abbreviations: N, number. 
* Please see Appendix for how categories of flushing and night sweats were constructed. 
† Percentages include column percentages.
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Mean BMD decreased with increasing frequency of flushing 
(P for trend <0.0001). In the univariate analyses for flushing, women 
with the highest frequency of flushing had a 0.045 g/cm2 [95% CI -0.06, 
-0.03] lower BMD compared to women with no symptoms of flushing. 
After adjustment for age and BMI, women who reported to have a high 
frequency of flushing had a 0.037 g/cm2 [95% CI -0.05, -0.03] lower BMD 
compared to asymptomatic women. Additional adjustments for other 
confounders attenuated the results, with women reporting the highest 
frequency of symptoms having a 0.022 g/cm2 [95% CI -0.03, -0.01] lower 
BMD compared to asymptomatic women. (Table 4) 
Table 4 Adjusted estimates for the relationship between frequency of flushing and bone  
mineral density in 5,600 Dutch women
β g/cm2 (95% CI) P for trend
Model 1
Absent Ref.
Low -0.02566 (-0.04, -0.02)
Moderate -0.03840 (-0.05, -0.03)
High -0.04496 (-0.06, -0.03) <0.0001
Model 2
Absent Ref.
Low -0.02222 (-0.03, -0.01)
Moderate -0.03386 (-0.05, -0.02)
High -0.03733 (-0.05, -0.03) <0.0001
Model 3
Absent Ref.
Low -0.01357 (-0.02, -0.004)
Moderate -0.02256 (-0.04, -0.01)
High -0.02179 (-0.03, -0.01) <0.0001
Abbreviations: N, number; CI, confidence interval.
Model 1 = univariate (crude) model, model 2 = adjusted for age (continuous) and body mass index 
(continuous), model 3 = model 2 and menopausal status (pre-, early or late peri-, early or late 
postmenopausal), smoking (never, past, current), education (primary, lower/intermediate general, 
lower vocational, higher general, intermediate vocational, higher vocational, university), exercise 
(yes, no), oral contraceptive use (never, past, current/recent) and hormone therapy use (never, past, 
current/recent).
Mean BMD became lower with increasing frequency of sweating 
(P for trend 0.03). In the univariate analysis of night sweats, women with 
the highest frequency had a 0.024 g/cm2 [95% CI -0.03, -0.01] lower BMD 
compared to women with no night sweats. After adjustment for age 
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and BMI, women who reported to have the highest frequency of night 
sweats had a 0.021 g/cm2 [95% CI -0.03, -0.01] lower BMD compared to 
asymptomatic women. Adjustment for other confounders attenuated the 
results slightly; women with the highest frequency of night sweats had a 
0.011 g/cm2 [95% CI -0.02, -0.001] lower BMD compared to women with 
no night sweats. (Table 5) 
Table 5 Adjusted estimates for the relationship between frequency of night sweats and  
bone mineral density in 5,600 Dutch women
β g/cm2 (95% CI) P for trend
Model 1
Absent Ref.
Low -0.00299 (-0.02, 0.01)
Moderate -0.00903 (-0.02, 0.003)
High -0.02397 (-0.03, -0.01) <0.0001
Model 2
Absent Ref.
Low -0.00050 (-0.01, 0.01)
Moderate -0.00959 (-0.02, 0.002)
High -0.02147 (-0.03, -0.01) <0.0001
Model 3
Absent Ref.
Low -0.00233(-0.02, 0.01)
Moderate -0.00318 (-0.01, 0.008)
High -0.01098 (-0.02, -0.001) 0.03
Abbreviations: N, number; CI, confidence interval.
Model 1 = univariate (crude) model, model 2 = adjusted for age (continuous) and body mass index 
(continuous), model 3 = model 2 and menopausal status (pre-, early or late peri-, early or late 
postmenopausal), smoking (never, past, current), education (primary, lower/intermediate general, 
lower vocational, higher general, intermediate vocational, higher vocational, university), exercise 
(yes, no), oral contraceptive use (never, past, current/recent) and hormone therapy use (never, past, 
current/recent).
All results were essentially similar in the subgroup of women 
not using OCs or HT, and in the subgroup of women with a natural 
menopause, and formal tests using interaction terms were not statistically 
significant (P-values for effect modification of OCs=0.47 or HT=0.57 and 
type of menopause=0.27). Menopausal status was not an effect modifier 
either (P-value for interaction 0.55). (data not shown)  
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disCussion
This study shows that women with the highest frequency of 
symptoms of flushing or night sweats have a lower BMD compared to 
asymptomatic women. 
Before interpreting the results of this study some methodological 
issues need to be mentioned. First, the cross-sectional nature of our study 
makes it difficult to draw conclusions concerning causal pathways. Future 
analyses of longitudinal data will help to address this limitation. Second, 
for the classification of VMS, we relied on self-reported data. However, 
any misclassification of VMS is likely to be nondifferential and would 
tend to bias the results towards the null, implicating that our findings are 
underestimations of the true effect. 
We did not have any information about severity of VMS. It was 
shown that a higher BMI was not only associated with a higher frequency 
of symptoms but also with more severe symptoms. However, frequency 
and severity of symptoms were highly correlated (r = 0.97, p < 0.001) in 
this study (19), suggesting that frequency and severity of symptoms may 
have similar associations with outcome variables. However, it would 
be interesting to extend these findings to studies in which measures of 
symptom severity are available.
In our study, we collected data concerning VMS by means 
of a questionnaire, and a common problem with this method is the 
interpretation of retrospective data. However, in our study, the time of 
recall of 1 week is a relatively short period, and it is highly unlikely that 
this has resulted in an inaccurate frequency measure (20). Daily diaries 
can also be used to collect self-reported data. However, this method may 
also not provide the most accurate information about hot flushes because 
of poor compliance and a hoarding phenomenon (saving all entries for 
one moment per day/week, or not entering at all) (21).
In our population, the percentage of women with a high frequency 
of symptoms is relatively low compared to previously published 
data for the Netherlands (22), suggesting that this percentage is an 
underestimation of the true percentage. The women who did not fill in the 
symptom questions had a mean BMD similar to that of women reporting 
a high frequency of complaints. Therefore, exclusion of these women will 
probably have led to underestimation of the true association. 
Finally, 45 women were excluded as they reported to have a bone 
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disease. Since these women had a lower BMD, excluding them from the 
analyses might have caused a biased estimate. However, results were 
similar when we included these women in the analyses, suggesting that 
excluding these women probably did not hamper our results. The present 
study had a number of notable strengths. The community-based sampling 
used in the EPOS study improves generalizability. In addition, careful 
adjustments in multivariate models for a number of variables reduce the 
probability that the results are due to uncontrolled confounding. Also the 
large sample size strengthens the reliability of our study. 
Although a large proportion of late postmenopausal women 
still reported to have a high frequency of symptoms, women in the late 
perimenopausal and in the early postmenopausal phase had the highest 
frequency of symptoms. These findings are in line with a recent study 
showing that fewer years since menopause was associated with symptom 
persistence (16). Our result that women with a surgically induced 
menopause reported the highest frequency of symptoms is also in line 
with this recent study (16). 
We found that symptoms of flushing had a stronger effect on BMD 
than symptoms of night sweats. We do not have a clear pathophysiological 
explanation for this finding. It may be speculated that this is a result of 
more accurately reporting of flushing compared to night sweats, and 
that therefore the chances of finding an association with flushing were 
increased. Another reason might be that flushing may be indicative of 
more severe “aberrations” compared to night sweats. However, more 
research into this is necessary.
The prevalence of HT use in our study was around 20%. This 
relatively low percentage is likely to be explained by the fact that in 
The Netherlands, the main indication to prescribe HT is the presence 
of menopausal symptoms, and not to prevent chronic diseases (23). Of 
the 2,200 women with symptoms of flushing, only 25% appeared to be a 
current HT user, although the prevalence of current users became higher 
with increasing frequency of symptoms. These findings encourage the 
idea that Dutch women only start to use HT when they experience a very 
high frequency of symptoms. 
In addition to hormonal factors, several investigators have 
examined the role of non-hormonal factors in the etiology of hot flushes, 
of which BMI is a frequent studied measure. Earlier, it was generally 
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believed that women with a higher body weight have a reduced risk of 
hot flushes, due to the higher levels of estradiol in overweight women as 
a result of a greater conversion of androgens to estrogens in peripheral 
fat tissue. However, these studies have used measures like the number 
of kilograms overweight (24) or percent ideal weight (25), which are 
currently considered less appropriate. More recent studies showed that 
a higher BMI is in fact associated with an increased risk of hot flushes 
(26-28). This might be explained by the increasing insulation of increasing 
amounts of body fat, resulting in raises in body core temperature (29). 
Moreover, adipose tissue also produces leptin and tumor necrosis factor-α 
that can suppress estrogen secretion (30), and affect the thermoregulatory 
system (31), and thus impacting the risk for hot flushes. These studies are 
in line with our findings. 
In this study we set out to clarify the role of VMS in relation to 
estrogenic effects on end organs. We used BMD as an outcome, because it is 
well-known that estrogens have strong effects on BMD. Women experience 
an accelerated bone loss after the drop in endogenous estrogen levels at 
menopause (32). Earlier findings from the EPOS study showed that age at 
menopause and the number of reproductive years as approximations of 
the duration of exposure to endogenous estrogens are strongly associated 
with BMD (11). Furthermore, supplementation of exogenous estrogens by 
way of postmenopausal HT increases postmenopausal BMD and reduces 
the risk of fractures (33). 
During the perimenopausal phase, an acceleration of bone loss is 
seen with a rate of 3-10% (34). As the mean length of this phase is about 
4 years (35), the yearly rate of bone loss is estimated at 0.75-2.5%. In our 
study, we found that women with the highest frequency of flushing have 
a 2.2% lower BMD compared to women with no symptoms. Hence, this 
percentage is comparable to the effects of 1 year aging.
A hot flush is a subjective sensation of heat that is associated with 
objective signs of cutaneous vasodilatation and a subsequent drop in core 
body temperature. While it is a common symptom of the menopause, 
its mechanism is not fully understood. Small elevations in core body 
temperature have been shown to precede most hot flushes. Moreover, 
it has been shown that the thermoneutral zone, in which sweating and 
shivering do not take place, is reduced from 0.4ºC in women without 
symptoms to zero in postmenopausal women with hot flushes (36). This 
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appears to be mainly caused by a lowering of the sweating threshold 
(37). A substantial body of evidence indicates that neurotransmitter 
norepinephrine (NE) plays a central role in the thermoregulation, acting 
in part through α2-adrenergic receptors (38). For instance, several studies 
suggested that brain NE release is greater in women with hot flushes 
compared to asymptomatic women (39), indicating that in women with 
symptoms the sympathetic activation is higher. This is supported by 
results from experimental animal studies that showed that elevated levels 
of brain NE are correlated with a narrowing of the thermoneutral zone 
(40;41). It has been hypothesized that estrogen withdrawal associated 
with the menopause may affect the α2-adrenergic receptors (42). A 
reduction in inhibitory pre-synaptic α2-receptors leads to elevated central 
NE levels, which leads to inappropriate heat loss mechanisms and an 
increased occurrence of hot flushes (38). From an epidemiological point 
of view, however, estrogen withdrawal alone does not suffice to explain 
the occurrence of flushing. This is supported by studies that found that 
endogenous estrogen levels do not differ between women who have hot 
flushes and those who do not (43). Therefore, increasing attention has 
been given to the theory that hormonal fluctuations contribute to hot 
flushes, and not the absolute estrogen levels itself (15;44). Further support 
for this hypothesis was shown in a study in postmenopausal women with 
gonadal dysgenesis who never had normal estrogen levels and do not 
experience flushes except when estrogen is administered and withdrawn 
(45). In addition, even low dosages of estrogen have been shown to 
decrease the frequency and severity of VMS too (46), again suggesting 
that a low estrogen level is not the main cause for symptoms. It may be 
speculated that supplementation of estrogens results in a neutralization 
of the effect of large estrogen fluctuations, and thereby decreasing 
symptoms. However, more research into this is necessary. 
There are several indications that the sympathetic nervous system 
also plays a role in the regulation of bone mass. A number of studies 
have generally shown that increased sympathetic activity provokes bone 
loss via an increase in bone resorption and a decrease in bone formation 
(47). Decreased bone formation appears to be caused by the inhibition of 
osteoblastic activity by binding to β2-adrenergic receptors on osteoblasts 
(48). However, several studies also demonstrated the existence of the 
α-adrenoceptor in human and mouse osteoblasts (49). These observations 
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indicate that sympathetic stimulation is the link between hot flushes and 
a decreased bone mass. 
Another explanation for the association found in this study might 
be an impaired conversion of inactive vitamin D to the physiologically 
active form of vitamin D. This might be a result of a diminished kidney 
function, which could primarily be caused by an increased blood pressure 
(50). This is also in line with our previous findings, showing that women 
with VMS also have a higher systolic and diastolic blood pressure 
compared to asymptomatic women (51). Vitamin D deficiency results in 
impaired bone mineralization, and possibly contributes to osteoporosis 
(52).
Our results are compatible with findings reported previously that 
women with symptoms of sweating had a lower forearm BMD (8). The 
conflicting findings from the Rancho Bernardo Study, where the opposite 
effect was found with BMD at axial and appendicular sites, could be 
explained by the higher age of the study group in addition to the high 
rate of HT use in the most symptomatic group (53). Recently, data of 
the MORE trial showed that women in the placebo group with severe 
symptoms of flushing had a higher, although not significant, 3-year 
percentage annualized decline in BMD at the femoral neck and lumbar 
spine compared to women with less severe hot flushes. Lack of statistical 
significance may be explained by the small numbers in the highest class 
of flushing (54). 
In the study by Naessen et al. it was reported that in addition to 
a lower forearm BMD, women with sweating symptoms also had lower 
levels of serum estradiol, and gained more in BMD when they started HT 
(8). The most recent results of the WHI trial showed that HT does have 
a beneficial cardiovascular effect among the younger postmenopausal 
women (55). One may speculate that these findings could be explained 
by the fact that among the younger women a larger proportion will 
suffer from VMS. These women may be therefore more susceptible to the 
preventive benefits of HT.
Our data show that the presence and frequency of VMS is 
associated with BMD. These findings might indicate that women with 
symptoms might be more susceptible to the beneficial effects of estrogens, 
possibly by means of the neutralization of large estrogen fluctuations. 
Further research is needed to extend these findings to other estrogen 
sensitive end-organs.
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Chapter 5
Vasomotor menopausal symptoms and 
vascular risk

Chapter 5.1 
Menopausal complaints are associated with 
cardiovascular risk factors
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Chapter 5.1
abstraCt
It has been hypothesized that women with vasomotor symptoms 
differ from those without with respect to cardiovascular risk factors or 
responses to exogenous hormone therapy (HT). We studied whether 
the presence and extent of menopausal complaints is associated with 
cardiovascular risk profile. Data were used from a population-based 
sample of 5,523 women, aged 46 to 57 years, enrolled between 1994 and 
1995. Data on menopausal complaints and potential confounders were 
collected by questionnaires. Total cholesterol, systolic and diastolic 
blood pressures and body mass index (BMI) were measured. Linear and 
logistic regression analysis was used to analyse the data. Night sweats 
were reported by 38% and flushing by 39% of women. After multivariate 
adjustment, women with complaints of flushing had a 0.27 mmol/L 
[95% confidence interval (CI) 0.15, 0.39] higher cholesterol level, a 0.60 
kg/m2 [95% CI 0.35, 0.84] higher BMI, a 1.59 mm/Hg [95% CI 0.52, 2.67] 
higher systolic blood pressure, and a 1.09 mm/Hg [95% CI 0.48, 1.69] 
higher diastolic blood pressure compared to asymptomatic women. 
Flushing was also associated with hypercholesterolemia (OR 1.52 [95% 
CI 1.25, 1.84]) and hypertension (OR 1.20 [95% CI 1.07, 1.34]). Results 
were similar for complaints of night sweating. The findings support the 
view that menopausal complaints are associated with a less favourable 
cardiovascular risk profile. These findings substantiate the view that 
differences in presence of menopausal symptoms as a reason for using 
HT could explain discrepant findings between observational research and 
trials. 
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introduCtion
A number of observational studies demonstrated a protective 
association between hormone therapy (HT) and cardiovascular disease 
(CVD) (1-3). Placebo-controlled randomized trials, however, could not 
confirm a cardioprotective effect, and showed no overall benefit of HT on 
the risk of cardiovascular events (4;5).
Many potential reasons have been proposed to explain this 
apparent discrepancy between the observational studies and the trials. 
An important difference is that in the observational studies the most 
common reason to initiate HT was to relieve menopausal complaints. In 
contrast, in the trials women with severe complaints were either excluded 
or comprised only a minority of the total randomized population. Results 
of a recent subgroup analysis of the combined WHI trials showed that 
women who initiated HT closer to menopause had a reduced coronary 
heart disease (CHD) risk compared with the increase in CHD risk among 
women initiating HT more distant from menopause (6). Moreover, among 
women 50 to 59 years old at enrolment in WHI, end of trial coronary 
calcium scores were lower in women assigned to estrogens than in those 
assigned to placebo (7). A younger age is likely to be accompanied by a 
higher frequency of menopausal complaints. 
We previously hypothesized that women with vasomotor 
menopausal symptoms (VMS) may differ from those without with 
respect to cardiovascular risk factors or responses to exogenous HT 
(8). Indeed, women with menopausal complaints have a lower level of 
plasma antioxidant activity, and an increased cardiovascular reactivity 
to stressful situations (9). In addition, two studies demonstrated that hot 
flushes are associated with an increased blood pressure (10;11). Moreover, 
a recent subgroup analysis of the combined WHI trials showed that the 
higher risks of CHD in women more distant from menopause appeared 
to be concentrated in the small subset of women with moderate or severe 
VMS (6). 
We examined whether the presence of menopausal complaints is 
associated with CVD risk profile in a large community-based sample of 
perimenopausal women.
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subjeCts and methods
Population
The Eindhoven Perimenopausal Osteoporosis Study (EPOS) is a 
large screening program, established to assess determinants of low bone 
mineral density in perimenopausal women. The screening of women 
was carried out between September 1994 and September 1995. The study 
protocol was approved by two institutional review boards and all women 
provided written informed consent. A detailed description of the study 
population has previously been published (12). 
The participants eligible for this study consisted of 6,700 women, 
born between 1938 and 1948, aged 46-57 years, who took part in the first 
cross-sectional part of the study. We excluded 1,052 women who did not 
provide information on VMS, leaving 5,648 women. Another 9 women 
were excluded because their blood pressure could not be measured, and 
22 women were excluded, as their body mass index (BMI) could not be 
calculated, and 94 women were excluded as they reported a history of 
CHD prior to the baseline measurements, resulting in 5,523 women for 
the analysis. Of the 5,648 women of which we had information concerning 
complaints, total cholesterol had been measured in a random selected 
sub-sample of 2,068 women.
Vasomotor menopausal symptoms
To assess the frequency of flushing, three questions were asked, 
one on the number of days a participant experienced hot flushes in the 
previous week; one on the average frequency of hot flushes at one day; 
and one on the highest number of hot flushes at one day. Two questions 
were asked to assess the frequency of night sweats, one on the number 
of nights a participant wakes up in the previous week because of night 
sweats; and one on the frequency of waking up per night because of night 
sweats. From these questions, a dichotomous variable was created for the 
absence or presence of flushing or night sweats. 
Flushing or night sweating was present if women reported to have 
more than zero complaints during the previous week or if they answered 
‘yes’ on one of the questions. In addition, four categories of flushing were 
constructed: absent, having flushes for less than or equal to 5 days per 
week, with an average of less or equal to 4 a day, with the highest amount 
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of flushes at one day being less or equal to 6 (low), having flushes for 2 till 
7 days per week, with an average of 6 or less a day, and the highest amount 
of flushes per day being less or equal to 12 (moderate), and having flushes 
for more than 5 days a week, with an average of 3-7 a day, with the highest 
amount of flushes at one day being 4-30 (high). Moreover, four categories 
of night sweats frequency were constructed: absent, having night sweats 
for 1 night per week and being awake once (low), having night sweats 
for more nights per week, but being awake once a night (moderate) and 
having night sweats for more nights per week and also being awake more 
than once a night (high). 
Cardiovascular risk factors
The cardiovascular risk factors examined in the present study 
were: 1) total cholesterol levels, 2) hypercholesterolemia, 3) systolic and 
diastolic blood pressure, 4) hypertension and 5) BMI. Nonfasting blood 
samples were taken and total cholesterol levels were assessed by using 
an automatic enzymatic procedure (13) at the laboratory of the Diagnostic 
Center Eindhoven. Hypercholesterolemia was defined as a total 
cholesterol level ≥ 6.5 mmol/L and/or the usage of a lipid lowering drugs 
(14). Furthermore, systolic and diastolic blood pressures were measured 
in a standardized manner using a mercury manometer. One measurement 
was taken after the participant had been seated quietly in a comfortable 
posture, with feet flat on the floor, with the back supported and the arm 
supported at or as close to the level of the heart as possible. Hypertension 
was classified as a systolic blood pressure ≥ 140 and/or a diastolic blood 
pressure ≥ 90 and/or the usage of at least one antihypertensive drug. 
Weight and height were measured and BMI was calculated as weight in 
kilograms divided by height in meters squared.
 
Confounders 
Women completed questionnaires on education, pregnancies, total 
duration of oral contraceptive use and HT, drinking of alcohol, smoking 
behaviour and sport habits. In addition, information was obtained about 
the use of antihypertensive and cholesterol lowering therapy (yes/no). 
Sports activities were classified as yes/no. Smoking was categorized as 
never, past or current smoking and HT use were categorized as current, 
yes but more than 1 year ago and never use. The participants were asked 
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about their education and whether education had been completed. From 
this information, the highest attained level of education was defined 
and classified into 4 categories: primary education; lower/intermediate 
general and lower vocational education; higher general and intermediate 
vocational education; higher vocational education and university (15).
Data analysis
All statistical analyses were performed using the Statistical 
Analysis System, version 9.1 (SAS Institute, Inc.). Characteristics of the 
study population are described for all women and for women with and 
without complaints separately by means and standard deviations for 
normally distributed continuous variables and numbers and frequencies 
for categorical variables. 
Linear regression analysis was used to analyse the association 
between the independent variables complaints of flushing or night 
sweating and the continuous dependent variables cholesterol, systolic 
and diastolic blood pressure and BMI. The linear regression coefficients 
(β) are presented with 95% confidence intervals (CIs). Univariate 
analysis (model 1) was performed to identify the crude relation between 
menopausal complaints and cardiovascular risk factors using the group 
of women with no complaints as the reference category. Additionally, 
three multivariate models were used: model 2, including age, model 3, 
including smoking, education, sports activities and HT use, and model 4, 
incorporating model 3 and BMI. 
Because women with menopausal complaints might visit their 
physician more frequently, and therefore have a higher chance of blood 
pressure being measured and high blood pressure being detected, we 
repeated the blood pressure analyses in the subgroup of women who 
did not use antihypertensive drugs. HT is very effective in reducing 
the menopausal symptoms and it is likely that women with the worst 
symptoms would be prescribed HT. Thus, although HT use is strongly 
linked to the presence of menopausal complaints, the therapy does not 
cause flushing, but rather the opposite is true. Therefore, HT use is a 
different potential confounding factor than others. For this reason we 
repeated all analyses in the subgroup of women not using HT.
Logistic regression analysis was performed to examine the relation 
between menopausal complaints and presence of hypertension, with 
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using the same potential confounders as in the linear regression analyses. 
P-values below 0.05 were considered statistically significant. 
results
In total, 50% reported no symptoms of flushing and night sweats. 
Flushing only was reported by 12% and night sweats only by 11% of all 
women, while 27% reported to have both symptoms. Presence of night 
sweats was more common among women with symptoms of flushes. The 
mean age of the study group was 50.3 ± 2.4 y (range 46 to 57 y) and was 
higher in women with complaints. In addition, women with complaints 
were more likely to be a current smoker, current HT user and to be lower 
educated than asymptomatic women. Besides, these women were less 
likely to exercise. (Table 1) 
Cholesterol. Women with complaints of flushing had a 0.39 
mmol/L [95% CI 0.27, 0.50] higher cholesterol level than women without 
(Table 2, model 1). The difference remained after multivariate adjustment 
(Table 2, model 4) (0.27 mmol/L [95% CI 0.15, 0.39]). Findings were similar 
for complaints of night sweating. 765 women had hypercholesterolemia 
(Table 1). After multivariate adjustment (Table 2, model 4), complaints 
of flushing as well as night sweating were associated with an increased 
prevalence of hypercholesterolemia (ORs 1.52 [95% CI 1.25, 1.84], 1.40 
[95% CI 1.16, 1.69] respectively).  
Blood pressure. Adjusted for age (Table 2, model 2), women 
with complaints of flushing had a 1.46 mm/Hg [95% CI 0.40, 2.51] 
higher systolic blood pressure and a 1.03 mm/Hg [95% CI 0.44, 1.62] 
higher diastolic blood pressure compared to asymptomatic women. 
The differences remained after multivariate adjustment (Table 2, model 
3); 1.59 mm/Hg [95% CI 0.52, 2.67] for systolic blood pressure, and 1.09 
mm/Hg [95% CI 0.48, 1.69] for diastolic blood pressure. Inclusion of BMI 
(Table 2, model 4) in the adjustments attenuated the differences between 
women with and without complaints but most were still statistically 
significant (0.81 mm/Hg [95% CI -0.22, 1.84], 0.62 mm/Hg [95% CI 0.04, 
1.19 respectively]. In total, 2,830 women were hypertensive (Table 1). After 
adjustment for confounders (Table 2, model 3), presence of flushing was 
positively associated with hypertension (OR 1.20 [95% CI 1.07, 1.34]). 
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Table 1 Baseline characteristics of the study population of 5,523 women
Presence of flushing
All women 
(N=5,523)
Absent 
(n=3,362)
Present 
(n=2,161)
Mean ± SD Mean ± SD Mean ± SD
Age, years 50.2 ± 2.4 49.9 ± 2.3 50.8 ± 2.4
Body mass index, kg/m2 25.5 ± 4.4 25.3 ± 4.3 25.9 ± 4.5
Systolic blood pressure, mm/Hg 133.2 ± 19.4 132.2 ± 18.9 134.7 ± 20.1
Diastolic blood pressure, mm/Hg 83.9 ± 10.8 83.4 ± 10.7 84.8 ± 10.9
Cholesterol, mmol/L 6.2 ± 1.4 6.0 ± 1.3 6.4 ± 1.4
N (%)* N (%) N (%)
Night sweating
   Absent 3,418 (61.9) 2,759 (82.1) 659 (30.5)
   Present 2,105 (38.1) 603 (17.9) 1,502 (69.5)
Hypertension
   No 2,693 (48.8) 1,805 (53.7) 1,025 (47.4)
   Yes 2,830 (51.2) 1,557 (46.3) 1,136 (52.6)
Hypercholesterolemia
   No 1,303 (63.0) 856 (67.9) 447 (55.3)
   Yes 765 (37.0) 404 (32.1) 361 (44.7)
Sports activities
   No 3,104 (57.2) 1,860 (56.0) 1,244 (59.1)
   Yes 2,319 (42.8) 1,459 (44.0) 860 (40.9)
Hormone therapy use
   Never 4,224 (77.2) 2,698 (80.9) 1,526 (71.5)
   Past 175 (3.2) 75 (2.3) 100 (4.7)
   Current 1,072 (19.6) 563 (16.9) 509 (32.8)
Smoking status
   Never 1,810 (33.8) 1,163 (35.4) 647 (31.3)
   Past 1,718 (32.1) 1,080 (32.9) 638 (30.8)
   Current 1,826 (34.1) 1,042 (31.7) 784 (37.9)
Education completed
   Primary 738 (13.7) 378 (11.5) 360 (17.3)
Lower/intermediate general, lower 
vocational
3,236 (60.1) 1,950 (59.1) 1,286 (61.7)
   Higher general, intermediate      
   vocational
724 (13.5) 475 (14.4) 249 (11.9)
   Higher vocational, university 686 (12.7) 495 (15.0) 191 (9.2)
Abbreviations: SD, standard deviation; N, number.  
* Percentages include column percentages.
When finally adding BMI to the model (Table 2, model 4), the associations 
were attenuated, but still in the same direction with an OR of 1.11 [95% CI 
0.99, 1.25]. In the subgroup of 5,074 women who did not use antihypertensive 
drugs the associations were somewhat attenuated, but were all in the same 
direction, and for night sweats still statistically significant. Results were 
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similar for complaints of night sweating (Table 2).
BMI. In the crude analyses (Table 2, model 1) of flushing women 
with complaints had a 0.67 kg/m2 [95% CI 0.43, 0.91] higher BMI compared 
to asymptomatic women. Including age and other confounders (Table 
2, model 3) in the regression model weakened the results, but women 
reporting flushing still had a 0.60 kg/m2 [95% CI 0.35, 0.84] higher BMI. 
Again, these results were essentially the same for complaints of night 
sweats (Table 2).
When restricting the analysis to women not using HT, results were 
essentially similar in this group for all outcomes studied, and formal 
testing using interaction terms were not statistically significant (P-values 
ranged from 0.16 to 0.93).
Discussion
Our data show that women with complaints of flushing or night 
sweats have an unfavourable cardiovascular risk profile compared to 
women without VMS, with increased cholesterol levels, systolic and 
diastolic blood pressures and BMI. 
The main strengths of our study are its size, and the community-
based sampling that improves generalizability of the findings. A 
limitation is that menopausal symptoms can not be measured and we 
had to rely on self-reported data on complaints. However, assuming 
that misclassification is nonselective if present, the true relation between 
VMS and CVD risk profile may be even stronger. For the definition of 
hypertension, we relied on only one blood pressure measurement. As it 
has been shown that blood pressure most likely decreases with follow 
up visits due to regression to the mean, the prevalence of hypertension 
in our study may be overestimated (16). Therefore, these findings should 
be interpreted with caution. For the continuous measure it is not as 
much of a problem. Furthermore, for the analyses of blood pressure we 
presented the data for all women and additionally for women not treated 
for hypertension. There are pros and cons for both analyses. Restriction 
to women without hypertension treatment results in exclusion of women 
with the highest blood pressures, whereas including them results in 
underestimation of the true blood pressure of the treated women. 
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Table 2 Adjusted estimates for the relationship between presence of menopausal 
complaints and cardiovascular risk factors in 5,523 Dutch women 
Flushing Night sweats Flushing Night sweats
           Cholesterol β mmol/L (95% CI)              Hypercholesterolemia OR (95% CI)
Model 1
Present 0.39 (0.27,0.50) 0.32 (0.19,0.44) 1.71 (1.43, 2.05) 1.48 (1.23, 1.78)
Model 2
Present 0.31 (0.19,0.43) 0.27 (0.15,0.39) 1.56 (1.30, 1.88) 1.41 (1.17, 1.70)
Model 3
Present 0.29 (0.17,0.41) 0.26 (0.14,0.38) 1.55 (1.28, 1.87) 1.41 (1.17, 1.70)
Model 4
Present 0.27 (0.15,0.39) 0.25 (0.13,0.37) 1.52 (1.25, 1.84) 1.40 (1.16, 1.69)
        Systolic blood pressure β mm/Hg 
      (95% CI)
         Diastolic blood pressure β mm/Hg 
        (95% CI)
Model 1
Present 2.49 (1.45,3.54) 2.02 (0.97,3.07) 1.37 (0.79,1.96) 1.10 (0.51,1.68)
Model 2
Present 1.46 (0.40,2.51) 1.48 (0.43,2.52) 1.03 (0.44,1.62) 0.91 (0.32,1.50)
Model 3
Present 1.59 (0.52,2.67) 1.80 (0.74,2.87) 1.09 (0.48,1.69) 1.05 (0.46,1.65)
Model 4
Present 0.81 (-0.22,1.84) 1.13 (0.11,2.14) 0.62 (0.04,1.19) 0.65 (0.08,1.21)
       Systolic blood pressure in untreated 
       women β mm/Hg (95% CI)
          Diastolic blood pressure in untreated 
            women β mm/Hg (95% CI)
Model 1
Present 1.92 (0.87,2.97) 1.90 (0.85,2.96) 1.25 (0.66,1.84) 1.07 (0.47,1.67)
Model 2
Present 0.90 (-0.16,1.96) 1.40 (0.35,2.45) 0.91 (0.31,1.51) 0.90 (0.30,1.49)
Model 3
Present 1.03 (-0.05,2.11) 1.71 (0.64,2.77) 0.96 (0.35,1.58) 1.02 (0.42,1.63)
Model 4
Present 0.41 (-0.63,1.45) 1.20 (0.17,2.23) 0.58 (-0.01,1.16) 0.71 (0.13,1.29)
        Hypertension OR (95% CI)          Body mass index β kg/m2 (95% CI)
Model 1
Present 1.29 (1.15, 1.43) 1.26 (1.13, 1.41) 0.67 (0.43,0.91) 0.55 (0.31,0.79)
Model 2
Present 1.17 (1.05, 1.31) 1.20 (1.08, 1.34) 0.62 (0.38,0.86) 0.51 (0.27,0.75)
Model 3
Present 1.20 (1.07, 1.34) 1.24 (1.10, 1.38) 0.60 (0.35,0.84) 0.51 (0.28,0.75)
Model 4
Present 1.11 (0.99, 1.25) 1.17 (1.04, 1.31) - -
Abbreviations: CI, confidence interval, OR, odds ratio.
Model 1 = univariate (crude) model, model 2 = adjusted for age (continuous), model 3 = model 2 with 
smoking (never, past, current), education (primary, lower/intermediate general, lower vocational, 
higher general, intermediate vocational, higher vocational, university), sports activities (yes, no) and 
hormone use (no, yes, but > 3 years ago, yes), model 4 = model 3 and body mass index (continuous).
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The fact that the associations with menopausal complaints in the 
untreated women are comparable to those including the treated women 
suggests that blood pressure misclassification in the treated women is not 
a major issue. This might be due to suboptimal treatment. Finally, the 
cross-sectional nature of our study makes it difficult to draw conclusions 
regarding causal pathways. 
From the onset of menopause women may experience troubling 
symptoms that can include VMS (hot flushes and night sweats), vaginal 
dryness, depression, irritability, sleep disturbances and changes in libido. 
Evidence from longitudinal studies showed that particularly VMS and 
vaginal symptoms are causally related to the menopausal transition 
(17;18). For the present analyses we focused on VMS, as data suggest 
that vaginal and VMS are likely to reflect different pathophysiological 
processes (19). 
The prevalence of HT use in our study was around 20%, which is 
lower compared to the prevalence in countries such as the United States. 
The higher HT use in the United States could be a consequence of the fact 
that in this country, HT was at least in the past more frequently prescribed 
for the prevention of chronic diseases. In The Netherlands, however, the 
main indication for HT-use is the presence of menopausal complaints, 
and not preventive purposes (20). The latter is also consistent with our 
findings that women with VMS were more likely to be a current HT user 
compared to asymptomatic women.
In previous studies on HT, users tended to be more healthy and 
health conscious than non-users (21). This difference could have led to 
an overestimation of the beneficial effects and an underestimation of 
the risks associated with HT use. In our cohort, however, we found that 
compared to never users, current users were more likely to be lower 
educated (72.6% vs. 78.1% respectively), to have hypertension (50.8% vs. 
53.3% respectively), and less likely to be a never smoker (35.1% vs. 29.6% 
respectively) and to exercise (56.8% vs. 58.4% respectively). These findings 
support the view that current users did not had a better cardiovascular 
risk profile than the never users, and that the healthy user effect probably 
does not hamper our results. 
It is a matter of debate whether or not it is necessary to adjust 
for BMI in the analyses regarding blood pressure. In our view, BMI is 
an important determinant of blood pressure (22;23) as well as causally 
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related to endocrine and metabolic changes with menopause and factors 
in the causal pathway should not be included in the regression models. 
The fact that adding BMI to the model attenuated the results supports the 
view that BMI lies in the causal pathway and that adjustment has led to 
an overcorrection. 
We dichotomized VMS. However, when symptoms of night 
sweats and flushing were categorized into absent, low, moderate and high 
frequency, mean cholesterol, systolic and diastolic blood pressure and 
BMI were significantly higher with increasing frequency of symptoms 
(please see http://hyper.ahajournals.org.). 
While vaginal symptoms appear to be more closely related to 
changes in androgens (24), VMS are believed to be related to estrogen 
withdrawal that occurs with the menopause. The latter is supported by the 
fact that HT is the most successful therapy for reducing their occurrence 
(25). However, as there is no significant correlation between plasma 
hormone levels and the occurrence of VMS (26), estrogen withdrawal 
alone can not fully explain the cause of menopausal symptoms. A growing 
body of evidence supports the hypothesis that hot flushes result from a 
reduced thermoneutral zone (27). This reduction appears to be closely 
related to increased central nervous levels of norepinephrine (NE), partly 
through α2-adrenergic receptors (28). The involvement of NE in central 
thermoregulation and the etiology of hot flushes is supported by results 
from experimental and animal studies that showed that increased central 
nervous system levels of NE narrows the width of the thermoneutral 
zone (29;30). This is consistent with results from studies that showed 
that yohimbine, an α2-adrenergic antagonist, elevates brain NE (31) 
and ultimately triggers hot flushes (32). Thus, α2-adrenoceptors in the 
hypothalamus may be responsible for the events of the hot flush (28). There 
is a line of evidence that suggests that the dramatic estrogen variability 
during the menopausal transition is involved in the etiology of hot flushes 
(33;34). Because estrogens modulate the α2-adrenergic receptors (35), it is 
possible that the fluctuations in estrogen levels affect the α2-adrenergic 
receptors. A decline in inhibitory presynaptic α2-receptors would lead to 
increased NE levels, which leads to inappropriate heat loss mechanisms 
and an increased occurrence of hot flushes (28). 
The association of VMS with a more adverse cardiovascular risk 
profile could result from a primary increase in sympathetic nervous system 
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activity. It has been observed that increased BMI (36) and hypertension 
(37) are associated with an increased secretion of NE from sympathetic 
nerves (38). Activation of the sympathetic nervous system has also been 
shown to increase the production of serum lipids and lipoproteins by 
altering lipid metabolic processes (39), although some studies have found 
no consistent effect (40;41). These findings warrant further investigation.
For the present study we have studied the effects of BMI, lipids 
and blood pressure. It has to be acknowledged, however, that time 
windows of exposure and outcome may vary markedly for different CVD 
risk factors. BMI and lipids, for instance, most likely reflects effects that 
have operated over longer period of times. Blood pressure, however, is a 
measure that reacts to impulses much quicker. This could be reflected in 
our findings as cholesterol and BMI showed the most marked differences, 
while the findings for blood pressure were weaker. It would be interesting 
to replicate and extent these findings in studies in which other markers 
of CVD risk are used, such as lipoprotein subfractions, inflammatory 
markers, etc., and in which CHD events are the outcome.
There are only few known risk factors for menopausal hot flushes. 
It has long been thought that women with a higher body weight have 
a decreased risk for VMS during menopause because of conversion of 
androgens to estrogens in fat tissue (42;43). However, these studies are 
relatively old (42;43), included very small sample size (43), and used 
measures for fat mass that are currently considered less appropriate 
(body weight or percentage ideal weight instead of BMI or fat mass from 
DEXA-scanning) (42). According to more recent investigations, including 
our own, women with more body fat are more likely to report hot flushes 
(44-46). An explanation might be that increased body fat raises core body 
temperature (47), which triggers hot flushes. 
Our results show that the presence and frequency of VMS is 
associated with a more harmful CVD risk profile. These findings lend 
support to our hypothesis that women with VMS differ from those 
without with respect to CVD risk factors. Our results substantiate the 
view that differences in presence of menopausal symptoms as a reason 
for using HT could explain discrepant findings between observational 
research and trials. 
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Perspective
It is beyond dispute that HT is the best remedy for VMS (25). Hot 
flushes are likely to arise as a result of a reduced thermoregulatory zone 
(27), which is thought to be primarily caused by a heightened sympathetic 
nervous system (28-30). These alterations in the sympathetic nervous 
system might be mediated by the estrogen withdrawal associated with 
menopause (35). However, estrogen levels stay low throughout the 
menopause and most hot flush symptoms subside with time. Thus, 
although a decrease in estrogen concentration could be the first change, 
it might not directly cause symptoms (48). It may be speculated that 
estrogen fluctuations in addition to a low absolute estrogen level are 
causing the symptoms (33;34). Moreover, supplementation of HT 
might increase the absolute estrogen levels in such a way that estrogen 
fluctuations are not powerful enough anymore to cause symptoms. In the 
present study we found that VMS are associated with an unfavourable 
cardiovascular risk profile. Cardiovascular risk factors are also associated 
with an sympathetic nervous system activity (36-39). As a heightened 
sympathetic nervous system is thought to be involved in the occurrence 
of menopausal symptoms as well as in the etiology of the cardiovascular 
risk profile, it is plausible that the favourable effects of estrogens on the 
cardiovascular system could derive from the inhibition of the sympathetic 
nervous system (49;50). These findings should trigger further research.
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abstraCt 
We investigated whether vasomotor menopausal symptoms 
(VMS) are related to an adverse cardiovascular risk profile. Furthermore, 
we examined the association between estradiol levels and VMS, and 
whether an association between VMS and cardiovascular risk factors 
can be explained by estradiol levels. We used data from a Swedish 
population-based sample of 5,857 women, aged 50 to 64 years. Data on 
VMS and potential confounders were collected by questionnaires. Body 
mass index (BMI), waist hip ratio (WHR), glucose, blood pressure, lipid 
profile and estradiol levels were measured. General linear models and 
linear regression analysis were used to analyze the data. Symptoms of 
flushing/sweats were reported by 55% and sweats by 31% of all women. 
Estradiol concentrations were significantly lower in women with VMS. 
After multivariate adjustment, women with symptoms of sweats had 
a statistically significantly higher BMI, WHR, total cholesterol level, 
low density lipoprotein (LDL) level, triglycerides level, glucose level, 
systolic and diastolic blood pressure. These patterns did not change 
after correction for estradiol. The associations between flushing/sweats 
combined and cardiovascular risk factors were less pronounced. Women 
with VMS have a less favorable cardiovascular risk profile. Although 
estradiol levels were significantly lower among women with VMS, the 
increased cardiovascular risk profile cannot be explained by circulating 
estradiol levels.
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introduCtion
We previously proposed that women with vasomotor menopausal 
symptoms (VMS) may differ from those without with respect to 
cardiovascular risk factors (1). In a large community-based sample of 
perimenopausal women, we indeed found that women with symptoms 
of flushing or night sweats have increased cholesterol levels, systolic and 
diastolic blood pressures and body mass index (BMI) compared to women 
without VMS (2). Recent findings showing that hot flushes are associated 
with subclinical cardiovascular disease (3), further support the idea that 
VMS may signal underlying adverse vascular changes.
Because hot flushes accompany the decline of estrogens in the vast 
majority of peri- and postmenopausal women (4) and because estrogen 
therapy has shown beneficial treatment effects (5), there is little doubt 
that estrogens play a role in the genesis of hot flushes. However, the exact 
mechanism of how estrogen levels are related to VMS is still unknown. 
Furthermore, the estrogen deficit accompanying menopause is also 
thought to play a dominant role in the increased cardiovascular disease 
(CVD) risk after menopause (6). Therefore, the relationship between VMS 
and CVD risk factors may reflect the effect of decreasing estradiol levels.
The present study was set up to extend our findings in another 
population-based sample of perimenopausal women in whom also other 
markers of CVD risk were measured, such as lipoprotein sub fractions and 
glucose. Furthermore, we aimed at examining the association between 
circulating estradiol levels and VMS, and whether a possible association 
between VMS and cardiovascular risk factors can be explained by estradiol 
levels. 
subjeCts and methods
Population
The present research was conducted within the population–based 
“The Women’s Health in the Lund Area (WHILA) Study”. The aim of the 
WHILA study is to evaluate women’s health status and their lifestyles 
and analyze the relevant social and/or medical risk factors for current 
and future diseases. The WHILA study covers all women (N=10,766) 
born between December 2, 1935, and December 1, 1945, and living 
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in the Lund area, Sweden, by December 1, 1995. Women were invited 
to a health screening procedure, which took place between 1996 and 
2000. The women were identified via a population register comprising 
all inhabitants. Details from the study have been published elsewhere 
(7). Informed consent was obtained and the ethics committee at Lund 
University approved the study. 
Of the total population of 10,776 women, 6,917 (64.2%) completed 
the generic questionnaire and underwent a physical and laboratory 
assessment, and were therefore eligible for the present study. We excluded 
819 women who did not provide information on VMS, leaving 6,098 
women. Another 15 women were excluded because their blood pressure 
could not be measured, 18 women were excluded as their waist to hip ratio 
(WHR) could not be calculated, 104 women were excluded because their 
lipid profile could not be measured, and 5 women were excluded due to 
a missing glucose level. Finally, 99 women were excluded because they 
reported a history of CVD prior to the baseline measurements, resulting 
in 5,857 women for the analysis. For the glucose analysis we excluded the 
women who reported to have diabetes at baseline (n=107), as diabetics 
mainly are treated because of a high glucose level and therefore their 
current glucose level is not a reflection of their true level, leaving 5,750 
women for analysis of glucose. 
Baseline measurements 
Women completed questionnaires concerning demographic 
background, physical activity, dietary habits, medical history, family 
history of diseases (parents or siblings with events before the age of 
60 years), reproductive events, menopausal status, smoking habits, 
and education. In addition, women were asked about the use of anti-
hypertensive medication (ATC-code C02) (yes/no). Physical activities 
during leisure time were categorized as low or regular activity. Smoking, 
oral contraceptives (OCs) use, and HT use were categorized as never, past 
or current. Menopausal status at enrolment was defined as follows: women 
were ‘premenopausal’ if they reported having regular natural menses; 
‘postmenopausal’ if they reported not having had menses over the past 
12 months; and ‘perimenopausal/unknown’ if they were inconsistent in 
their answers regarding regular menses and not having had menses over 
the past 12 months, therefore assuming they were having irregular cycles. 
Women with incomplete or missing questionnaire data, or who reported 
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current use of OCs or HT, were classified as perimenopausal/unknown 
if they were between 46 and 55 years of age, and postmenopausal if they 
were older than 55 years (8). Education was categorized into three groups; 
primary school (in total 7 years), secondary school (in total 12 years), and 
university degree, according to the highest attained level of education 
stated by the respondent. 
Vasomotor symptoms 
To assess the presence of VMS, two questions were asked. The 
first question was “Do you have problems of sweats/hot flushes?” and 
was asked in the reproductive history section of the questionnaire. The 
second question was “Did you experience symptoms of sweats during 
the preceding three months?” and was asked in a general section 
concerning somatic symptoms. This section also contained questions 
on other symptoms such as feeling cold, headache, feeling of tiredness, 
sleeping problems, irritability and depression. Both questions were to be 
answered with yes or no. The questionnaire was a composite of several 
pre-existing and validated questionnaires (9). Some questions were 
validated in a subset prior to general mailing. A specially trained midwife 
nurse collected the questionnaires at the time of the examinations and 
personally interviewed each woman, and potential problems were 
addressed. At the interview, 19% of the subjects made some corrections 
in their written answers, which was mainly due to thoughtless mistakes 
rather than to misunderstanding of the text. The questionnaires were 
answered before the blood samples were drawn.
Cardiovascular risk factors
Blood pressure was measured twice at the right arm after 15 
minutes rest in seated position using a mercury sphygmomanometer 
with a cuff size adjusted to the circumference of the arm. The average of 
two recordings, measured to the nearest 2 mmHg, was the blood pressure 
used for the statistical analyses. Body weight and height were measured 
and BMI was calculated as weight in kilograms divided by height in 
meters squared. All women were measured in underwear and bare footed. 
All instruments were calibrated on a daily basis. WHR was obtained by 
dividing waist circumference in centimetres by hip circumference in 
centimetres.
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Laboratory analysis
Non fasting serum levels of the lipid profile and blood glucose 
were measured by a Cholestech LDX-instrument (Cholestech Corporation, 
Hayward, CA, USA) on capillary whole blood. The instrument measured 
values within a range for serum cholesterol between 2.59 and 12.90 
mmol/L, for serum high density lipoprotein (HDL) between 0.39 and 
2.59 mmol/L and for serum triglycerides between 0.51 and 7.34 mmol/L. 
Serum low density lipoprotein (LDL) was calculated. 
KRYPTOR®-Estradiol 17B (BRAHMS Ag, Henningsdorf, 
Germany) were used for automated immunofluoroscent assays of estradiol 
in human serum. KRYPTOR® uses TRACE® (Time Resolved Amplified 
Cryptate Emission) technology, based on a non-radiative transfer of 
energy. Detection limits and coefficients of variations for estradiol were 
3.5 pmol/L and 7.1% respectively. All measurements were carried out in 
the same laboratory and by the same examiners.
Data analysis
All statistical analyses were performed using the Statistical 
Analysis System, version 9.1 (SAS Institute, Inc.). Characteristics of the 
study population are described for all women and for women with 
and without symptoms separately by means and standard deviations 
for normally distributed continuous variables and frequencies and 
percentages for categorical variables. 
Estradiol concentrations were logarithmically transformed. For 
women with and without VMS, the geometric means and 95% confidence 
intervals (CIs) of estradiol levels were calculated. Next, general linear 
models were used to examine the association between estradiol levels and 
presence of VMS, adjusted for age and hormone use. 
Linear regression analyses was used to estimate the relation of 
symptoms of flushing/sweats combined or sweats only with BMI, WHR, 
cholesterol, HDL, LDL, triglycerides, glucose, systolic and diastolic blood 
pressure. The linear regression coefficients (β) are presented with 95% 
CIs. Univariate analysis (model 1) was performed to identify the crude 
association between VMS and cardiovascular risk factors using the group 
of women with no symptoms as the reference category. We adjusted 
regression models for age, smoking, education, physical activity during 
leisure time and menopausal status (model 2). To elucidate whether and 
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to what extent the observed associations of VMS and cardiovascular risk 
factors might be explained by intermediates, further analysis also adjusted 
for estradiol (model 3) and BMI (model 4). 
To rule out the influence of the use of antihypertensive medication 
on blood pressure, we repeated the blood pressure analyses in women 
not using antihypertensive drugs. Furthermore, evidence showed that 
women with a surgical menopause have an increased risk of CVD, and 
generally also experience more symptoms compared to women with 
a natural menopause (10). Therefore, we studied a possible modifying 
effect of type of menopause by restricting our analyses to the subgroup of 
women with a natural menopause. HT is a successful therapy to reduce 
VMS, and it is plausible that women with the most severe symptoms 
would be given HT. Therefore, sex hormone use may also modify our 
results. For this reason, we also repeated all analyses in the subgroup of 
women not using HT or OCs. 
results
In total, 55% of all women reported symptoms of flushing/sweats 
and 31% reported symptoms of sweats only. The mean age of the total 
group was 56.3 ± 3.0 years (range 50 to 64 years) and was lower in women 
with VMS. Moreover, symptomatic women were less likely to have 
regular physical activity during leisure time and to be highly educated 
compared to asymptomatic women. (Table 1) 
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Table 1 Characteristics of the study population of 5,857 women according to presence of 
hot flushes/sweats and sweats only
Presence of hot flushes/sweats Presence of sweats
All women
(N=5,857)
Absent
(N=2,637)
Present
(N=3,220)
Absent
(N=3,979)
Present
(N=1,878)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age, years 56.3 ± 3.0 56.5 ± 3.1 56.1 ± 2.9 56.5 ± 3.0 55.9 ± 2.9
BMI, kg/m2 25.3 ± 4.1 25.2 ± 4.2 25.4 ± 4.1 25.1 ± 4.0 25.8 ± 4.3
Waist/hip ratio 0.78 ± 0.06 0.78 ± 0.06 0.78 ± 0.06 0.77 ± 0.06 0.79 ± 0.07
SBP, mm/Hg 131.9 ± 17.1 132.4 ± 17.1 131.6 ± 17.0 131.6 ± 16.9 132.7 ± 17.4
DBP, mm/Hg 85.0 ± 9.3 85.0 ± 9.2 85.0 ± 9.4 84.8 ± 9.2 85.5 ± 9.4
TC, mmol/L 5.9 ± 1.1 5.9 ± 1.1 6.0 ± 1.1 5.9 ± 1.1 6.0 ± 1.07
HDL, mmol/L 1.74 ± 0.43 1.75 ± 0.43 1.74 ± 0.43 1.75 ± 0.42 1.73 ± 0.44
LDL, mmol/L 3.46 ± 0.99 3.44 ± 0.99 3.49 ± 0.97 3.44 ± 0.98 3.53 ± 0.97
Triglycerides, 
mmol/L
1.62 ± 0.76 1.60 ± 0.75 1.63 ± 0.77 1.57 ± 0.74 1.70 ± 0.80
Glucose, mmol/L 6.15 ± 1.40 6.18 ± 1.50 6.12 ± 1.31 6.12 ± 1.38 6.21 ± 1.44
N (%)* N (%) N (%) N (%) N (%)
Hysterectomy
   No 5,186 (88.5) 2,340 (88.7) 2,846 (88.4) 3,524 (88.6) 1,662 (88.5)
   Yes 671 (11.5) 297 (11.3) 374 (11.6) 455 (11.4) 216 (11.5)
Oophorectomy
   No 5,271 (93.3) 2,383 (93.6) 2,888 (93.0) 3,579 (93.3) 1,692 (93.4)
   Yes 378 (6.7) 162 (6.4) 216 (7.0) 259 (6.8) 119 (6.6)
Menopausal status
   Premenopausal 444 (7.6) 306 (11.6) 138 (4.3) 319 (8.0) 125 (6.7)
   Postmenopausal 4,516 (77.1) 1,1986 (75.3) 2,530 (78.6) 3,035 (76.3) 1,481 (78.9)
Perimenopausal/
unknown
897 (15.3) 345 (13.1) 552 (17.1) 625 (15.7) 272 (14.5)
Physical activity
   Low 3,284 (56.7) 1,450 (55.6) 1,834 (57.6) 2,161 (55.0) 1,123 (60.5)
   Regular 2,505 (43.3) 1,157 (44.4) 1,348 (42.4) 1,772 (45.1) 733 (39.5)
Hormone therapy use
   Never 2,483 (42.4) 1,278 (48.5) 1,205 (37.4) 1,601 (40.2) 882 (47.0)
   Past 1,430 (24.4) 579 (22.0) 851 (26.4) 939 (23.6) 491 (26.1)
   Current 1,944 (33.2) 780 (29.6) 1,164 (36.2) 1,439 (36.2) 505 (26.9)
Smoking status
   Never 3,763 (64.3) 1,734 (65.8) 2,029 (63.1) 2,599 (65.4) 1,164 (62.1)
   Past 1,133 (19.4) 482 (18.3) 651 (20.2) 763 (19.2) 370 (19.7)
   Current 956 (16.3) 419 (15.9) 537 (16.7) 614 (15.4) 342 (18.2)
Education completed
   Basic 982 (17.1) 435 (16.8) 547 (17.3) 626 (16.0) 356 (19.3)
   Secondary 2,714 (47.1) 1,162 (44.8) 1,552 (49.0) 1,814 (46.3) 900 (48.9)
   University 2,062 (35.8) 995 (38.4) 1,066 (33.7) 1,476 (37.7) 586 (31.8)
Abbreviations: SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; TC, total cholesterol; N, number. 
* Percentages include column percentages.
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Estradiol. After adjustment for age and hormone use, estradiol 
levels were significantly lower in the women with flushes/sweats as 
compared to the women without (30.5 [95% CI 29.2, 32.0] vs. 36.7 [95% CI 
34.8, 38.6] pmol/L respectively, Table 2, model 3). Estradiol concentrations 
were also significantly lower in the women with symptoms of sweats 
only as compared to asymptomatic women (28.1 [95% CI 26.4, 29.8] vs. 
35.8 [95% CI 34.4, 37.3] pmol/L respectively, Table 2, model 3).
Table 2   Unadjusted and adjusted geometric mean of estradiol levels (pmol/L) by 
symptoms of flushing and sweats
Presence of hot flushes/sweats Presence of sweats
Absent Present Absent Present
Geometric mean 
(95% CI)
Geometric mean 
(95% CI)
Geometric mean 
(95% CI)
Geometric mean 
(95% CI)
Model 1 34.0 (32.1-36.0) 32.5 (30.9-34.1) 36.4 (34.8-38.2) 27.0 (25.3-28.8)a
Model 2 34.6 (32.7-36.6) 32.0 (30.4-33.6) 37.1 (35.5-38.8) 26.0 (24.3-27.7)a
Model 3 36.7 (34.8-38.6) 30.5 (29.2-32.0)b 35.8 (34.4-37.3) 28.1 (26.4-29.8)a
Abbreviation: CI, confidence intervals. 
Model 1 = univariate (crude) model; model 2 = adjusted for age (continuous); model 3 = model 2 and 
oral contraceptives use (never, past, current) and hormone therapy (HT) use (never, past, current).
a P-value < 0.0001 b P-value 0.02
BMI & WHR. Symptoms of flushing/sweats were associated with 
increased BMI, but not with WHR. Symptoms of sweats were associated 
with increased BMI as well as WHR. After multivariate adjustment 
women reporting sweats had a 0.71 kg/m2 [95% CI 0.48, 0.93] higher BMI 
and a 0.012 [95% CI 0.008, 0.015] higher WHR compared to women with 
no sweats. (Table 3, models 2) Including estradiol in the models did not 
change the results (Table 3, model 3).
Lipids. Women with symptoms of flushing/sweats had statistically 
higher total cholesterol and LDL levels compared to asymptomatic women. 
No statistically significant associations were found for flushing/sweats 
and HDL and triglycerides. Symptoms of sweats only were associated 
with a 0.03 mmol/L [95% CI -0.05, -0.004] lower HDL level (Table 3, model 
1). However, this difference did not remain after multivariate adjustment 
(-0.02 mmol/L [95% CI -0.04, 0.004]) (Table 3, model 2). However, after 
multivariate adjustment, symptoms of sweats only was associated with 
a 0.14 mmol/L [95% CI 0.08, 0.20] higher total cholesterol level, a 0.10 
mmol/L [95% CI 0.05, 0.15] higher LDL level and a 0.12 mmol/L [95% 
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CI 0.08, 0.16] higher triglycerides level (Table 3, models 2). Additionally 
including estradiol (Table 3, models 3) and BMI (Table 3, models 4) in the 
models did not materially change the results. 
Blood pressure. Women reporting symptoms of flushing/sweats 
had a lower systolic blood pressure, although these results did not reach 
statistical significance (Table 3). No association was found for flushing/
sweats and diastolic blood pressure. However, women with symptoms of 
sweats only had a 1.68 mm/Hg [95% CI 0.74, 2.62] higher systolic blood 
pressure and a 0.79 mm/Hg [95% CI 0.27, 1.31] higher diastolic blood 
pressure (Table 3, models 2) compared to asymptomatic women. Results 
were not altered after including estradiol in the models (Table 2, models 
3). Inclusion of BMI (Table 3, models 4) in the adjustments attenuated 
the differences between women with and without sweats but remained 
significant for sweats only and systolic blood pressure (1.51 mm/Hg [95% 
CI 0.55, 2.47]). Results were similar in the subgroup of 5,304 women who 
did not use antihypertensive drugs. 
Glucose. We did not find an association for symptoms of flushing/
sweats and glucose level. Symptoms of sweats only were associated with 
a 0.07 mmol/L [95% CI 0.01, 0.14] higher glucose level (Table 3, model 
1). Including confounders or estradiol level (Table 3, model 2 + 3) in the 
regression model did not change these results. After including BMI to the 
model (Table 3, model 4) the estimate for sweats only was still in the same 
direction, but the CI became wider (0.06 mmol/L [95% CI -0.01, 0.13]).
All results were essentially similar in the subgroup of women with 
a natural menopause, and in the subgroup of women not using OCs or 
HT (data not shown).  
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Table 3   Adjusted estimates for the relationship between presence of vasomotor symptoms 
and cardiovascular risk factors
Models
Hot flushes/
sweats
Sweats Hot flushes/sweats Sweats
BMI β kg/m2 (95% CI) WHR β (95% CI)
Model 1 0.18 (-0.03, 0.39) 0.71 (0.48, 0.93) 0.002 (-0.001, 0.006) 0.012 (0.008, 0.015)
Model 2 0.21 (0.00, 0.42) 0.71 (0.48, 0.93) 0.003 (-0.001, 0.006) 0.012 (0.008, 0.015)
Model 3 0.21 (-0.01, 0.43) 0.69 (0.46, 0.92) 0.003 (-0.001, 0.006) 0.011 (0.008, 0.015)
Total cholesterol β mmol/L (95% CI) HDL β mmol/L (95% CI)
Model 1 0.06 (0.01, 0.12) 0.14 (0.08, 0.20) -0.003 (-0.02, 0.02) -0.03 (-0.05, -0.004)
Model 2 0.06 (0.01, 0.12) 0.14 (0.08, 0.20) 0.001 (-0.02, 0.02) -0.02 (-0.04, 0.004)
Model 3 0.05 (-0.01, 0.10) 0.12 (0.06, 0.18) 0.003 (-0.02, 0.03) -0.02 (-0.04, 0.005)
Model 4 0.04 (-0.02, 0.10) 0.11 (0.05, 0.17) 0.007 (-0.01, 0.03) -0.002 (-0.03, 0.02)
LDL β mmol/L (95% CI) Triglycerides β mmol/L (95% CI)
Model 1 0.05 (0.002, 0.10) 0.10 (0.05, 0.16) 0.03 (-0.01, 0.07) 0.13 (0.09, 0.17)
Model 2 0.06 (0.004, 0.11) 0.10 (0.05, 0.15) 0.02 (-0.02, 0.06) 0.12 (0.08, 0.16)
Model 3 0.04 (-0.01, 0.09) 0.08 (0.03, 0.14) 0.02 (-0.02, 0.06) 0.12 (0.08, 0.17)
Model 4 0.03 (-0.02, 0.09) 0.07 (0.01, 0.13) 0.01 (-0.03, 0.05) 0.09 (0.05, 0.13)
 
 
SBP β mm/Hg (95% CI) DBP β mm/Hg (95% CI)
Model 1 -0.76 (-1.64, 0.12) 1.13 (0.19, 2.06) -0.03 (-0.50, 0.45) 0.69 (0.18, 1.20)
Model 2 -0.38 (-1.27, 0.50) 1.68 (0.74, 2.62) -0.02 (-0.50, 0.47) 0.79 (0.27, 1.31)
Model 3 -0.18 (-1.09, 0.74) 2.07 (1.10, 3.05) -0.001 (-0.51, 0.50) 0.88 (0.34, 1.41)
Model 4 -0.35 (-1.25, 0.55) 1.51 (0.55, 2.47) -0.12 (-0.61, 0.37) 0.48 (-0.05, 1.00)
SBP in untreated women β mm/Hg 
(95% CI)
DBP in untreated women β mm/Hg 
(95% CI)
Model 1 -0.71 (-1.61, 0.20) 0.93 (-0.04, 1.90) 0.07 (-0.43, 0.56) 0.63 (0.10, 1.16)
Model 2 -0.34 (-1.26, 0.57) 1.55 (0.57, 2.53) 0.06 (-0.44, 0.57) 0.74 (0.20, 1.28)
Model 3 -0.16 (-1.11, 0.78) 1.92 (0.91, 2.93) 0.05 (-0.47, 0.57) 0.86 (0.30, 1.42)
Model 4 -0.31 (-1.24, 0.62) 1.40 (0.41, 2.40) -0.06 (-0.56, 0.45) 0.48 (-0.07, 1.02)
Glucose β mmol/L (95% CI)
Model 1 -0.02 (-0.08, 0.04) 0.07 (0.01, 0.14)
Model 2 -0.01 (-0.07, 0.05) 0.08 (0.01, 0.14)
Model 3 -0.01 (-0.07, 0.05) 0.07 (0.01, 0.14)
Model 4 -0.01 (-0.08, 0.05) 0.06 (-0.01, 0.13)
Abbreviations: BMI, body mass index; CI, confidence intervals; WHR, waist/hip ratio; HDL, high 
density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood 
pressure. 
Model 1 = univariate (crude) model, model 2 = adjusted for age (continuous), smoking (never, past, 
current), education (basic school, secondary school, and university degree), physical activity (low, 
regular), and menopausal status (premenopause, postmenopause, perimenopause/unknown), 
model 3 = model 2 and estradiol (continuous), model 4 = model 3 and BMI (continuous).
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disCussion
This large population-based cross-sectional study of 
postmenopausal women shows that symptoms of sweats only were 
associated with increased BMI, WHR, systolic and diastolic blood 
pressures, glucose, total cholesterol, LDL, and triglycerides levels. The 
associations for combined flushing and sweats with cardiovascular risk 
factors were less pronounced, but were largely in the same direction 
of a less favorable risk profile. Although VMS are related to decreased 
estradiol concentrations, the associations with CVD risk factors could not 
be explained by the women’s circulating estradiol levels.
To appreciate the findings, some aspects of the present study 
need to be addressed. A possible limitation includes the cross-sectional 
design of the study. However, we expect that effects of VMS on 
several risk factors, such as blood pressure, are more acute effects, and 
therefore this has probably not influenced our results to a large extent. 
Nevertheless, it would be interesting to extend these findings in studies 
in which CVD events are the outcome. Another limitation includes the 
method of gathering information on VMS. First, the symptoms were 
self reported. However, these questions have been evaluated by earlier 
reports on menopausal symptoms with good reliability (11). Moreover, 
misclassification of VMS is not likely to be related to cardiovascular risk 
factors, and random misclassification usually leads to bias towards the 
null. Second, the question on flushing/sweats combined was asked in a 
section about reproductive history and menopause, while the question on 
sweats only was asked in a somatic symptom section. Therefore, it is not 
fully clear whether symptoms of sweats reflect menopausal night sweats. 
However, we assume this question was meant to ascertain night sweats, 
as for instance the somatic symptom section also included questions on 
symptoms that are very typical for the menopausal transition. Furthermore, 
women with sweats were having more sleep problems (58% vs 43%), but 
were less likely to have regular exercise (40% vs 45%). In addition, the 
prevalence of sweats only was very comparable with the percentage of 
women with night sweats in our previous study in a somewhat younger 
population (2). Finally, the question on sweats only specifically defined 
the time scale of within the last three months, which was not the case 
for flushing/sweats. This may have led to a less accurate measure of the 
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combined variable, which reduces the chances of picking up associations. 
This might be an explanation for our finding that symptoms of sweats 
only had a stronger effect on cardiovascular risk factors than symptoms 
of flushing/sweats combined. 
In our analyses, we additionally adjusted for estradiol level, 
which was measured only once. However, as estradiol levels fluctuate 
dramatically during the menopausal transition, it is likely that a single 
serum measurement cannot capture these wide fluctuations. Thus, 
estradiol exposure may not have been fully controlled. Future work should 
further examine the role of estradiol on the relationship between VMS and 
cardiovascular risk factors with more detailed hormonal assessments. 
Obviously, it is a point of discussion whether or not it is necessary 
to adjust for BMI in the analyses regarding blood pressure and lipids. In 
our view, BMI is an essential determinant of blood pressure (12), and also 
causally related to endocrine and metabolic changes with menopause and 
factors in the causal pathway should not be included in the regression 
models. The fact that adding BMI to the models weakened the results 
supports the view that BMI lies in the causal pathway and that adjustment 
has led to an overcorrection. 
The focus of studies unraveling the etiology of VMS has mainly 
been on hot flushes and not that much on symptoms of sweating. However, 
we assume the mechanism of sweating is very similar to what is known 
about the mechanism of hot flushes. Reasons to believe this include that 
during hot flushes sweating and skin conductance, an electrical measure 
of sweating, increase (13). Also, the whole body sweat rate is measured to 
be about 1.3 g/min in 1 subject during a hot flush (14). And in a study of 
Freedman, measurable sweating occurred during 90% of the hot flushes 
(13). In our study, prevalence of sweats only was associated with the most 
severe symptoms of flushing (results not shown). 
Briefly, a hot flush is a sensation of heat and flushing that occurs 
suddenly (15). Small, but statistically significant elevations in core body 
temperature often precede hot flushes recorded in controlled laboratory 
conditions. Furthermore, the thermoneutral zone has been shown to be 
0 ºC for symptomatic women, whereas among asymptomatic women, 
it is about 0.4 ºC, similar to that found among younger women (16). 
Catecholamine norepinephrine (NE) plays an important role in the 
thermoregulation (15). Brain NE release is greater in women with hot 
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flushes compared to asymptomatic women (13), indicating that in women 
with symptoms the sympathetic activation is higher. 
Catecholamines, notably epinephrine and NE – are possible 
mediators for various vascular abnormalities (17). For instance, it 
has been demonstrated that long administration of catecholamines 
in experimental animals results in increased content of cholesterol in 
arterial walls (18). Circulating levels of catecholamines are found to be 
elevated in hypertensive patients (19), but also in patients with a history 
of myocardial infarction or stroke (20). Primary mechanisms that may be 
involved include changes in the release and cellular action of sympathetic 
transmitters, which leads to sympathetic dysfunction (21). Given the fact 
that catecholamines are also involved in the etiology of VMS, an increase 
in sympathetic nervous system activity might be the primary cause for the 
association of VMS with an adverse cardiovascular risk profile although 
definitive conclusions can not currently be made.
We found that estradiol concentrations were significantly lower 
among women with VMS as compared to women without VMS. Because 
CVD risk is known to be increased after menopause (22;23), it is of interest 
to study whether the relationship between VMS and cardiovascular risk 
factors is a reflection of the effect of estradiol. Our results do not seem to 
support this view, as additional adjustment for estradiol levels did not 
change our found associations, indicating that the presence of VMS was 
still independently associated with an unfavorable cardiovascular risk 
profile. Furthermore, given the fact that estrogen concentrations remain 
low throughout menopause and that symptoms usually subside with 
time after menopause, it is not very likely that estrogen deficiency as 
such is the only risk factor for symptoms and more complex mechanisms 
need to be considered (24). Recently, it has been suggested that hormonal 
fluctuations that occur during menopause are involved as well (15;25;26). 
More research into this is necessary to fully understand the current 
findings.
Previously we reported that women with VMS have increased 
cholesterol levels, systolic and diastolic blood pressures and BMI 
compared to women without symptoms (2). In the present study we were 
able to replicate this and extend these findings to other markers of CVD 
risk, such as WHR, glucose, LDL and triglycerides levels. Furthermore, 
a recent study found that women with hot flushes had reduced flow-
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mediated dilation and greater aortic calcification (3). Another recent study, 
however, showed no differences in lipids, lipoproteins, sex hormone 
binding globulin, or high sensitive C-reactive protein between women 
with and without of mild hot flushes (27). However, with the small 
sample size and low number of women with symptoms, the statistical 
power was only 40% to find an association between VMS and cholesterol 
levels in that study based on the effect sizes in our study. The conflicting 
results from the Rancho Bernardo Study, where night sweats were not 
associated with BMI, lipid levels and blood pressure, could be explained 
by the much higher age of the study group, suggesting that the study 
population might not be comparable to ours (28).  
Together, our results further support our hypothesis that women 
with VMS, differ from those without with respect to cardiovascular risk 
factors. Although estradiol levels were significantly lower among women 
with VMS, the increased cardiovascular risk profile cannot be explained 
by circulating estrogen levels.
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Vasomotor menopausal symptoms are associated 
with increased risk of coronary heart disease
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abstraCt
Emerging evidence suggests that women with vasomotor 
menopausal symptoms (VMS) may have an adverse cardiovascular 
disease (CVD) risk profile. We investigated whether VMS are related to 
an increased risk of future coronary heart disease (CHD), and whether 
possible associations can be explained by CVD risk factors. Data were 
used from a Dutch and Swedish population based sample of 10,787 
women, enrolled between 1995-2000, aged 46-64 years and free of 
CVD at baseline. Data on VMS were collected by questionnaires. Blood 
pressure and body mass index (BMI) were measured in all women, and 
total cholesterol levels were measured in a subgroup of the population. 
Multivariate Cox regression models were used to analyse the data. After 
a mean ± SD follow-up of 10.3 ± 2.1 years, 303 women were diagnosed 
with CHD. Symptoms of flushing were not associated with risk of CHD. 
However, women with symptoms of (night) sweats had an increased 
risk for CHD (hazard ratio (HR) 1.41 [95% confidence interval (CI) 1.12, 
1.76]). This association did not change after adjustment for potential 
confounders nor for potential intermediate risk factors as BMI and blood 
pressure. Women with both symptoms had an increased risk for CHD 
(HR 1.35 [95% CI 1.05-1.76]) as compared to asymptomatic women. The 
risks attenuated after multivariate adjustment. Women with menopausal 
symptoms of (night) sweats have a significantly increased risk of CHD, 
which can not be explained by the levels of CVD risk factors.
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introduCtion
There is growing evidence that women with menopausal hot 
flushes and night sweats may have an adverse cardiovascular disease 
(CVD) risk profile. We previously reported that women with these 
vasomotor symptoms (VMS) have increased cholesterol levels, systolic 
and diastolic blood pressures and body mass index (BMI) compared 
to women without symptoms (1). We confirmed and extended these 
findings in another study showing that VMS are not only related to the 
risk factors mentioned above, but also with increased waist hip ratio, low 
density lipotrotein (LDL) and triglycerides levels (unpublished results). In 
addition, in the Study of Women’s health Across the Nation heart (SWAN) 
study, women with hot flushes also had a reduced flow-mediated dilation 
(FMD) and more extensive aortic calcification (AC) (2). 
In contrast, a recent paper from the Rancho Bernardo Study 
reported that a history of night sweats was associated with a reduced 
risk of coronary heart disease (CHD) mortality, although this association 
was no longer statistically significant after adjusting for CVD risk factors 
(3). Data on the association between VMS and CHD morbidity are not 
available thus far and are needed to further interpret the available data. 
We examined whether VMS are related to future risk of CHD in 
a cohort of 10,787 women around menopause who were followed for 10 
years. In addition, we aimed at examining whether a possible association 
between VMS and CHD can be explained by CVD risk factors. For these 
purposes we pooled data from two cohorts, established in The Netherlands 
and in Sweden.
subjeCts and methods
Population
The Eindhoven Perimenopausal Osteoporosis Study (EPOS) is 
a prospective cohort study among 6,700 Dutch women aged 46-57 who 
participated in a screening program, established to assess determinants of 
low bone mineral density, between 1994 and 1995 (4). The Women’s Health 
in the Lund Area (WHILA) Study consists of 6,917 Swedish women aged 
50-64 who participated in a health screening procedure, which took place 
between 1996 and 2000 (5). For the present analysis, we merged these two 
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cohorts into one study population. 
For the present analysis 13,617 women were eligible. Women were 
excluded if they did not consent to linkage with vital status registries, 
could not be traced in these registries (n=966), had an unknown date 
of inclusion or death (n=6) or did not provide information on VMS 
(n=1,721). Furthermore, prevalent cases of CHD, identified by linkage to 
the Swedish registries (1973-1996) and by self-report using the baseline 
general questionnaire (both cohorts) were excluded (n=137), resulting in 
10,787 women for the analysis (4,790 from EPOS and 5,997 from WHILA).
Baseline measurements
At baseline, a general questionnaire containing questions on 
demographic characteristics, presence of chronic diseases and related 
potential risk factors, reproductive events and menopausal status was 
administered. Comparable information on lifestyle, disease history and 
reproductive events was collected in the EPOS and WHILA cohorts. Coding 
of this information was standardized and merged into one database. 
Smoking behavior was categorized as never, past or current smoking. 
The highest attained level of education of the women was classified into 
three categories: low (primary education up to completing intermediate 
vocational education), medium (up to higher secondary education) and 
high (those with higher vocational education and university). Physical 
activity during leisure time was categorized as inactive or active. Hormone 
therapy (HT) and oral contraceptives (OCs) use was categorized as never, 
past or current. Menopausal status at enrolment was defined as follows: 
women were ‘premenopausal’ if they reported having regular menses, 
‘perimenopausal’ if women experienced irregular menses compared with 
their usual menstruation pattern and ‘postmenopausal’ if they reported 
not having had menses over the past 12 months or longer. Women with 
incomplete questionnaire data, or who reported current use of OCs or HT, 
were classified as perimenopausal if they were between 46 and 55 years of 
age, and postmenopausal if they were older than 55 years (6).
Cardiovascular risk factors
In EPOS, systolic and diastolic blood pressure was measured in 
a standardized manner using a mercury manometer. One measurement 
was taken after the participant had been seated quietly in a comfortable 
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posture, with feet flat on the floor, with the back supported and the arm 
supported at or as close to the level of the heart as possible. In WHILA, 
systolic and diastolic blood pressure was measured twice at the right arm 
after 15 minutes rest in seated position, using a mercury manometer with 
a cuff size adjusted to the circumference of the arm. The average of two 
recordings was calculated. For both cohorts, body weight was measured 
in light indoor clothing without shoes. BMI was calculated as weight 
divided by height squared (kg/m2). Among the 4,790 EPOS women of 
which we had information concerning VMS, total cholesterol had been 
measured in a random selected sub-sample of 1,784 women, by using 
an automatic enzymatic procedure (7). In WHILA, total cholesterol was 
measured in all women by established methods using a Cholestech LDX-
instrument (Cholestech Corporation, Hayward, CA, USA).
Vasomotor menopausal symptoms
To assess the presence of flushing in EPOS women, three questions 
were asked, one on the number of days a participant experienced hot 
flushes in the previous week; one on the average frequency of hot flushes 
during one day; and one on the highest number of hot flushes in one day. 
Two questions were asked to assess the frequency of night sweats, one on 
the number of nights a participant woke up in the previous week because 
of night sweats; and one on the frequency of waking up per night due to 
night sweats. From these questions, a dichotomous variable was created 
for the absence or presence of flushing or night sweats. Flushing or night 
sweats were present if women reported to have had at least one symptom 
during the previous week or if they answered ‘yes’ to one of the questions.
To assess the presence of VMS in WHILA, two questions were 
asked. The first question was “Do you have problems with sweats/
hot flushes?” and was asked in the reproductive history section of the 
questionnaire. The second question was “Did you experience symptoms 
of sweats during the preceding three months?” and was asked in a 
general section concerning somatic symptoms. This section also contained 
questions on other menopausal symptoms such as feeling cold, headache, 
feeling of tiredness, sleeping problems, palpitations, irritability and 
depression. Both questions were answered by yes or no. Women were 
defined as suffering from flushing or sweats if they answered ‘yes’ to one 
of the questions. 
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In the present analysis, presence of hot flushes and of (night) 
sweats was defined from these questions and classified as yes or no. 
Furthermore, a variable was created indicating no symptoms, flushing 
only, (night) sweats only, or both.
Morbidity and mortality follow-up
For the EPOS women, data on morbidity were obtained from 
the PHARMO Record Linkage system (8), which includes the drug-
dispensing records from community pharmacies and hospital discharge 
records of more than 2 million inhabitants of over 40 demographically 
defined areas in The Netherlands, including Eindhoven. The hospital 
records include detailed information concerning the primary discharge 
diagnoses and dates of hospital admission and discharge. All diagnoses 
are coded according to ICD-9. The database was linked to the cohort on 
the basis of birth date, sex, postal code, and general practitioner with 
a validated probabilistic method (8). Information on vital status was 
obtained through linkage with the municipal administration registries. 
Causes of death were obtained from the Dutch Central Bureau of Statistics, 
coded according to ICD-10.
For the WHILA women, follow-up information was obtained via 
linkage with registries. Mortality is registered in the Swedish Cause of 
Death Registry, and morbidity, based on hospital discharge summaries, is 
registered in the Hospital Discharge Registries, a validated alternative to 
revised hospital discharge and death certificates (9;10). In these registries, 
also ICD-9 and ICD-10 codes were used. Using personal 10-digit numbers, 
individual cohort members were linked to registries (11).
For our analyses, coronary events (CHD) (ICD-9; 410-414, and 
427.5 or ICD-10 I20, and I23-I25) were the endpoints of interest. Whenever 
multiple events of CHD occurred, the first diagnosis was taken as 
endpoint. For all women who had a CHD event, follow up ended at the 
date of diagnosis or, when hospital admission had not occurred, at the 
date of death. 
Mortality from non-cardiovascular causes and withdrawn alive 
were considered censoring events. Non-fatal events from the women 
participating in the EPOS study were registered from January 1st 1998 
until July 27th 2007, and fatal events were registered from January 1st 
1995 until July 27th 2007. Women participating in the WHILA study were 
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followed from their cohort entry date until January 1st 2007. 
Data analysis
Baseline characteristics are described for all women and for the 
individual EPOS and WHILA cohorts by means and standard deviations 
for normally distributed continuous variables and numbers and 
percentages for categorical variables. The person-time for each woman 
was calculated from the month of return of the baseline questionnaire to 
the month of diagnosis of CHD, the month of death from other causes, or 
the end of follow-up. The association between VMS and incident CHD 
was investigated using Cox regression models. First, we investigated the 
associations between symptoms of hot flushes, (night) sweats and risk of 
CHD. Second, to gain insight in whether hot flushes and (night) sweats 
differ in mechanisms of action, we also evaluated the risks for CHD in 
separate groups of women having only symptoms of hot flushes, only 
(night) sweats, or both symptoms. 
In all analyses, women reporting no VMS were considered 
as the reference category. At first, we fitted a crude model (model 1). 
Subsequently, we fitted models adjusted for age at enrollment, physical 
activity, smoking, education, menopausal status, and OCs or HT use 
(model 2). Finally, to study whether variations in CVD risk factors were 
a perceived mechanism by which VMS might be linked to CHD, we also 
present the results of additional models (model 3), adjusting for BMI, 
blood pressure, because they were present in the entire population, and 
(model 4) the risk factors of model 3 plus cholesterol levels, being available 
for a subgroup (n=7,626) of the population. 
To minimize the possibility that the use of exogenous hormones 
modified risk of CHD, we conducted a separate analysis for never-users 
of OCs and HT and formally tested the effect modification by adding 
an interaction term between hormone use and VMS to the model. 
Furthermore, as postmenopausal women are at increased risk of CHD 
(12) and experience more VMS than premenopausal women (13), we also 
used interaction terms to examine whether menopausal status modified 
the effect.
Results were considered statistically significant at 2-sided P ≤ 
0.05. All statistical analyses were performed using the Statistical Analysis 
System, version 9.1 (SAS Institute, Inc.).
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results
Baseline characteristics of the 10,787 women from the individual 
EPOS and WHILA cohorts and the studies combined are shown in Table 1. 
The study had a mean follow-up of 10.3 ± 2.1 years and comprised 111,106 
person-years. The mean age at baseline was 53 years and was higher in 
the WHILA than in the EPOS cohort. Adjusting for age explained the 
higher prevalence of flushing, HT use and percentage of postmenopausal 
women in the WHILA cohort, and the lower prevalence of OCs use in 
WHILA than the EPOS cohort. Percentages of women with a medium 
level of completed education and current smokers were higher in the 
EPOS cohort than the WHILA cohort. All other variables were similar for 
both cohorts. In total, 48% of all women reported symptoms of flushing 
and 35% reported symptoms of (night) sweats. Symptoms of flushing only 
were reported by 20% and (night) sweats only by 7% of all women, while 
28% reported both symptoms. During follow-up, a total of 303 women 
experienced an incident CHD event during follow-up, of which 14 were 
fatal. 
Presence of flushing was not associated with risk of CHD (hazard 
ratio (HR) 1.12 [95% confidence interval (CI) 0.89-1.40]), a pattern that did 
not change after multivariate adjustment (Table 2). 
In the crude (Table 2, model 1) and multivariate (Table 2, model 2) 
analyses, symptoms of (night) sweats were associated with a significantly 
increased risk of CHD (HR 1.41 [95% CI 1.12, 1.76] and HR 1.34 [95% CI 
1.06-1.69] respectively). Results remained similar when BMI and blood 
pressure (Table 2, model 3) were added to the model, with an HR of 1.28 
[95% CI 1.01-1.61]. However, when finally adjusting for total cholesterol 
levels in the subgroup for which this was available, the estimate became 
slightly lower and did not remain statistically significant any longer (HR 
1.11 [95% CI 0.82-1.49] (Table 2, model 4)).
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Table 1 Baseline characteristics of the total study population of 11,552 women
Characteristics EPOS WHILA All women
Mean ± SD Mean ± SD Mean ± SD
N 4,790 5,997 10,787
Follow-up time, months 144.7 ± 16.7 106.7 ± 17.3 123.6 ± 25.4
Age, years 50.3 ± 2.4 56.3 ± 3.0 53.6 ± 4.1
Body mass index, kg/m2 25.5 ± 4.4 25.4 ± 4.2 25.5 ± 4.3
SBP, mm/Hg 133.4 ± 19.4 132.1 ± 17.1 132.7 ± 18.2
DBP, mm/Hg 84.1 ± 10.9 85.1 ± 9.3 84.7 ± 10.0
Cholesterol, mmol/L 6.2 ± 1.4* 6.0 ± 1.1 6.0 ± 1.2
N (%) † N (%) N (%)
Hypertension 2,358 (49.2) 2,975 (49.6) 5,333 (49.4)
Hypercholesterolemia 657 (36.8) 1,761 (29.4) 2,418 (31.1)
Coronary heart disease 180 (3.8) 123 (2.1) 303 (2.8)
Hot flushes, yes 1,909 (39.9) 3,299 (55.0) 5,208 (48.3)
(Night) sweats 1,853 (38.7) 1,935 (32.3) 3,788 (35.1)
Only hot flushes 572 (11.9) 1,609 (26.8) 2,181 (20.2)
Only (night) sweats 516 (10.8) 245 (4.1) 761 (7.1)
Both symptoms 1,337 (27.9) 1,690 (28.2) 3,027 (28.1)
Hysterectomy 860 (18.0) 695 (11.6) 1,555 (14.4)
Ovariectomy 365 (7.7) 397 (6.9) 762 (7.2)
Education completed
   Low 656 (14.1) 1,016 (17.2) 1,672 (15.8)
   Medium 3,433 (73.5) 2,777 (47.1) 6,210 (58.8)
   High 581 (12.4) 2,103 (35.7) 2,684 (25.4)
Smoking status
   Never 1,539 (32.6) 3,846 (64.2) 5,385 (50.3)
   Past 1,708 (36.2) 990 (16.5) 2,698 (25.2)
   Current 1,473 (31.2) 1,156 (19.3) 2,629 (24.5)
Physically active 1,987 (42.3) 2,559 (43.2) 4,546 (42.8)
Oral contraceptives use 651 (13.6) 196 (3.3) 847 (7.9)
Hormone therapy use 922 (19.4) 1,969 (32.8) 2,891 (26.9)
Menopausal status
   Premenopausal 593 (12.4) 453 (7.6) 1,046 (9.7)
   Perimenopausal 2,156 (45.0) 1,239 (20.7) 3,395 (31.5)
   Postmenopausal 2,041 (42.6) 4,305 (71.8) 6,346 (58.8)
Abbreviations: SD, standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, 
diastolic blood pressure. 
* Only available for a subpopulation of 1,784 women. † Percentages include column percentages.
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Table 2  Hazard ratio’s for vasomotor symptoms and coronary heart disease risk among 
the total study population
Hot flushes
(n=5,482)
(Night) sweats
(n=4,064)
HR (95% CI) HR (95% CI)
Model 1 1.12 (0.89, 1.40) 1.41 (1.12, 1.76)
Model 2 1.04 (0.83, 1.32) 1.34 (1.06, 1.69)
Model 3 1.01 (0.80, 1.28) 1.28 (1.01, 1.61)
Model 4 0.88 (0.66, 1.18) 1.11 (0.82, 1.49)
 
Abbreviations: HR, hazard ratio; CI, confidence interval.
Model 1 = univariate (crude) model, model 2 = adjusted for age (continuous), education level 
(low, medium, high), smoking (never, past, current), physical activity (inactive, active), hormone 
therapy use (never, past, current), oral contraceptives use  (never, past, current), menopausal status 
(premenopausal, postmenopausal, perimenopausal), model 3 = model 2 with body mass index 
(continuous) and systolic and diastolic blood pressure (continuous), model 4 = model 3 and total 
cholesterol (continuous), available in a subgroup of 7,626 women.
Finally, we analysed the CHD risks in women having symptoms 
of hot flushes only, (night) sweats only, or both symptoms. Symptoms of 
flushing only were not associated with risk of CHD (Table 4). Compared 
to asymptomatic women, women with (night) sweats only had a non-
significant increased risk for CHD (HR 1.35 [95% CI 0.90-2.03, Table 3, 
model 2). Adding blood pressure, BMI (Table 3, model 3) and total 
cholesterol (Table 3, model 4) to the model did not change this result. 
Women with both symptoms had a significantly increased risk for CHD, 
with an HR of 1.35 [95% CI 1.05-1.76] in the crude analysis. When adding 
confounders to the model, this association was attenuated (HR 1.25 [95% 
CI 0.96-1.64, Table 4, model 2).
When restricting the analysis to women not using OCs or HT, 
results were essentially similar in this group for all symptoms studied, 
and the tests of the interaction terms were not statistically significant 
(P-values for effect modification for all symptoms ranged from 0.54 to 
0.58 for OCs and 0.27 to 0.89 for HT). Menopausal status was not an effect 
modifier either (P-values for effect modification ranged from 0.47 and 
0.98 for all symptoms). (data not shown)
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Table 3 Hazard ratio’s for vasomotor symptoms and coronary heart disease risk among 
the total study population
No symptoms
(n=5,219)
Only hot flushes
(n=2,269)
Only (night) 
sweats (n=851)
Both symptoms
(n=3,213)
HR (95% CI) HR (95% CI) HR (95% CI)
Model 1 Ref. 0.88 (0.63, 1.24) 1.36 (0.91, 2.04) 1.36 (1.05, 1.76)
Model 2 Ref. 0.84 (0.59, 1.20) 1.35 (0.90, 2.03) 1.25 (0.96, 1.64)
Model 3 Ref. 0.84 (0.59, 1.20) 1.32 (0.88, 1.98) 1.19 (0.91, 1.56)
Model 4 Ref. 0.85 (0.57, 1.28) 1.38 (0.81, 2.34) 0.98 (0.69, 1.38)
Abbreviations: HR, hazard ratio; CI, confidence interval.
Model 1 = univariate (crude) model, model 2 = adjusted for age (continuous), education level 
(low, medium, high), smoking (never, past, current), physical activity (inactive, active), hormone 
therapy use (never, past, current), oral contraceptives use  (never, past, current), menopausal status 
(premenopausal, postmenopausal, perimenopausal), model 3 = model 2 with body mass index 
(continuous) and systolic and diastolic blood pressure (continuous), model 4 = model 3 and total 
cholesterol (continuous), available in a subgroup of 7,626 women.
disCussion
Our data show that women with (night) sweats have a 41% increased 
risk for CHD, an association that remained statistically significant after 
adjusting for blood pressure and BMI. The fact that this association was 
no longer statistically significant after correction for total cholesterol is 
probably caused by a reduced power, due to the low number of women 
and CHD cases that were left. Presence of flushing was not associated 
with risk of CHD. However, women with both symptoms of flushing and 
(night) sweats have a 36% increased risk for CHD in the crude analyses, 
but not in the multivariate analyses, which is also likely to be caused by 
a reduced power.
Hot flushes and night sweats are considered to be the hallmark of 
the menopausal transition in midlife women (14). In the present study, 
we found that presence of (night) sweats was an important risk factor for 
CHD rather than presence of flushing. Since most studies exploring the 
etiology of VMS mainly concentrated on hot flushes, little is known about 
the origin of night sweats. We do not have a clear pathophysiological 
explanation for our finding. Perhaps, night sweats reflect the most severe 
hot flushes. Studies that assessed symptom severity are needed to examine 
whether severe hot flushes are related to CHD risk too. This study shows 
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the effects of VMS to be complex. In order to gain a better understanding 
of which subgroups of menopausal women are at greater CHD risk, more 
studies are also needed to examine the risks of night sweats and hot 
flushes separately.
We previously found that VMS were related to an adverse CVD 
risk profile in the EPOS study (1), and these results were confirmed in the 
SWAN study (2). Our results are conflicting with the findings of another 
recent study, showing no differences in lipids, lipoproteins, sex hormone 
binding globulin, or high sensitive C-reactive protein between women 
with and without or mild hot flushes (15). However, given the small sample 
size and the low number of women with hot flushes, the statistical power 
to find an association between VMS and cholesterol levels in that study 
based on effect sizes in our study was only 40%. Furthermore, all of these 
studies used a cross-sectional design, which makes it difficult to draw 
firm conclusions regarding causal pathways. In addition, these studies 
used risk factors and subclinical CVD as indices of CVD in contrast to 
the clinical events used as outcomes in the present study and the Rancho 
Bernardo Study (3). The latter study used CHD mortality as an outcome, 
and found that night sweats were associated with a reduced risk of CHD 
mortality, although this association was no longer statistically significant 
after adjusting for CVD risk factors. To our knowledge, our study is the 
first that investigated the effect of VMS on CHD morbidity. 
An increased CHD risk among women with (night) sweats could 
result from their increased levels of CVD risk factors. However, this 
is unlikely to fully explain the findings as after adjustment for several 
traditional CVD risk factors, the association between (night) sweats and 
CHD still remained present. These findings are in agreement with the 
SWAN study (2), in which lower FMD and more extensive AC among 
symptomatic women were robust to adjustment for CVD risk factors also. 
A possible mechanism linking (night) sweats to CHD is the 
sympathetic nervous system activity, which is thought to be higher in 
the symptomatic women (16-18). An increase in sympathetic nervous 
system activity is also involved in various vascular abnormalities (19-21). 
Conceivably, this may explain the higher CHD risk in women with (night) 
sweats.
As the estrogen decline at menopause is likely to accompany the 
development of VMS (22) as well as an increased risk of CHD (12;23), it 
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is possible that the relationship between VMS and CHD is a reflection of 
the effect of low estradiol levels. Hormonal fluctuations that occur during 
menopause have been suggested to be involved in the genesis of VMS too 
(18;24;25). Future studies are needed to examine whether these hormonal 
fluctuations may account for our observed effect of an increased CHD risk 
in women with VMS.
The main strengths of our study are its size and the long follow-
up, the latter enabling us to study clinically manifest CHD endpoints, 
which are more informative than intermediate endpoints. Furthermore, 
after adjustment for age, baseline characteristics were very similar for 
both cohorts. Therefore, it is not likely that any systematic differences in 
underlying methodology in both cohorts were present. In addition, as 
adjusting for or stratifying by cohort yielded similar results, we believe it 
was justified to combine both cohorts to address our research questions.
A limitation resulting from the pooling of the two cohorts includes 
the methods of collecting information on VMS. First, VMS were self 
reported. However, any misclassification is probably non-differential with 
regard to CHD, leading to a dilution of the true effect. Second, in WHILA, 
it is not entirely clear whether symptoms of sweats reflect menopausal 
sweats. However, as the prevalence of sweats was very comparable to that 
of menopausal night sweats in EPOS (32 versus 39%), and women with 
(night) sweats had more sleep problems as compared to asymptomatic 
women (76% versus 52%), it is likely that the question on sweats in 
WHILA was interpreted by the women as menopausal symptoms too. 
Although a certain extent of misclassification cannot be excluded, we 
would expect this to lead to a dilution of the true effect. Furthermore, 
flushing only was reported by 20% of all women, and (night) sweats 
only by 7% of all women, while 28% reported to have both symptoms. 
The latter is consistent with the fact that symptoms of hot flushes and 
night sweats usually go together (26). Finally, in WHILA, the question on 
sweats defined a time of recall of 3 months, which was not the case for 
the question on flushing. This may have led to more accurate information 
about (night) sweats compared to flushing, resulting in increased chances 
of picking up associations. 
In conclusion, women with menopausal symptoms of (night) 
sweats have a significantly increased risk of future CHD, which can not 
be explained by the levels of CVD risk factors. 
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Chapter 6 
Hormone therapy and risk of coronary heart 
disease by vasomotor menopausal symptoms
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abstraCt
We previously hypothesized that the presence of vasomotor 
menopausal symptoms (VMS) may be a marker for susceptibility to 
cardiovascular preventive effects of postmenopausal hormone therapy 
(HT). We examined whether the association between HT use and 
coronary heart disease (CHD) risk differed for women with and without 
VMS. Between 1995 and 2000, information on HT and VMS was collected 
from a pooled population-based sample of 8,833 Dutch and Swedish peri- 
and postmenopausal women. Multivariate Cox regression models were 
used to analyse the data. 252 CHD cases occurred during 10.3 y (mean) of 
follow-up. Neither for women with nor for women without flushing ever 
HT use was associated with CHD risk, compared with never HT use. Also 
among women with (night) sweats, ever HT use did not affect CHD risk; 
among women without (night) sweats, ever HT use was associated with a 
borderline significant increased CHD risk compared to never use (hazard 
ratio (HR) 1.31 [95% confidence interval (CI) 0.91-1.89]) (P = 0.15 for 
interaction). Among women with intense VMS, ever HT use significantly 
decreased CHD risk compared with never HT use (HR 0.39 [95% CI 0.18-
0.87]), whereas among women without intense VMS, ever HT use was 
associated with a borderline significant increased CHD risk (HR 1.29 [95% 
CI 0.97-1.72]) (P = 0.03 for interaction). Our findings indicate that HT use 
is not risk increasing and potentially beneficial with regard to CHD risk 
for women with the proper indication, i.e. VMS. In those without VMS, 
HT use may increase the risk. 
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introduCtion
The disparity among findings from the observational studies (1-3) 
and randomized trials (4;5) on the effects of postmenopausal hormone 
therapy (HT) on the risk of coronary heart disease (CHD) has created 
considerable debate. The most common indications for which HT is 
prescribed are hot flushes and night sweats, the classical vasomotor 
menopausal symptoms (VMS) (6). These symptoms are experienced 
by as many as 80% of women during the menopausal transition (7), of 
which nearly one third seeks medical care (8). After the report of the 
main findings of the Heart and Estrogen/Progestin Replacement Study 
(HERS) (4) and Women’s Health Initiative (WHI) trial (5), there has been 
a substantial decline in HT prescriptions (9). Also for women with VMS, 
physicians as well as the women themselves are in doubt whether HT is 
safe, and guidelines are conflicting (10;11).
We recently hypothesized that the presence of VMS may mark 
susceptibility to cardiovascular preventive effects of HT (12). Our previous 
findings of an adverse cardiovascular risk profile (13) and an increased 
CHD risk (data not displayed in publication) among women with VMS 
indeed indicate that these women differ from those without VMS and 
may therefore experience particular benefits. 
However, recent findings of the WHI and HERS trials seem to 
suggest the opposite; in these studies the increased CHD risk associated 
with HT was particularly concentrated among women reporting VMS 
at baseline (14;15). However, women in these trials were preferentially 
selected on the absence of VMS and the small group of older women on 
which these findings are based are unlikely to be representative of the 
sizable number of women requiring HT because of VMS in the population 
at large (16;17). 
In the current study, we examined whether the association between 
HT use and CHD risk differed between women with and without VMS 
in a population-based cohort of 8,833 peri- and postmenopausal women 
who were followed for 10 years.
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subjeCts and methods
Population
The Eindhoven Perimenopausal Osteoporosis Study (EPOS) is 
a prospective cohort study among 6,700 Dutch women aged 46-57 who 
participated in a screening program, established to assess determinants 
of low bone mineral density, between 1994 and 1995 (18). The Women’s 
Health in the Lund Area (WHILA) Study consists of 6,917 Swedish women 
aged 50-64 who participated in a health screening procedure, which took 
place between 1996 and 2000 (19). For the present study, we merged these 
two cohorts into one study population. 
For the present analysis 13,617 women were eligible. Women were 
excluded if they did not consent to linkage with vital status registries, 
could not be traced in these registries (n=966), had an unknown date of 
inclusion or death (n=6) or did not provide information on VMS (n=1,721), 
or HT use (n=45). We also excluded the premenopausal women (n=987), 
since these women were by definition no current HT users. Furthermore, 
we excluded prevalent cases of CHD (n=131), stroke (n=101), venous 
thrombosis (n=306) or pulmonary embolism (n=34) or cancer (n=456), 
other than a basal cell carcinoma, being identified through linkage to the 
Swedish registries (1973-1996), Eindhoven Cancer Registry (1976-1994) 
and by self-report using the baseline general questionnaire (both cohorts). 
The final study population consisted of 8,796 women (3,921 from EPOS 
and 4,943 from WHILA).
Baseline measurements
At baseline, a general questionnaire containing questions on 
demographic characteristics, presence of chronic diseases and related 
potential risk factors, reproductive events and menopausal status was 
administered. Coding of this information was standardized and merged 
into one database. Smoking behavior was categorized as never, past or 
current smoking. The highest attained level of education of the women 
was classified into three categories: low (primary education up to 
completing intermediate vocational education), medium (up to higher 
secondary education) and high (those with higher vocational education 
and university). Physical activity during leisure time was categorized as 
inactive or active. Hormone therapy (HT) and oral contraceptives (OCs) 
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use was categorized as never or ever. Menopausal status at enrolment was 
defined as follows: women were ‘perimenopausal’ if they experienced 
irregular menses compared with their usual menstruation pattern and 
‘postmenopausal’ if they reported not having had menses over the past 
12 months or longer. Women with incomplete questionnaire data, or who 
reported current use of OCs or HT, were classified as perimenopausal if 
they were between 46 and 55 years of age, and postmenopausal if they 
were older than 55 years (20).
Physical examination 
In EPOS, systolic and diastolic blood pressure was measured in 
a standardized manner using a mercury manometer. One measurement 
was taken after the participant had been seated quietly in a comfortable 
posture, with feet flat on the floor, with the back supported and the arm 
supported at or as close to the level of the heart as possible. In WHILA, 
systolic and diastolic blood pressure was measured twice at the right arm 
after 15 minutes rest in seated position, using a mercury manometer with 
a cuff size adjusted to the circumference of the arm. The average of two 
recordings was calculated. For both cohorts, body weight was measured 
in light indoor clothing without shoes. Body mass index (BMI) was 
calculated as weight divided by height squared (kg/m2). 
Vasomotor symptoms
To assess the presence of flushing in EPOS women, three questions 
were asked, one on the number of days a participant experienced hot 
flushes in the previous week; one on the average frequency of hot flushes 
during one day; and one on the highest number of hot flushes in one 
day. Two questions were asked to assess the frequency of night sweats, 
one on the number of nights a participant woke up in the previous week 
because of night sweats; and one on the frequency of waking up per night 
due to night sweats. From these questions, a dichotomous variable was 
created for the absence or presence of flushing or night sweats. Flushing 
or night sweats were present if women reported to have had at least one 
symptom during the previous week or if they answered ‘yes’ to one of 
the questions. In addition, four categories of flushing were constructed: 
absent, low, moderate and high (21).
To assess the presence of VMS in WHILA, two questions were asked. 
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The first question was “Do you have problems with sweats/hot flushes?” 
and was asked in the reproductive history section of the questionnaire. 
The second question was “Did you experience symptoms of sweats 
during the preceding three months?” and was asked in a general section 
concerning somatic symptoms. This section also contained questions on 
other menopausal symptoms such as feeling cold, headache, feeling of 
tiredness, sleeping problems, palpitations, irritability and depression. 
Both questions were answered by yes or no. Women were defined as 
suffering from flushing or sweats if they answered ‘yes’ to one of the 
questions. Symptom severity of flushing was graded on a visual analogue 
scale (0-10 cm). Absence of symptoms was marked at 0, and scoring 10 
indicated a symptom at the highest level. Based on these scores, symptom 
severity was further classified into three degrees, i.e. mild (grade 1-2), 
moderate (grade 3-6) and severe (grade 7-10).
In the present analysis, presence of hot flushes and of (night) 
sweats was defined from these questions and classified as yes or no. In 
addition, to get an impression of the burden of the symptoms, we created 
the variable intensity of VMS defined as intense when women reported 
symptoms of (night) sweats as well as a high frequency of flushing in 
EPOS or a severely graded flushing in WHILA. 
Morbidity and mortality follow-up
For the EPOS women, data on morbidity were obtained from 
the PHARMO Record Linkage system (22), which includes the drug-
dispensing records from community pharmacies and hospital discharge 
records of more than 2 million inhabitants of over 40 demographically 
defined areas in The Netherlands, including Eindhoven. The hospital 
records include detailed information concerning the primary discharge 
diagnoses and dates of hospital admission and discharge. All diagnoses 
are coded according to ICD-9. The database was linked to the cohort on 
the basis of birth date, sex, postal code, and general practitioner with 
a validated probabilistic method (22). Information on vital status was 
obtained through linkage with the municipal administration registries. 
Causes of death were obtained from the Dutch Central Bureau of Statistics, 
coded according to ICD-10.
For the WHILA women, follow-up information was obtained via 
linkage with registries. Mortality is registered in the Swedish Cause of 
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Death Registry, and morbidity, based on hospital discharge summaries, is 
registered in the Hospital Discharge Registries, a validated alternative to 
revised hospital discharge and death certificates (23;24). In these registries, 
also ICD-9 and ICD-10 codes were used. Using personal 10-digit numbers, 
individual cohort members were linked to registries (25).
For our analyses, coronary events (CHD) (ICD-9; 410-414, and 
427.5 or ICD-10 I20, and I23-I25) were the endpoints of interest. Whenever 
multiple events of CHD occurred, the first clinical diagnosis was taken as 
endpoint. For all women who had a CHD event, follow up ended at the 
date of diagnosis or, when hospital admission had not occurred, at the 
date of death. Mortality from non-cardiovascular causes and withdrawn 
alive were considered censoring events. Non-fatal events from the women 
participating in the EPOS study were registered from January 1st 1998 
until July 27th 2007, and fatal events were registered from January 1st 
1995 until July 27th 2007. Women participating in the WHILA study were 
followed from their cohort entry date until January 1st 2007. 
Data analysis
Baseline characteristics are described for all women and for 
never and ever HT users by means and standard deviations for normally 
distributed continuous variables and frequencies and percentages for 
categorical variables. The person-time for each woman was calculated 
from the month of return of the baseline questionnaire to the month of 
diagnosis of CHD, the month of death from other causes, or the end of 
follow-up. The association between HT use and incident CHD, stratified 
for baseline presence of hot flushes, (night) sweats, and intense VMS 
was investigated using Cox regression models. In all analyses, never HT 
users were considered as the reference category. Models were stratified by 
center to control for differences in questionnaire design and other center 
effects. We started with fitting a crude model (model 1). Subsequently, we 
fitted models adjusted for age at enrollment, physical activity, smoking, 
educational level, menopausal status, and OCs use (model 2). We formally 
tested the effect modification by adding an interaction between HT use 
and VMS to the models containing the individual variables and the 
confounders. Results were considered statistically significant at 2-sided 
P ≤ 0.05. All statistical analyses were performed using the Statistical 
Analysis System, version 9.1 (SAS Institute, Inc.).
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results
The analyses are based on a mean follow-up time of 10.3 ± 2.1 
years and comprised 91,299 person-years. In total, 46% of the women 
reported ever HT use, 51% reported symptoms of flushing, of which 13% 
had the highest frequency/severity, 36% reported symptoms of (night) 
sweats, 29% reported to have both symptoms, and 9% were classified as 
having intense VMS. The mean age at baseline was 53.8 ± 4.1 y (range 
46 to 64) and was higher in the ever HT users than in the never users. 
While reports of flushing, hysterectomy and ovariectomy were higher 
in the ever HT users, the prevalence of (night) sweats, postmenopausal 
status and current OCs use was slightly lower among the ever HT users. 
The prevalences of current smoking, physically active, and low education 
was similar for never and ever HT users. During follow-up, a total of 252 
women experienced an incident CHD event, of which 8 were fatal. (Table 1)
Compared with never HT use, ever HT use was not associated 
with risk of CHD for neither women with (hazard ratio (HR) 1.14 [95% 
confidence interval (CI) 0.78-1.66] nor for women without (HR 1.12 [95% 
CI 0.76-1.64]) symptoms of flushing (Table 2, models 1). These results did 
not materially change when confounders were added to the model, with 
HRs of 1.12 [95% CI 0.77-1.63] for women with and 1.15 [95% CI 0.78-1.69] 
for women without flushing (Table 2, models 2). The interaction between 
flushing and HT use was not statistically significant (P-value 0.73).
Compared with never HT use, ever HT use was not associated 
with CHD risk for neither women with (HR 0.97 [95% CI 0.65-1.44]) nor 
for women without (HR 1.25 [95% CI 0.87-1.81]) symptoms of (night) 
sweats in the crude models (Table 2, models 1). This result remained 
similar among the symptomatic women after adding confounders to the 
model (HR 0.90 [95% CI 0.60, 1.35]). However, among women without 
(night) sweats, ever HT use was associated with a borderline significantly 
increased CHD risk compared to never use after multivariate adjustment 
(HR 1.31 [95% CI 0.91-1.89]). (Table 2, models 2) The interaction between 
(night) sweats and HT use was not statistically significant (P-value 0.15).
Next, we studied the role of intensity of VMS. In the crude analysis, 
ever HT use was associated with a borderline significant decreased CHD 
risk for women with intense VMS, with an HR of 0.48 [95% CI 0.22-1.03] 
as compared to never HT use (Table 2, model 1). Adding potential 
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Table 1 Baseline characteristics of the total study population according to hormone 
therapy use.
Characteristics All women Never HT users Ever HT users
Mean ± SD Mean ± SD Mean ± SD
N 8,864 4,792 4,072
Follow-up time, months 123.5 ± 25.2 129.8 ± 25.4 116.0 ± 22.9
Age, years 53.8 ± 4.1 52.8 ± 4.1 55.0 ± 3.7
Body mass index, kg/m2 25.4 ± 4.2 25.6 ± 4.4 25.2 ± 3.9
SBP, mm/Hg 132.9 ± 18.1 133.8 ± 18.9 131.8 ± 17.1
DBP, mm/Hg 84.8 ± 10.1 85.0 ± 10.6 84.5 ± 9.4
N (%)* N (%) N (%)
Treatment for hypertension 879 (9.9) 431 (9.0) 448 (11.0)
Coronary heart disease cases 252 (2.8) 142 (3.0) 110 (2.7)
Hot flushes, 
    Yes 4,472 (50.5) 2,139 (44.6) 2,333 (57.3)
    Highest frequency/ severity 1,119 (12.6) 493 (10.3) 626 (15.4)
(Night) sweats, yes 3,160 (35.7) 1,787 (37.3) 1,373 (33.7)
Hot flushes and (night) sweats 2,554 (28.8) 1,409 (29.4) 1,145 (28.1)
Intense VMS 765 (8.6) 390 (8.1) 375 (9.2)
Hysterectomy 1,325 (15.0) 581 (12.2) 744 (18.3)
Ovariectomy 583 (6.7) 194 (4.1) 389 (9.8)
Education completed
   Low 1,385 (16.0) 766 (16.4) 619 (15.5)
   Medium 5,150 (59.3) 2,969 (63.5) 2,181 (54.5)
   High 2,148 (24.7) 943 (20.2) 1,205 (30.1)
Smoking status
   Never 4,439 (50.5) 2,151 (45.3) 2,288 (56.5)
   Past 2,238 (25.4) 1,410 (29.7) 828 (20.4)
   Current 2,120 (24.1) 1,184 (25.0) 936 (23.1)
Physically active 3,746 (42.9) 2,031 (43.2) 1,715 (42.6)
Oral contraceptives use 784 (8.9) 573 (12.0) 211 (5.2)
Menopausal status
   Perimenopausal 2,367 (26.7) 1,217 (25.4) 1,150 (28.2)
   Postmenopausal 6,497 (73.3) 3,575 (74.6) 2,922 (71.8)
Abbreviations: SD, standard deviation; HT; hormone therapy; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; VMS, vasomotor menopausal symptoms. 
* Percentages include column percentages.
confounders to the model enhanced this association: HR became 0.39 
[95% CI 0.18-0.87] (Table 2, model 2). After multivariate adjustment, ever 
HT use was associated with a borderline significant increased risk of CHD 
(HR 1.29 [95% CI 0.97-1.72]) among the women without intense VMS, 
compared to never HT use (Table 2, model 2). The test for interaction 
between ever HT use and intense VMS was statistically significant 
(P-value 0.03).
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Table 2   Hazard ratio’s for hormone therapy use and coronary heart disease risk according 
to presence of vasomotor symptoms.
Presence of flushing Presence of (night) sweats Presence of intense VMS
Absent Present Absent Present Absent Present
HR 
(95% CI)
HR 
(95% CI)
HR 
(95% CI)
HR 
(95% CI)
HR 
(95% CI)
HR 
(95% CI)
Model 1
1.12 
(0.76, 1.64)
1.14 
(0.78, 1.66)
1.25 
(0.87, 1.81)
0.97 
(0.65, 1.44)
1.28 
(0.96, 1.70)
0.48 
(0.22, 1.03)
Model 2
1.15 
(0.78, 1.69)
1.12 
(0.77, 1.63)
1.31 
(0.91, 1.89)
0.90 
(0.60, 1.35)
1.29 
(0.97, 1.72)
0.39 
(0.18, 0.87)
P interaction 0.72 0.15 0.03
Abbreviations: HR, hazard ratio; CI; confidence interval; VMS, vasomotor menopausal symptoms. 
Model 1 = univariate (crude) model, model 2 = adjusted for age (continuous), education level (low, 
medium, high), smoking (never, past, current), physical activity (inactive, active), menopausal 
status (postmenopausal or perimenopausal), and oral contraceptives use (never, ever).
Models were stratified by study center.
disCussion
Our results suggest that among women with intense VMS, HT 
use materially decreases risk of CHD compared with no HT use. On the 
contrary, HT use may increase the CHD risk among women without 
intense VMS. 
The strengths of this study are its large size and the fact that it 
is population-based. Importantly, women in this study did not start HT 
to prevent CHD, but rather because the presence and severity of VMS 
provided a clinical indication for use. For the present analysis we pooled 
data from two cohorts and some differences in baseline characteristics 
were present. Although these differences were likely to be caused by 
the higher age in the WHILA population, we additionally stratified our 
analyses for study center, in order to compensate for possible errors 
generated by differences in the questionnaire design and other study 
specific characteristics. 
There are a few issues regarding the measurement of VMS and 
HT that should be considered. First, VMS and HT were self reported and 
measured on only a single occasion.  However, any misclassification is 
most likely to be non-differential with regard to CHD, possibly leading 
to a dilution of the true effect. Second, in WHILA, it is not entirely clear 
whether symptoms of sweats reflect menopausal sweats. However, the 
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prevalence of sweats in WHILA was very similar to that of night sweats 
in EPOS, and sleep problems were more common among women with 
(night) sweats than in asymptomatic women. Therefore, it is likely that 
the women have truly reported menopausal sweats. Finally, the EPOS 
study obtained data on frequency of flushing and the WHILA study 
obtained data on severity of flushing. However, frequency and severity 
of hot flushes have earlier been found to be highly correlated (r=0.97, 
p<0.001) (26). Therefore, we expect frequency and severity of flushing to 
have similar associations with CHD.
It could be argued that a healthy user bias could have explained 
our findings. However, frequency of treatment for hypertension, current 
smokers, physically active, and low educated women were similar for 
women using and not using HT. In addition, we adjusted for education, 
therefore, we consider this an unlikely explanation for our findings.
Our findings are in contrast with the findings from the further 
exploratory analyses of the WHI (14) and the HERS (15) trials, where HT 
appeared to be associated with an increased risk of CHD among women 
with VMS (14), but not among women without VMS in the first year 
of follow-up (15). The low number of women with VMS in these study 
populations could be an explanation for this contrast. This is likely to 
have occurred by either the exclusion of women with severe VMS, since 
these symptoms could reduce adherence to placebo treatment, or through 
self-selection, as the presence of severe VMS could be a reason for women 
not to participate in the trials because of the risk receiving a placebo. 
Women with VMS in the trials are therefore likely to be not representative 
for the women using HT in the current study, since these women usually 
started HT for a clinical indication because they had VMS. Another 
explanation could be the higher age of the women enrolled in the trials 
and the inclusion of women with a current history of CHD increasing 
the likelihood of an already existent (advanced) atherosclerosis. It has 
been suggested that a healthy endothelium is necessary for the beneficial 
effects of HT (27).
Since the pathophysiology of VMS is still unknown, we cannot 
explain with certainty why the effect of HT differed for women without 
and with VMS. VMS are extreme thermoregulatory responses resulting 
from a disruption in the ability to keep body temperature within a 
specific optimal range (28). This disruption is thought to be primarily 
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caused by an increased sympathetic nervous system activity (29-31). A 
direct relationship between plasma estradiol levels and the occurrence of 
VMS has not been unequivocally demonstrated (32;33), but the dramatic 
fluctuations in hormone levels during the perimenopausal transition 
and the declining estradiol levels in postmenopause are thought to 
disrupt the sympathetic nervous system activity, and thereby altering 
the thermoregulatory process as well (34-36). An increase in sympathetic 
nervous system activity is also involved in various vascular abnormalities 
(37-39). This hypothesis predicts that supplementation of HT stabilizes 
these hormonal fluctuations, leading to an inhibition of the sympathetic 
nervous system (40;41), and thereby showing favourable effects of HT on 
the cardiovascular system. 
Our findings, obtained in a large population-based study, support 
the view that HT use is not risk increasing and potentially beneficial 
with regard to the development of CHD, for women with an indication, 
i.e. intense VMS. In those in whom this indication is lacking our results 
suggest the presence of an increased CHD risk. These findings should 
preferably be confirmed in randomized comparisons.
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In Europe, cardiovascular disease (CVD) is the leading cause of 
death in women, representing 54% of deaths and outweighing other causes 
such as cancer (17%), lung disease (6%), and injuries and poisoning (5%) 
(1). Of note, morbidity due to CVD outweighs breast cancer morbidity. 
However, physicians and women are equally unaware of these numbers 
(2;3). To prevent untimely CVD in women, it is of utmost importance to 
understand the etiology, pathophysiology, and risk factors of the disease 
in particular to the extent these differ between women and men. CVD 
remains a focus of multidisciplinary research interest. In the present thesis 
we focused on studying female specific risk factors for coronary heart 
disease (CHD). These are likely to relate to specific endocrine mechanisms 
and are related to the distinguishing characteristics of female fertility 
and reproduction. As an example, our review, as described in chapter 2, 
emphasizes that a history of preeclampsia is consistently associated with 
higher CHD risk later in life. Also menopause slightly increases the risk 
of CHD, and the earlier the menopause, the higher the risk. However, 
the exact role of hormone therapy (HT), vasomotor menopausal (VMS) 
symptoms, and polycystic ovary syndrome (PCOS) as independent risk 
factors for CHD has yet to be established.
hormone therapy and risk oF Coronary heart disease 
Since long, a low lifetime endogenous estrogen exposure is 
suggested to promote CVD and subsequent death after menopause. 
However, the translation of the logical consequence that HT 
supplementation to postmenopausal women would be beneficial into 
clinical practice has not been successful. Whereas observational studies 
have demonstrated a consistent 30-50% reduction in CHD in users versus 
nonusers of HT (4-8), randomized controlled trials (RCTs) have shown 
either a null effect or slightly increased risk of CHD outcomes in women 
randomized to HT versus placebo (9;10). Although at the surface this 
contradiction is hard to explain and has cast considerable doubt on the 
validity of observational data, close scrutiny of the differences in cohort 
characteristics between randomized controlled trials and observational 
studies has provided several explanations.
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why results diFFer?
Age at starting treatment
A major difference between participants in the observational 
studies and those in the trials was the age at initiation of HT. In the trials, 
most of the women were at ages that are, on average, substantially older 
than those at which most women in the general population initiate HT. 
In the observational studies, hormone use is general started around 
menopause. This difference in age at starting treatment raises concern that 
the trial results may not apply to treatment initiated early in menopause. 
Indeed, the Women’s Health Initiative (WHI) trial found a trend toward 
lower risk of CHD with decreasing time since menopause; the relative 
risk was 0.76, 1.10, and 1.28 among women whose time since menopause 
was less than 10, 10 to 19, and 20 or more years, respectively (11). In 
addition, among women 50 to 59 years old at enrolment in WHI, end of 
trial coronary calcium scores were lower in women assigned to estrogens 
than in those assigned to placebo (12).
Pre-existing disease
Even though the WHI subjects were designated healthy, many 
had pre-existing disease or other CVD risk factors (older, obese, smoking, 
hypertensive, diabetic) and the process of atherosclerosis may have been 
active. It has been suggested that the estrogen’s cardioprotective effect 
may depend on the presence of a healthy endothelium (13;14). It is possible 
that exogenous estrogen has beneficial cardiovascular effects in younger 
women who have relatively intact endothelial function and minimal 
atherosclerosis at onset of menopause, but not in older women with more 
advanced atherosclerotic plaques (15). This so called “timing hypothesis” 
is the driving force behind the Kronos Early Estrogen Prevention 
Study, or KEEPS. This trial currently evaluates the effectiveness of oral 
or transdermal estradiol (both with progesterone) versus placebo in 
preventing atherosclerosis progression in women aged 42-58 years who 
are within 36 months of their final menstrual period (16).
Presence of vasomotor menopausal symptoms
We previously argued that major differences between outcomes of 
clinical trials and observational studies might also relate to the presence 
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of VMS (17). VMS include both hot flushes and night sweats and affect 
up to 80% of women during the menopausal transition (18). Almost a 
third of postmenopausal women report symptoms that last up to 5 years 
after natural menopause, and VMS can persist for up to 15 years in 20% 
or more of women (19). VMS are viewed largely as a symptom affecting 
quality of life and are the leading reason women seek menopause-
related health care (20). The observational studies on postmenopausal 
HT reflected common clinical practice where women typically initiated 
HT because they experienced menopausal symptoms. However, women 
recruited for randomization into the clinical trials had to be willing to 
start HT at the flip of a coin, and hence their decision was not driven 
by the presence and severity of menopausal symptoms. Conceivably, the 
study populations in the clinical trials included only a small proportion 
of the symptomatic women, with most of them having a mild to moderate 
severity of symptoms. This is likely to have occurred by either the 
exclusion of women with severe VMS, since these symptoms could reduce 
adherence to placebo treatment; through self-selection, as the presence of 
severe VMS could be a reason for women not to participate in the trials; 
or simply because of the inclusion of older women well after menopause.
We suggested previously that women suffering from VMS may 
differ from those without with respect to responses to HT or susceptibility 
to estrogens (17). The studies presented in chapters 4, 5, and 6 address 
this hypothesis. In chapter 4, we first set out to clarify the role of VMS on 
bone mineral density, because it is known that the bone is an end organ 
that is sensitive to estrogens or estrogenic effects (21-24). Our finding that 
women with VMS have a significantly lower bone mineral density as 
compared to the asymptomatic women, suggests that VMS are related to 
estrogenic effects on bone mineral density. 
In the present thesis we also found that VMS are related to a less 
favourable CVD risk profile; women with hot flushes and night sweats had 
higher cholesterol levels, body mass index, systolic and diastolic blood 
pressures (chapter 5.1). We further extended these findings by showing 
that women with VMS also had a higher waist/hip ratio, glucose, low 
density lipoprotein (LDL) cholesterol and triglycerides levels (chapter 
5.2). These results were further confirmed in the Study of Women’s health 
Across the Nation heart (SWAN) (25).
 However, since all of these studies used risk factors and subclinical 
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CVD as indices of CVD, still no hard conclusions could be made with 
regard to the risk of clinical CVD events. Only a recent paper of the 
Rancho Bernardo Study used CHD mortality as an outcome, and found 
that a history of night sweats was associated with a reduced risk of CHD 
mortality, although this association was no longer statistically significant 
after adjusting for CVD risk factors (26). We subsequently studied the 
relationship between VMS and CHD morbidity in a pooled dataset from 
two population based studies, established in The Netherlands (27) and 
in Sweden (28). Notably, we observed that women with VMS had a 
41% increased risk of manifest CHD, which interestingly could not be 
explained by the increased levels of CVD risk factors (chapter 5.3). 
Measurement of vasomotor symptoms 
The interpretations of the findings associating VMS and chronic 
disease risk is complicated by the lack of standard definitions of 
frequency and severity of VMS and the varying methods of collection of 
VMS data, which include both subjective and objective methods. Many 
studies, including those presented in this present thesis, rely on self-
reported measures of VMS frequency and severity with questionnaires 
or diaries with potential biases due to effects of memory, mood, emotion, 
or expectations and limitations of retrospective reporting (29). Objective 
measures of VMS such as sternal skin conductance monitoring performed 
within the laboratory and ambulatory settings show a higher correlation 
in the laboratory setting compared with an ambulatory setting because 
participants tend to underreport VMS (29;30). In future studies the 
measurements of VMS should therefore be considered carefully. The 
objective method of sternal skin conductance should be used when precise 
measurements of VMS frequency are required. However, compared to 
subjective methods, objective methods only provide information on 
the occurrence, but not on duration, severity or intensity of VMS, and 
are hardly feasible when large study populations need to be measured. 
Diaries, rating scales, and questionnaires appear to be more appropriate 
to obtain data on occurrence (frequency), severity and intensity, bother 
and duration in large study populations. However, as researchers cannot 
assume that VMS that are not reported are not perceived, a need exists to 
differentiate perceived VMS from reported VMS (31). Standardization of 
VMS definitions, and validated collection tools for VMS data will further 
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improve the ability to assess the degree and significance of potential 
associations of VMS and health risks.
vasomotor symptoms and health risks; how to understand? 
Until now, our understanding of the mechanisms and factors 
that trigger VMS and their associated risk of CHD is still incomplete. 
VMS arise as a result of a reduced thermoregulatory zone (32), caused 
by an increased sympathetic nervous system activity (33-35). Estrogens 
are known to modulate the sympathetic nervous system activity (36). 
Furthermore, the estrogen decline accompanying menopause is likely 
to play a dominant role for the increased CVD risk after menopause 
(37). Our finding of a decreased bone mineral density in women with 
VMS also suggests that low estrogen levels play a role. Therefore, the 
relationship between VMS and CVD risk (factors) may be a reflection 
of low estrogen levels. However, there are many studies that seem 
inconsistent with an etiologic role of estrogen deficiency. For instance, in 
our study, as described in chapter 5.2, although the presence of VMS was 
related to lower circulating estradiol levels, VMS were still independently 
associated with an unfavourable CVD risk profile after additional 
adjustment for estradiol levels. Furthermore, pre-pubertal girls have low 
circulating estrogen levels, but do not experience VMS, whereas they may 
occur in pregnancy when there is a high level of estrogen production (35). 
In addition, estrogen levels remain low throughout menopause and many 
women pass menopausal transition without experiencing any VMS. It is 
also apparent that for most women symptoms wane with time despite 
an even lower estrogen influence. Therefore, other mechanisms should 
be sought. In particular, the dramatic fluctuations in estrogen levels in 
perimenopausal women may trigger the sympathetic nervous system 
(38-40). There is, however, little scientific information about the extent 
to which VMS and CHD risk (factors) are associated with fluctuating 
estrogen levels, and whether and how these fluctuations could explain 
the increased CHD risk in women with VMS. 
Estrogen fluctuations: link between vasomotor symptoms and coronary 
heart disease?
It would be of interest (1) to study whether fluctuating estradiol 
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levels are causally related to the occurrence of VMS; (2) whether this 
is mediated through increased sympathetic nervous system activity; 
(3) and whether this results in a less favourable CVD risk profile. Ideal 
study designs for the first and second research questions would be a 
case-crossover study (for the short term effects) and a case-control study 
(for the longer term effects). The case-crossover study can comprise 
perimenopausal women experiencing frequent and severe VMS. In these 
women periods of VMS (case period) can be compared to periods without 
VMS (control period) on the same day. The case-control study can comprise 
the same women (now serving as cases in the case-control comparison), 
while the second group (controls in the case-control comparison) can 
consist of perimenopausal women not experiencing VMS. For the third 
research question, a cross-sectional study can be performed in the total 
group of women as described above. During the study period, body core 
temperature, electrocardiography, and blood pressure can be monitored 
continuously. Furthermore, at fixed sampling intervals during and in 
between VMS, endothelial function can be measured and blood samples 
taken for estradiol, other CVD risk factors (glucose and lipids) and 
indicators for sympathetic nervous system activity. The results of this 
study are important to provide insight in the causal pathway underlying 
the association between VMS and CVD risk (factors). Ultimately, these 
findings could facilitate targeting of preventive strategies for in peri- 
and postmenopausal women with VMS. This is badly needed because 
physicians confronted with symptomatic women are currently in doubt 
whether they should prescribe HT for symptom relief. 
Hormone therapy in women with vasomotor symptoms
As we suggested in chapter 6, women suffering from VMS might 
be the subgroup experiencing the potential cardiovascular benefits of 
HT. Our results showed that among women with intense VMS, HT use 
materially decreases risk of CHD compared with no HT use (hazard ratio 
(HR) 0.39 [95% confidence interval (CI) 0.18-0.87]). On the contrary, HT 
use may increase the CHD risk among women without intense VMS (HR 
1.29 [95% CI 0.97-1.72]). The test for interaction between ever HT use and 
intense VMS was statistically significant (P-value 0.03). Our findings cast 
strong doubt on the recent findings of the WHI and Hearth and Estrogen/
progestin Replacement Study (HERS) trials that suggest the opposite; in 
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these studies the increased CHD risk associated with HT was particularly 
concentrated among women reporting VMS at baseline (11;41). Because 
of a lack of observational studies examining this association in particular, 
it remains unclear which women can safely receive HT and which are at 
increased risk from HT. It is probable that the timing of HT administration 
as well as the status of vascular health may determine the effects of 
estrogens on the cardiovascular system. The initiation of HT in young 
healthy women with VMS, close to menopausal transition, could reverse 
endothelial dysfunction and possible also slow down the progression of 
atherosclerosis in its early stages. Further studies are necessary to better 
delineate the interrelationships between HT use, VMS, and risk of CVD. 
It is encouraging that the Finish SYMPTOM trial (http://www.hus.fi) 
has been initiated to compare vascular and cardiac function in recently 
menopausal women with or without severe VMS, as well as to investigate 
vascular response to oral versus transdermal HT. However, this trial uses 
a surrogate outcome. To provide more definitive answers on our questions 
stated above, it is also of high priority to set up studies in which clinical 
CHD events are the outcome. 
Cardiovascular disease: cause or consequence of vasomotor symptoms?
In the present thesis we found that women with VMS are at 
increased risk for CHD. However, the causative pathway of this association 
is not very clear. Although we proposed that the increased CHD risk may 
be consequence of VMS, this cannot be concluded with confidence since 
our studies were either cross-sectional or were not able to control for CHD 
risk prior to the onset of VMS. Conversely, VMS may not induce a change 
in CVD risk, but a woman’s atherosclerotic status may influence the 
development of VMS. Consequently, our observation that women with 
VMS are at increased CHD risk might, in part, reflect an unfavourable 
CVD risk profile present before the onset of VMS. There is some evidence 
to support this hypothesis, since a previous study has also found a link 
between predisposition to CVD and an early age at menopause (42). 
Hence, this scenario obviously merits further investigation. Unfortunately, 
there are surprisingly few studies that have attempted to identify CVD 
risk factors that predispose women to VMS. Well-known modifiable CVD 
risk factors include body weight, hypertension and diabetes mellitus. It 
has been proposed that body size also has a critical role in risk of VMS. 
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However, whether VMS are caused by a high (43) or low (44) body weight 
is not clear. Furthermore, no earlier studies have examined the association 
between weight changes, hypertension, diabetes mellitus and risk of VMS. 
Non-modifiable CVD risk factors include certain menstrual cycle 
characteristics, such as irregular cycles, as described in chapter 3.2, and 
reproductive health factors (45;46). However, the relationship of menstrual 
cycle characteristics and VMS remains largely unexplored. Reproductive 
history in relation to VMS has been examined in a few studies but with 
inconsistent results (44;47-49). 
A few studies have shown that reporting of VMS was significantly 
more frequent among women who experienced premenstrual tension 
(50;51). However, most of these studies are old or based on small sample 
sizes. Additionally, there are no studies that examined risk factors for 
night sweats, and only few studies examined risk factors in relation to 
more frequent, severe or intense symptoms, causing the most disruption 
in quality of life. Future studies should examine the relationships 
between CVD risk factors and the development of VMS later in life. This 
will provide insights in the causal risk factors of VMS. Additionally, such 
studies will contribute to the scientific understanding of the adverse 
affect of VMS on CVD risk and may also lead to better treatments and 
preventive measures for VMS. This hypothesis could be tested in a large 
study with a longitudinal design with repeated measurements of most of 
the exposures and outcomes over time with a long follow-up. 
ConClusion
From the studies described in the present thesis, we found that 
VMS are important risk factors for CHD, and that HT could reduce the 
risk among women with VMS. Our findings suggest that the presence 
of VMS in the observational studies and the absence of VMS in the 
randomized trials could contribute to the discordant outcomes of these 
two types of studies on HT and CHD risk. Further studies are necessary to 
better delineate the interrelationships between HT use, VMS, and risk of 
CVD. Furthermore, mechanistic studies are needed to determine whether 
neuroendocrinological mechanisms, such as estradiol fluctuations, are 
part of the mechanism. In addition, the scenario that premenopausal 
CVD risk promotes the development of VMS needs to be examined. 
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Further analyses could also explore whether VMS also are related to other 
common postmenopausal comorbidities, such as breast cancer. However, 
in order to increase our understanding of the potential associations of 
VMS and health risk, there is a need for uniformity in terminology and 
methodology of assessing VMS. Our results are not only interesting from 
an etiologic point of view, but may also be clinically relevant, since VMS 
status could potentially be incorporated into existing CVD risk algorithms 
in order to improve CVD risk stratification among women.
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In western countries, cardiovascular disease (CVD) is the leading 
cause of morbidity and mortality in women. To prevent untimely 
CVD in women, it is of utmost importance to understand the etiology, 
pathophysiology, and risk factors of the disease. In the present thesis we 
focused on studying female specific risk factors for coronary heart disease 
(CHD). In particular, we aimed at investigating a perceived association 
between polycystic ovary syndrome (PCOS), androgens, menstrual cycle 
characteristics and incidence of CHD. Furthermore, we studied the role 
of the presence of vasomotor menopausal symptoms (VMS) on estrogenic 
effects, CVD risk factors and clinical endpoints of CHD. Finally, we 
evaluated whether postmenopausal hormone therapy (HT) use is safe 
with regard to CHD risk in women with VMS.
In chapter 2, a review summarizes the literature on risk factors 
for CHD that are specific for women as well as non-gender specific risk 
factors and how their effects differ between men and women. A history 
of preeclampsia, menopausal status, age at menopause, and potentially 
PCOS increase the risk of CHD, although the exact role of PCOS as an 
independent risk factor has yet to be established. Existing data concerning 
the CHD risk associated with use of HT are mixed. The suggestion that 
HT may be beneficial in young peri- or postmenopausal women needs 
to be confirmed in future studies. Evidence on use of low-dose oral 
contraceptives consistently suggests no increased CHD risk. With respect 
to the classical risk factors, cigarette smoking, hypertriglyceridemia and 
low high-density lipoprotein levels have greater impact in women than in 
men, whereas the higher prevalence of diabetes, hypertension and obesity 
in postmenopausal women also predispose them to a greater CHD risk as 
compared with men. 
Chapter 3 addresses the association between PCOS, androgens, 
irregular cycles and risk of CHD. In chapter 3.1, we applied a recently 
proposed way of assessing presence of PCOS postmenopausally. In 
contrast to the study that proposed this definition, we did not find an 
increased risk of CHD for women with postmenopausally determined 
PCOS. Also androgen levels were not associated with CHD risk. It is 
still unclear whether postmenopausal characteristics are able to define a 
premenopausally existing condition. 
In the female population at large, there is a considerable group of 
women not fulfilling diagnostic criteria for PCOS, but still having long or 
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irregular menstrual cycles. Those women have been suggested to have 
an increased CVD risk, but whether this is independent of associated 
altered sex hormone levels and/or CVD risk factors is not known. In 
chapter 3.2, we examined these questions using data from 23,571 women, 
aged 20-70 years, and participating in the Dutch European Prospective 
Study Into Cancer and Nutrition (EPIC) cohort. A regular long cycle ( ≥30 
days) was not associated with risk of CHD compared to shorter regular 
cycles, whereas irregular menstrual cycles, compared to a regular cycle 
length of 27-29 days, significantly increased CHD risk (hazard ratio (HR) 
1.31 [95% confidence interval (CI) 1.07-1.59]), and borderline significantly 
increased type 2 diabetes risk (HR 1.20 [95% CI 0.94-1.53]). Irregular 
cycles were also associated with a 0.34 mmol/L [95% CI 0.07-0.62] higher 
glucose level, but not to blood pressure, lipid-, C-reactive protein (CRP)-
, and hormone levels after multivariate adjustment. We conclude that 
women with a history of irregular menstrual cycles have a significantly 
moderately increased risk of CHD, and tend to have an increased risk of 
type 2 diabetes, which can not be explained by metabolic risk factors nor 
altered hormone levels. 
Since long, a low lifetime endogenous estrogen exposure is 
suggested to promote CVD and subsequent death after menopause. The 
view that the CVD risk might be reversed by replacing the endogenous 
estrogens by exogenous estrogens in the form of HT has therefore 
became popular. Indeed, observational studies report risk reductions 
up to 30-50%, but the clinical trials unexpectedly showed that HT does 
not provide coronary protection. However, whereas VMS are the main 
indication for HT in the population, women with severe VMS were either 
excluded in the clinical trials or comprised only a minority of the total 
randomized population. We previously hypothesized that the presence 
of VMS determines the susceptibility to the preventive effects of HT on 
end organs. In chapter 4, we first set out to clarify the role of VMS on bone 
mineral density, because it is known that the bone is an end organ that is 
sensitive to estrogens or estrogenic effects. For this study we used data of 
5,600 women, aged 46-57 years, who participated in the Dutch Eindhoven 
Perimenopausal Osteoporosis Study (EPOS). Data on VMS were collected 
by questionnaires and bone mineral density of the lumbar spine was 
measured using DXA. Flushing was reported by 39% and night sweats by 
38% of all women. The average BMD was 1.01 ± 0.14 g/cm2 and decreased 
192
Chapter 8
with increasing frequency of VMS. After multivariate adjustments, 
women with the highest frequency of flushing had a 0.022 g/cm2 [95% 
CI -0.03, -0.01] lower BMD compared to asymptomatic women. Women 
who reported to have the highest frequency of night sweats had a 0.011 g/
cm2 [95% CI -0.02, -0.001] lower BMD compared to asymptomatic women. 
These findings suggest that VMS are related to estrogenic effects on bone 
mineral density.
In chapter 5 we investigated underlying differences in CVD risk 
between women with and without VMS. In chapter 5.1, we studied 
whether the presence and frequency of VMS are associated with the CVD 
risk profile in 5,523 women of the EPOS study. Total cholesterol, systolic 
and diastolic blood pressures and body mass index (BMI) were measured. 
After multivariate adjustment, women with flushing had a 0.27 mmol/L 
[95% CI 0.15, 0.39] higher cholesterol level, a 0.60 kg/m2 [95% CI 0.35, 
0.84] higher BMI, a 1.59 mm/Hg [95% CI 0.52, 2.67] higher systolic 
blood pressure, and a 1.09 mm/Hg [95% CI 0.48, 1.69] higher diastolic 
blood pressure compared to asymptomatic women. Flushing was also 
associated with hypercholesterolemia (odds ratio (OR) 1.52 [95% CI 1.25, 
1.84]) and hypertension (OR 1.20 [95% CI 1.07, 1.34]). Results were similar 
for symptoms of night sweating. 
In chapter 5.2, we aimed to extend the previous findings in another 
study population in whom also other markers of CVD risk were measured, 
such as lipoprotein sub fractions and glucose. We also examined the 
association between circulating estradiol levels and VMS, and whether 
a possible association between VMS and CVD risk can be explained by 
circulating estradiol levels. Data were used from the Swedish Women’s 
Health in the Lund Area (WHILA) study, consisting of 5,857 women, aged 
50 to 64 years. In this study, symptoms of flushing/sweats were reported 
by 55% and sweats by 31% of all women. Estradiol concentrations were 
significantly lower in women with VMS. After multivariate adjustment, 
women with symptoms of sweats had a statistically significantly higher 
BMI, waist hip ratio, total cholesterol level, low density lipoprotein 
(LDL) level, triglycerides level, glucose level, systolic and diastolic blood 
pressure. These patterns did not change after correction for estradiol. The 
associations between flushing/sweats combined and CVD risk profile 
were less pronounced. These findings further support the view that VMS 
are associated with a less favourable CVD risk profile, which can not be 
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explained by circulating estradiol levels.
In chapter 5.3, we investigated the association between VMS risk 
of CHD events, and whether a possible association could be explained 
by CVD risk factors. For this study, we pooled the data of the EPOS 
and WHILA cohorts, consisting of 10,787 women in total. After a mean 
follow-up of 10 years, 303 women were diagnosed with CHD. Symptoms 
of flushing were not associated with risk of CHD. However, women 
with (night) sweats had an increased CHD risk (HR 1.41 [95% CI 1.12, 
1.76]). This association did not change after adjustment for potential 
confounders nor for potential intermediate risk factors as BMI and blood 
pressure. After adjusting for total cholesterol levels in the subgroup for 
which this was available, the estimate slightly decreased and did not 
remain statistically significant (HR 1.11 [95% CI 0.82-1.49]. This is likely 
to be caused by a reduced power, due to the low number and CHD cases 
that were left. Women with both symptoms of flushing and (night) sweats 
had an increased risk for CHD (HR 1.35 [95% CI 1.05-1.76]) as compared 
to asymptomatic women, but these risks attenuated after multivariate 
adjustment. We conclude that women with menopausal symptoms of 
(night) sweats have a significantly increased risk of CHD, which can not be 
fully explained by the levels of CVD risk factors. These findings indicate 
that women with VMS may therefore experience particular benefits of HT. 
In chapter 6, we examined whether the association between HT 
use and CHD risk differed for women with and without VMS. Neither 
for women with nor for women without flushing, ever HT use was 
associated with CHD risk, compared with never HT use. Also among 
women with (night) sweats, ever HT use did not affect CHD risk; among 
women without (night) sweats, ever HT use was associated with a 
borderline significant increased CHD risk compared to never use (HR 
1.31 [95% CI 0.91-1.89]) (P = 0.15 for interaction between VMS and HT). 
However, among women with intense VMS, ever HT use significantly 
decreased CHD risk compared with never HT use (HR 0.39 [95% CI 0.18-
0.87]), whereas among women without intense VMS, ever HT use was 
associated with a borderline significant increased CHD risk (HR 1.29 [95% 
CI 0.97-1.72]) (P = 0.03 for interaction between VMS and HT). Our findings 
indicate that HT use is not risk increasing and potentially beneficial with 
regard to CHD risk for women with the proper indication, i.e. intense 
VMS. In those in whom this indication is lacking, HT use may increase 
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the CHD risk. 
Finally, in the general discussion in chapter 7, we discuss whether 
our findings confirm our earlier proposed hypothesis that the presence 
of VMS determines the susceptibility to the preventive effects of HT on 
end organs.  We also discuss possible mechanisms that could underlie our 
found associations of an increased CHD risk among symptomatic women. 
Furthermore, we conclude that HT could reduce the risk among women 
with VMS, but not in women who do not have VMS.  Our findings suggest 
that the presence of VMS in the observational studies and the absence of 
VMS in the randomized trials could contribute to the discordant outcomes 
of these two types of studies on HT and CHD risk.
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In westerse landen zijn hart- en vaatziekten de belangrijkste 
doodsoorzaak voor vrouwen. Om hart- en vaatziekten te kunnen 
voorkomen is het van uiterst belang de oorzaak en risicofactoren van 
deze ziekten goed te begrijpen. In dit proefschrift zijn vrouwspecifieke 
risicofactoren voor coronaire hartziekten onderzocht. Bij coronaire 
hartziekten zijn de kransslagaderen vernauwd waardoor de toelevering 
van zuurstof en voedingsstoffen aan het hart wordt belemmerd. De 
risicofactoren polycysteus ovarium syndroom (PCOS), androgenen, 
menstruele cyclus karakteristieken en vasomotore menopauzale 
symptomen (VMS) zijn onderzocht. Verder hebben we onderzocht of 
vrouwen met VMS veilig postmenopauzale hormoontherapie kunnen 
gebruiken met betrekking tot hun risico op coronaire hartziekten.
PCOS is een aandoening die gekenmerkt wordt door de 
aanwezigheid van cysten in de eierstokken, hoge spiegels van androgenen, 
en onregelmatig of niet optredende menstruaties. Androgenen zijn 
mannelijke hormonen. Bij menstruele cyclus karakteristieken gaat het 
om lange perioden tussen de menstruaties of onregelmatig optredende 
menstruaties. VMS zijn overgangsklachten zoals opvliegers en 
nachtzweten.
 In hoofdstuk 2 hebben we de beschikbare literatuur over 
risicofactoren voor coronaire hartziekten voor vrouwen samengevat. Een 
geschiedenis van zwangerschapshypertensie, menopauzale status, een 
eerdere menopauzeleeftijd en mogelijk ook PCOS verhoogt het risico op 
coronaire hartziekten. Echter, de exacte rol van PCOS als onafhankelijke 
risicofactor moet nog worden vastgesteld, omdat de bestaande gegevens 
daarover niet eenduidig zijn. Ook de bestaande data over het risico op 
coronaire hartziekten voor vrouwen die hormoontherapie gebruiken 
is niet eenduidig. De suggestie dat hormoontherapie beschermend 
kan zijn voor jonge peri- of postmenopauzale vrouwen moet dan ook 
verder worden onderzocht. Het gebruik van een lage dosis van orale 
anticonceptiva verhoogt het coronaire hartziekten risico niet. 
 Hoofdstuk 3 beschrijft de resultaten van ons onderzoek naar de 
risicofactoren PCOS, androgenen, en menstruele cyclus karakteristieken 
op het ontwikkelen van coronaire hartziekten. In hoofdstuk 3.1 hebben 
we een recent voorgestelde manier voor het postmenopauzaal vaststellen 
van PCOS gebruikt. In tegenstelling tot de studie die deze definitie had 
voorgesteld, vonden wij geen verhoogd risico op coronaire hartziekten 
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voor vrouwen met postmenopauzaal vastgestelde PCOS. Ook bleken 
androgeenspiegels geen risicofactor voor coronaire hartziekten. Het blijft 
daarom onduidelijk of postmenopauzale karakteristieken geschikt zijn 
om een premenopauzale aandoening, zoals PCOS, te definiëren. 
 Onder vrouwen is ook een grote groep aanwezig die niet aan 
de PCOS criteria voldoet, maar wel lange of onregelmatige menstruele 
cycli heeft. Eerder onderzoek suggereert dat deze vrouwen een verhoogd 
risico op coronaire hartziekten hebben, maar of dit onafhankelijk is van 
de met PCOS geassocieerde afwijkende hormoonspiegels en/of hart- en 
vaatziekten risicofactoren, is vooralsnog niet bekend. In hoofdstuk 3.2 
hebben we deze vragen onderzocht. We hebben hiervoor gebruik gemaakt 
van de gegevens van 23,571 vrouwen, in de leeftijd van 20-70 jaar, die 
deelnamen aan het Nederlandse deel van de ‘European Prospective 
Study Into Cancer and Nutrition’ (EPIC). Een regelmatige lange cyclus 
van 30 of meer dagen was niet aan het coronaire hartziekten risico 
gerelateerd in vergelijking met een regelmatige kortere cyclus. Vrouwen 
met een onregelmatige cyclus hadden een 31% hoger risico op coronaire 
hartziekten (hazard ratio (HR) 1,31 [95% betrouwbaarheidsinterval 
(BI) 1,07-1,59]) dan vrouwen met een regelmatige cyclusduur van 27-
29 dagen. Verder hadden vrouwen met een onregelmatige cyclus een 
20%, maar net niet significant, verhoogd risico op type 2 diabetes (HR 
1,20 [95% BI 0,94-1,53]). Onregelmatige cycli waren ook aan een hogere 
glucose spiegel gerelateerd, maar niet aan bloeddruk, lipiden-, C-reactief 
proteïne (CRP)- en hormoonspiegels. We concluderen dat vrouwen met 
een geschiedenis van onregelmatige cycli een matig verhoogd risico op 
coronaire hartziekten hebben, dat echter niet verklaard kan worden door 
afwijkende hart- en vaatziekten risicofactoren en hormoonspiegels. 
  Lang is gedacht dat het tekort aan endogene oestrogenen het risico 
op hart- en vaatziekten na de menopauze verhoogt. Een logische gedachte 
is dan dat het toedienen van hormoontherapie aan postmenopauzale 
vrouwen het risico op hart- en vaatziekten verlaagt. Observationele studies 
laten inderdaad zien dat het gebruik van hormoontherapie gepaard gaat 
met een 30-50% risicoreductie van coronaire hartziekten. Echter, uit 
gerandomiseerde trials blijkt dat hormoontherapie geen bescherming 
biedt of zelfs leidt tot een verhoogd risico op coronaire hartziekten. Eerder 
hebben wij gepostuleerd dat de verschillen in uitkomsten tussen deze 
typen studies verklaard kunnen worden door de aan- of afwezigheid van 
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VMS. Terwijl VMS voor de vrouwen die deelnamen aan de observationele 
studies waarschijnlijk de reden waren om hormoontherapie te starten, 
werden in de trials de vrouwen met ernstige VMS juist geëxcludeerd of 
vormden een klein deel van de totale studiepopulatie. Vrouwen met VMS 
verschillen mogelijk van vrouwen zonder VMS met betrekking tot hart- 
en vaatziekten risico, of hun reactie op hormoontherapie of gevoeligheid 
voor oestrogenen. 
In hoofdstuk 4 hebben we de rol van VMS op botdichtheid 
onderzocht, omdat het bekend is dat botten een eindorgaan zijn dat 
gevoelig is voor oestrogenen of de effecten hiervan. Voor dit onderzoek 
hebben we gebruik gemaakt van de gegevens van de 5,600 vrouwen in 
de leeftijd van 46-57 jaar die deelnamen aan de Nederlandse ‘Eindhoven 
Perimenopauzale Osteoporose Studie’ (EPOS). Opvliegers werden 
door 39% en nachtzweten door 38% van alle vrouwen gerapporteerd. 
Na correctie voor leeftijd en andere factoren hadden vrouwen met de 
hoogste frequentie van opvliegers een 0,022 g/cm2 [95% BI -0,03, -0,01] 
lagere botdichtheid dan vrouwen zonder opvliegers. Vrouwen met de 
hoogste frequentie van nachtzweten hadden een 0,011 g/cm2 [95% BI 
-0,02, -0,001] lagere botdichtheid dan vrouwen zonder nachtzweten. Deze 
resultaten ondersteunen de opvatting dat VMS aan oestrogene effecten 
op botdichtheid zijn gerelateerd. 
 In hoofdstuk 5 zijn de onderliggende verschillen in het risico(profiel) 
van hart- en vaatziekten tussen vrouwen met en zonder VMS onderwerp 
van studie. In hoofdstuk 5.1 hebben we onderzoek gedaan naar de 
relatie tussen de aanwezigheid en frequentie van VMS en het hart- en 
vaatziekten risicoprofiel in de 5,523 deelnemende vrouwen van de EPOS 
studie. In 2,068 van deze vrouwen was totaal cholesterol gemeten. Na 
correctie voor levensstijlfactoren hadden vrouwen met opvliegers een 
0,27 mmol/L [95% BI 0,15 - 0,39] hogere cholesterolspiegel, een 0,60 
kg/m2 [95% BI 0,35-0,84] hogere body mass index (BMI), een 1,59 mm/
Hg [95% BI 0,52-2,67] hogere systolische bloeddruk en een 1,09 mm/
Hg [95% BI 0,48-1,69] hogere diastolische bloeddruk in vergelijking met 
vrouwen zonder opvliegers. Ook hadden vrouwen met opvliegers vaker 
hypercholesterolemie en hypertensie. Deze resultaten golden ook voor 
symptomen van nachtzweten.
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 In hoofdstuk 5.2 was ons doel om deze bevindingen te repliceren in 
een andere studiepopulatie en uit te breiden naar andere risicofactoren, 
zoals het lipidenprofiel en glucose. Ook hebben we onderzocht of een 
mogelijke associatie tussen VMS en het hart- en vaatziekten risicoprofiel 
verklaard kan worden door oestradiol spiegels. Voor deze doelen hebben 
we gebruik gemaakt van gegevens van de Zweedse ‘Women’s Health 
in the Lund Area’ (WHILA) studie, bestaande uit 5,857 vrouwen in de 
leeftijd van 50-64 jaar. Opvliegers/zweten werd door 55% en zweten door 
31% van alle vrouwen gerapporteerd. Na correctie voor levensstijlfactoren 
hadden vrouwen met zweten een statistisch significante hogere BMI, 
middelheup omtrek, bloeddruk, lipiden en glucose spiegel dan vrouwen 
zonder deze symptomen. Ondanks het feit dat VMS gerelateerd waren aan 
lagere oestradiol spiegels, konden de associaties met hart- en vaatziekten 
risicofactoren niet verklaard worden door de oestradiol spiegels. 
Klachten van opvliegers/zweten waren ook aan een ongunstiger hart- en 
vaatziekten risicoprofiel gerelateerd, maar minder sterk dan klachten van 
alleen zweten. 
 In hoofdstuk 5.3 hebben we onderzocht of VMS ook aan klinisch 
manifeste coronaire hartziekten eindpunten zijn gerelateerd en of 
een eventueel verband verloopt via een effect op hart- en vaatziekten 
risicofactoren. Voor dit doel hebben we de gegevens van de EPOS en 
WHILA studies samengenomen. Onze studiepopulatie bestond nu uit 
10,787 vrouwen. Na een gemiddelde follow-up duur van 10 jaar werden 
303 vrouwen met coronaire hartziekten gediagnosticeerd. Opvliegers 
waren niet aan het risico op coronaire hartziekten gerelateerd. Vrouwen 
met (nacht) zweten hadden echter een 41% verhoogd risico op coronaire 
hartziekten (HR 1,41 [95% BI 1,12-1,76]). Deze associatie veranderde 
niet na correctie voor BMI en bloeddruk. Echter, na correctie voor totaal 
cholesterol in de subgroep van vrouwen bij wie dit aanwezig was, 
verzwakte de associatie en bleef niet meer statistisch significant (HR 1,11 
[95% CI 0,82-1,49]). De cholesterolspiegel was echter maar bij een klein deel 
van de vrouwen in EPOS bepaald, dus voor deze analyse bleven weinig 
vrouwen over. Waarschijnlijk was daardoor de power niet voldoende 
om associaties te kunnen oppikken. Vrouwen met zowel opvliegers als 
(nacht)zweten hadden een 35% verhoogd coronaire hartziekten risico (HR 
1,35 [95% BI 1,05-1,76]) in vergelijking met vrouwen zonder symptomen, 
maar niet meer na correctie voor hart- en vaatziekten risicofactoren. We 
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concluderen dat vrouwen met menopauzale symptomen van (nacht)
zweten een verhoogd coronaire hartziekten risico hebben, wat niet volledig 
verklaard kan worden door de hart- en vaatziekten risicofactoren. Deze 
bevindingen suggereren dat vrouwen met VMS een mogelijke subgroep 
is die baat heeft bij het gebruik van hormoontherapie. 
 In hoofdstuk 6 hebben we onderzocht of de associatie tussen 
hormoontherapie en coronaire hartziekten verschillend was voor 
vrouwen met en zonder VMS bij aanvang van de studies. Voor zowel 
vrouwen met als zonder opvliegers was hormoontherapie gebruik niet 
aan het coronaire hartziekten risico gerelateerd in vergelijking met 
vrouwen die nooit hormoontherapie hebben gebruikt. Ook voor vrouwen 
met (nacht)zweten was hormoontherapie gebruik niet aan coronaire 
hartziekten risico gerelateerd. Bij de vrouwen zonder (nacht)zweten was 
hormoontherapie gebruik aan een net niet significant verhoogd coronaire 
hartziekten risico gerelateerd in vergelijking met vrouwen die nooit 
hormoontherapie hebben gebruikt (HR 1,31 [95% BI 0,91-1,89] (P-waarde 
= 0,15 voor interactie tussen VMS en hormoontherapie). Echter, bij de 
vrouwen met intense VMS, gedefinieerd als (nacht)zweten in combinatie 
met de meest frequente/ernstige opvliegers, was hormoontherapie 
gebruik geassocieerd met een 61% lager risico op coronaire hartziekten 
(HR 0,39 [95% BI 0,18-0,87]) dan bij de vrouwen die nooit hormoontherapie 
hadden gebruikt. Bij de groep vrouwen die geen intense VMS hadden 
was hormoontherapie gebruik juist geassocieerd met een net niet 
significant verhoogd coronaire hartziekten risico (HR 1,29 [95% BI 0,97-
1,72] (P-waarde = 0,03 voor interactie tussen VMS en hormoontherapie). 
Onze bevindingen suggereren mogelijk dat hormoontherapie niet 
risicoverhogend is met betrekking tot de ontwikkeling van coronaire 
hartziekten voor vrouwen met een indicatie, namelijk intense VMS. Bij 
vrouwen zonder deze indicatie lijkt het risico op coronaire hartziekten 
juist wel verhoogd te zijn.
 Tot slot bediscussiëren we in hoofdstuk 7 of de bevindingen 
zoals beschreven in dit proefschrift onze eerdere hypothese, dat de 
aanwezigheid van VMS de gevoeligheid voor de voordelige effecten 
van hormoontherapie op eindorganen bepaalt, bevestigt. Biologische 
mechanismen die mogelijk ten grondslag liggen aan het verhoogde 
coronaire hartziekten risico bij vrouwen met VMS worden besproken. 
Onze bevindingen suggereren dat de aanwezigheid van VMS bij vrouwen 
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in de observationele studies en de afwezigheid van VMS bij vrouwen 
in de gerandomiseerde studies kunnen bijdragen aan een verklaring 
voor de discrepante bevindingen tussen deze twee typen studies over 
hormoontherapie en coronaire hartziekten risico. 
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Promoveren is fun! Deze uitspraak stond steevast op het 
whiteboard in werkkamer 4.126 geschreven en was uiterst geschikt voor 
wanneer ik dat de afgelopen drie en een half jaar eens vergeten was. 
Gelukkig was dit niet vaak, want heel veel mensen hebben een bijdrage 
geleverd om mijn promotietijd ook echt leuk te maken! Een aantal van 
hen wil ik graag persoonlijk bedanken.
Prof.dr. Y.T. van der Schouw, beste Yvonne, na mijn ervaring met jou 
als afstudeerbegeleidster wist ik dat ik ook voor mijn promotieonderzoek 
bij jou goed terecht zou komen. Je hebt dit ook absoluut waargemaakt! 
Je hebt een erg prettige manier van begeleiden. Ik heb heel veel van je 
geleerd en waardeer je grote inzet voor dit proefschrift. Ondanks je 
drukke werkzaamheden kon ik altijd een beroep op je doen, zowel 
voor inhoudelijke ‘vrouwen issues’ als voor persoonlijke ‘woman talk’. 
Ook aan de barbecue avondjes en ons tripje naar Madrid heb ik goede 
herinneringen. Bedankt voor je vertrouwen, steun en motivatie! 
Prof.dr. D.E. Grobbee, beste Rick, je hebt me in het begin van mijn 
promotie heel goed op weg geholpen en ook later bleef je altijd goed op de 
hoogte van mijn vorderingen. Ik heb veel waardering voor je benadering 
van problemen en je analyserend vermogen. Jij wist het altijd weer in 
een breder kader te plaatsen, wat dit proefschrift absoluut ten goede is 
gekomen. Heel veel dank daarvoor!
Prof.dr. G.N. Samsioe, dear Göran, it has been a great privilege 
to work with you and I especially admire your knowledge in the field 
of gynecology. Thank you very much for your enthusiasm, constructive 
comments and ideas. They always gave me new inputs to improve the 
papers further. And during my stay in Sweden, you made me feel like 
home, which I really appreciated. Thank you very much! 
Prof.dr. P.M Nilsson, dear Peter, also many thanks to you for the 
fruitful collaboration and for your valuable comments and suggestions 
on my papers as well as your kind encouragements. I also would like 
to thank Göran and you for giving us the upportunity to use the data of 
the WHILA study. Without you this research would certainly not have 
existed!
Prof.dr. V.J.M. Pop, dr. J.J. Keyzer en drs. C. Wijnands – van Gent, 
beste Victor, Jules en Colette, ook zonder jullie had dit onderzoek niet 
bestaan! Ik ben jullie heel dankbaar voor het feit dat we de dataset van de 
EPOS studie hebben mogen gebruiken. Ik wil jullie ook bedanken voor 
205
Dankwoord
de kritische blik op mijn papers. Victor, ik hoop dat we samen zeker nog 
eens toekomen aan de ‘schildklier-paper’! Colette, ook veel dank omdat 
ik altijd bij je terecht kon met al mijn vragen over de data. Leuk dat je in 
de tussentijd ook de epidemiologie opleiding hebt afgerond!
Andere co-auteurs, voor zover niet genoemd, bedankt voor jullie 
bijdragen en de prettige samenwerking. Dear Yen, thank you for your 
enthusiasm and all the work you have done during your Master thesis. 
Bernard Slotboom, bedankt voor al de datasets die je me hebt 
aangeleverd. Nicole Boekema, je hebt me fantastisch geholpen bij het 
creëren van allerlei ingewikkelde variabelen! Hartelijk dank daarvoor, ook 
voor je hulp bij alle andere vragen op het gebied van datamanagement. 
Joline Beulens, ook jij bedankt voor al je suggesties en hulp op allerlei 
gebieden! Verder wil ik ook Ingrid Hille en Giene de Vries bedanken voor 
de gezelligheid en alle dingen die jullie voor mij geregeld hebben.
De onco-cardio club, bedankt voor de gezellige twee-wekelijkse 
bijeenkomsten en het bespreken van de ups en downs van onze projecten. 
Mijn ex-roomies van kamer 4.126: Anne, Anneloes, Caroline, 
Frederieke, Ghislaine, Ilonca, Marianne, Marie-Elise, Marjolein en Lotte. 
Zonder jullie was het werk veel minder leuk geweest! Het was altijd erg 
gezellig op de ‘meidenkamer’ alias ‘kippenhok’. Ik heb ontzettend met 
jullie kunnen lachen op de momenten dat het ons aan inspiratie even 
ontbrak. Ook heb ik genoten van alle uitjes die we samen hebben gehad. 
Ik ben heel blij dat we de Sinterklaas traditie in ere houden, ook al vieren 
we het tegenwoordig na kerst. Ik hoop dat we elkaar nog vaak blijven 
zien! 
Annemieke, Florianne, Ilonca en Lotte, mijn schrijfkamergenootjes, 
heel veel dank voor jullie luisterende oren en bemoedigende woorden 
in de laatste fase van mijn promotie! Gelukkig hebben we ook heel erg 
veel gelachen samen, ik kijk hier echt met plezier op terug! Annemieke, 
naast het feit dat je op het werk mijn overbuuf was, bleken we ook thuis 
bijna buren te zijn. Ik vind het jammer dat ik je niet eerder beter heb leren 
kennen; ik heb een hele leuke tijd met je gehad. Veel dank daarvoor en ik 
hoop dat we elkaar nog vaak blijven zien!
Anneke, Arnoud, Bauke, Carline, Ivonne, Jaap, Lennie, Madeleine, 
Margriet, Martijn, Maud, Pauline en alle andere (oud) collega promovendi 
van het Julius Centrum, bedankt voor de ontzettend gezellige tijd! Alle 
koffiemomenten, lunches, borrels, etentjes en het promovenski-weekend 
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inclusief bananenboten; het was allemaal even leuk! 
Lieve Marjolein, ik heb bewondering voor je altijd relaxte en 
positieve houding die mij absoluut heeft geholpen om beter te kunnen 
relativeren. Dank voor je zorgzaamheid, steun en alle gezelligheid, ook 
naast het werk! Ik kijk dan ook met veel plezier terug naar onze avondjes 
samen, ook met de mannen erbij. Ik ben heel blij met je back-up straks 
tijdens de verdediging!
De afgelopen jaren heb ik ook veel steun ervaren van vrienden en 
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